NEWSLETTER TRANSPLANT

International figures on donation and transplantation 2018



EDQM Volume 24 2019



O MINISTERIO A DE SANIDAD, CONSUMO Y BIENESTAR SOCIAL





COUNCIL OF EUROPE

CONSEIL DE L'EUROPE

INTERNATIONAL FIGURES ON ORGAN, TISSUE & HAEMATOPOIETIC STEM CELL DONATION & TRANSPLANTATION ACTIVITIES. DOCUMENTS PRODUCED BY THE COUNCIL OF EUROPE EUROPEAN COMMITTEE (PARTIAL AGREEMENT) ON ORGAN TRANSPLANTATION (CD-P-TO). YEAR 2018.

NATIONAL DATA PROVIDED BY:

AUSTRIA Dave Green (FT) BELGIUM Dave Green (ET) **BULGARIA** Dessislava Tsoneva CROATIA Martina Anušić Juričić Dave Green (ET) CYPRUS Chrystalla Despoti CZECH REPUBLIC Michaela Vrbová DENMARK Ilse Duus Weinreich (SKT) **ESTONIA** Virge Pall FINLAND Ilse Duus Weinreich (SKT) FRANCE Christelle Cantrelle GERMANY Brigitte Ossadnik Dave Green (ET) GREECE Anna Tzoka HUNGARY Sándor Mihály IRELAND Brenda Poole ITALY Francesca Puoti LATVIA Janis Jushinskis LITHUANIA Vita Petronytė LUXEMBURG Dave Green (ET) MALTA Paul Calleia NETHERLANDS Dave Green (ET)

POLAND Piotr Malanowski **PORTUGAL** Catarina Bolotinha Dan Adrian Luscalov SI OVAKIA Danile Kuba Magdaléna Krátka **SLOVENIA** Dave Green (ET) SPAIN Elisabeth Coll Itziar Martínez Carmen Martín SWEDEN Ilse Duus Weinreich (SKT) UNITED KINGDOM Joseph Parsons (ET) EUROTRANSPLANT Members: Austria, Belaium, Croatia, Germany, Hunaary, Luxembura, Netherlands and Slovenia (SKT) SCANDIATRANSPLANT Members: Denmark, Finland, Norway, Sweden and Iceland ALGERIA Mohamed Bourahla ARMENIA Ashot Sarkissian AUSTRALIA Byron Arcia BELARUS Fedaruk Dzmitry **BOSNIA AND HERZEGOVINA** CANADA Michael Terner GEORGIA

Gia Tomadze

Vasanthi Ramesh

Tamar Ashkenazi

Ilse Duus Weinreich (SKT)

ICELAND

INDIA

ISRAEL

POMANIA

KUWAIT Mustafa Al-Mousawi MALAYSIA Raia Farah Faizura **NEW ZEALAND** Kylie Hurst NORWAY Ilse Duus Weinreich (SKT) OATAR **Riadh Eadhil** Yasser Shafi **REPUBLIC OF MOLDOVA** Igor Codreanu **RUSSIAN FEDERATION** Lyayla Gabbasova SAUDI ARABIA Paul Mark Follero Besher Al-Attar SUDAN Mahmoud Obeid SWITZERLAND Franziska Beyeler SYRIAN ARAB REPUBLIC Bassam Saeed THE REPUBLIC OF NORTH MACEDONIA Goce Spasovski TURKEY İlker Ünsal UNITED STATES OF AMERICA Sarah Taranto

ARGENTINA Sergio Madera BOLIVIA Adolfo Zárate Cabello BRAZIL Daniela Ferreira Salomao Thais Lucena de Oliveira CHILE Juan E. Sánchez COLOMBIA Edwin A. Cárdenas Adriana Segura Yazmin R. Arias COSTA RICA César A Gamboa Martha Romero Roselyn Serrano **CUBA** M. Antonio Enamorado DOMINICAN REPUBLIC Fernando R. Morales Alexander Altman ECUADOR Mauricio Heredia **EL SALVADOR** Raúl Palomo **GUATEMALA** Salvador López Rudolf García-Gallont HONDURAS MEXICO J. Salvador Aburto José André Madrigal NICARAGUA Mabel I. Sandoval PANAMA Cesar J. Cuero Camilo Chong PARAGUAY Gustavo A. Melgareio Marcelo Martínez PFRU Juan A. Almevda URUGUAY Milka Bengochea VENEZUELA Evelyn Alonzo

Organización Nacional de Trasplantes (ONT) – Spain

Beatriz Domínguez-Gil Beatriz Mahillo Marina Álvarez Mar Carmona

Published jointly with the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM), 7 allée Kastner, CS 30026, F-67081 STRASBOURG. ISSN: 2171-4118 © 2019 Council of Europe and Organización Nacional de Trasplantes. Cover photo © Fotolia – Romolo Tavani.

Editor: Beatriz Domínguez-Gil

NEWSLETTER TRANSPLANT 2019



CONTENTS

• Letter from the Editor	
International Figures on Organ Donation and Transplantation Activity. Year 2018	
International Data on Organ Donation and Transplantation Activity and Waiting List. Year 2018	
 International Data on Tissues and Haematopoietic Stem Cell Donation and Transplantation Activity. Year 2018	
Council of Europe Reference Documents. Year 2018	
Council of Europe Reference Documents. Year 2018	

FOR THE PURPOSES OF THIS NEWSLETTER THE FOLLOWING DEFINITIONS WERE USED:

Actual deceased organ donor

An actual deceased organ donor is a person from whom at least one organ has been recovered for the purpose of transplantation, in contrast to a utilised donor, who is an actual donor from whom at least one organ has been transplanted. The number of utilised donors is therefore lower or equal than the number of actual donors.

Donor after brain death

A donor after brain death (DBD) is a deceased organ donor in whom death has been determined by neurologic criteria.

Donor after circulatory death

A donor after circulatory death (DCD) is a deceased organ donor in whom death has been determined by circulatory and respiratory criteria.

Total Tx (all combinations included)

Includes the transplantation of the corresponding organ with or without the simultaneous transplant of a different type of organ (s).

Double-kidney Tx

One double-kidney Tx is counted as 1 Tx.

Tx from living donors

A living donor is a living human being from whom organs have been recovered for the purpose of transplantation. A living Donor has one of the following relationships with the recipient:

A/ Related: The donor is genetically and/or emotionally related to the recipient.

A1/ Genetically Related: A genetic relation exists between donor and recipient (e.g. brother/sister, parent/offspring). A2/ Emotionally Related: The donor is a genetically unrelated family member (e.g. spouse) of the recipient or a friend.

B/ Unrelated = Non Related: The donor has no genetic or emotional relationship with the recipient. The relation between donor and recipient must be outlined further by a sub-specification.

B1/ Paired exchange or cross-over: By a controlled programme, unrelated donor and recipient pairs exchange grafts beyond any emotional or genetic relation, with the aim of overcoming immunological restrictions.

B2/ Non-directed altruistic or anonymous: By a controlled programme, the donor can provide a graft to society which allocates this to a previously unknown recipient by defined rules.

B3/ Directed altruistic: By a controlled programme, the donor provides a graft to a recipient of the donor's choice.

Heart-lung Tx

One heart-lung Tx is counted as 1 lung Tx, 1 heart Tx and 1 heart-lung Tx.

Double-lung Tx

One double-lung Tx is counted as 1 Tx.

Total number of patients transplanted

When more than one organ is transplanted into the same recipient, only one recipient is counted (e.g. kidney-liver-heart Tx = counted as one recipient).

Paediatric

Includes only paediatric activity (patients aged < 18 years).

Waiting List (WL)

Example: At 1/1/201X there were 200 patients active on the WL. Along the year, 100 patients are newly included on the WL (first row). In total, 300 patients have been ever active on the WL during the year (second row). Along the year, 200 patients were transplanted (number recorded in a different questionnaire), 50 patients remain active at the end of the year (third row), 25 patients died (fourth row) and 25 patients were excluded (number not to be reported, but derived from previous figures).

Patients included on the WL for the first time in the course of 201X	100
Total number of patients ever active on the WL during 201X	300
Patients awaiting for a transplant (only active candidates) on 31/12/201X	50
Patients who died while on the WL during 201X	25

("The United Nations Fund report (UNFPA: http://www.unfpa.org/public/) is used as the data source for estimates of population size)

Letter from the Editor



Letter from the Editor

Beatriz Domínguez-Gil, MD, PhD Director Organización Nacional de Trasplantes, Spain Editor of Newsletter Transplant

Dear friends

It is with pleasure that I introduce a new issue of the Newsletter Transplant, one of the most valuable tools produced by the Committee of Transplantation of the Council of Europe (CD-P-TO) in conjunction with the Spanish Organización Nacional de Trasplantes (ONT). Since 1996, this publication has allowed the CD-P-TO to share information on donation and transplantation activities in member states of the Council of Europe (CoE) - and beyond - and to present some of the proiects developed by this committee and documents of relevance to the field. The Newsletter Transplant is in itself an opportunity to demonstrate the active contribution of the CD-P-TO to secure fundamental human rights, as well as to increase organ availability, improve the effectiveness of transplantation systems and enhance the quality and safety of organs, tissues and cells for clinical use.

Without doubt, monitoring of practices in donation and transplantation of substances of human origin in member states is essential for the sake of transparency and international benchmarking. This is the main aim of the Newsletter Transplant, and the reason it has become an international reference. In this new issue, the Newsletter Transplant reports data from almost 70 countries throughout the world for the year 2018 (global data refer to 2017). The information presented relates to organ donation and transplantation activities, management of the waiting lists, rate of refusals to organ donation and transplant centres. Data are displayed by age group and gender for both organ donors and recipients. Let me take this opportunity to remind you that the underlying data collection is also hosted by the Global Observatory on Organ Donation and Transplantation (http://www.transplant-observatory.org/) developed and maintained by the ONT on behalf of the World Health Organization. The Observatory allows users to download data and create figures online. For obvious reasons, not all information that is collected from countries is displayed in the Newsletter Transplant and the Observatory, but additional data can be provided to final users on an ad hoc basis and upon request.

Information presented in the *Newsletter Transplant* is not limited to the organ field, but also covers tissues and cells. Provided by the Centro Nazionale di Trapianti (CNT) in Italy, which conducts the corresponding annual data collection, the *Newsletter Transplant* also presents data on the donation, procurement, processing, distribution and clinical use of tissues and cells from a significant number of countries.

This issue of the Newsletter Transplant also presents an important document produced by the CD-P-TO addressing illicit and unethical practices in the field of tissues and cells. In this document, the CD-P-TO analyses the international legal framework that regulates the process of donation and clinical use of tissues and cells of human origin. It concludes that an international agreement is needed to prohibit and criminalise certain unethical practices of particular severity, in terms of violation of the fundamental principles of human dignity and integrity. This work is intended to support decision-making bodies at the Council of Europe to decide on the need to elaborate an Additional Protocol to the Council of Europe Convention against Trafficking in Human Organs to address the trafficking of human tissues and cells.

The CD-P-TO has also contributed to the elaboration and dissemination of this Convention, which provides clarity on the practices in the field of organ donation and transplantation that must be criminalised and mechanisms to be strengthened for cooperation and victim protection. This issue of the *Newsletter Transplant* includes the current status of signatures and ratifications and invites countries that have not already done so to move forward in their accession to this important legal instrument.


I take this opportunity to remind you of the importance and usefulness of the technical guides in the fields of organs, tissues and cells that are regularly updated by the CD-P-TO. These are invaluable tools for regulators and health professionals throughout Europe and beyond.


Please allow me to finish this letter by thanking all those who make the *Newsletter Transplant* possible - members of the CD-P-TO, national focal points provid-


ing data on a regular basis and the EDQM secretariat. But, most importantly, let me thank the members of the ONT whose continuous work, commitment and enthusiasm are essential for an exercise that every year showcases the European progress in the fascinating field of transplantation.


International Figures on Organ Donation and Transplantation Activity. Year 2018




































GOBIERNO DE ESPAÑA

MINISTERIO DE SANIDAD, CONSUMO Y BIENESTAR SOCIAL

EUROPEAN UNION DATA




Kidney	Liver	Heart	Lung	Pancreas	Small Bowel	Organs
Transplants	Transplants	Transplants	Transplants	Transplants	Transplants	Transplanted
21227 (19.9% LD)	7940 (2.8% LD)	2287	1980	745	42	34221

11325 ACTUAL DECEASED ORGAN DONORS (9540 DBD and 1785 DCD)

2018 data

N= 28 COUNTRIES (509.7 million inhabitants)



























Senate 1

- MONT

LATIN AMERICAN COUNTRIES




Kidney	Liver	Heart	Lung	Pancreas	Small Bowel	Organs
Transplants	Transplants	Transplants	Transplants	Transplants	Transplants	Transplanted
12832 (31.9% LD)	3435 (8.5% LD)	640	210	259	5	17381

5756 ACTUAL DECEASED ORGAN DONORS (5756 DBD and 0 DCD)

2018 data


N= 18 COUNTRIES (619.1 million inhabitants)




37447 ACTUAL DECEASED ORGAN DONORS (29462 DBD and 7985 DCD)


- Information of 82 Member States on organ transplantation activities is included in the GODT

- 139024 organ transplants were reported for 2017




<u>....</u>






The boundaries and names shown and the designations used on this map do not imply the expression of any opision whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Data Source: Global Observatory on Donation & Transplantation. Map Production Information Evidence and Research (IER) World Health Organization






The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whittoever on the part of the World Health Organization concerning the legal status of any country, territory, oity or area or of its authorities, or concerning the delimitation of the frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Data Source: Global Observatory on Denation & Transplantation. Map Production: Information Evidence and Research (IER) World Health Organization





The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed knes on maps represent approximate border lines for which there may not yet be full agreement. Data Source: Global Observatory on Donation & Transplantation, Map Production: Information Evidence and Research (IER) World Health Organization







on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines

& Transplantation. Map Production: Information Evidence and Research (IER)







or concerning the delimitation of its fironitiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Evidence and Reswarch (IER) World Health Organization



International Data on Organ Donation and Transplantation Activity and Waiting List. Year 2018



				DONATION ACT	VITY			
			EURO	PEAN UNION C	OUNTRIES			
Country Population (million inhabitants): UNFPA	Austria 8.8	Belgium 11.5	Bulgaria 7.0	Croatia 4.2	Cyprus 1.2	Czech Republic 10.6	Denmark 5.8	Estonia 1.3

France

65.2

Finland

5.5

· • • • • • • • • • • • • • • • • • • •		-			'			-												-
							DON	ATION												
Actual deceased organ donors	Number	РМР	Number	РМР	Numbe	r PMP	Number	PMP	Number	PMP	Number	PMP	Number	РМР	Number	РМР	Number	РМР	Number	РМР
Actual deceased organ donor																				
-both DBD and DCD included-	216	24.5	344	29.9	16	2.3	169	40.2	2	1.7	282	26.6	100	17.2	33	25.4	117	21.3	1881	28.8
Actual deceased donors: Number of men	125	14.2	209	18.2	9	1.3					174	16.4	50	8.6	24	18.5	58	10.5	1045	16.0
Actual deceased donors: Number of DD > 60 years	69	7.8	124	10.8	1	0.1			0	0.0	110	10.4	50	8.6	5	3.8	58	10.5	912	14.0
Actual donors after circulatory death –DCD–	15	1.7	103	9.0	0	0.0			0	0.0	13	1.2	0	0.0	0	0.0	0	0.0	138	2.1
II/ Witnessed cardiac arrest (uncontrolled)											0	0.0							17	0.3
III/ Withdrawal of life-sustaining therapy (controlled)											13	1.2							121	1.9
IV/ Cardiac arrest while brain dead											0	0.0							0	0.0
Utilised deceased organ donors	Number	PMP	Number	PMP	Numbe	r PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	РМР	Number	PMP	Number	РМР
Utilised deceased organ donors																				
-both DBD and DCD included-	202	23.0	335	29.1	16	2.3	151	36.0	2	1.7	259	24.4	85	14.7	33	25.4	108	19.6	1823	28.0
Utilised deceased donors: Number of men	117	13.3	204	17.7	9	1.3					154	14.5	43	7.4	24	18.5	54	9.8	1015	15.6
Utilised deceased donors: Number of DD > 60 years	59	6.7	117	10.2	1	0.1			0	0.0	83	7.8	41	7.1	5	3.8	50	9.1	866	13.3
Utilised donors after circulatory death -DCD-	14	1.6	98	8.5	0	0.0	0	0.0	0	0.0	11	1.0	0	0.0	0	0.0	0	0.0	132	2.0
II/ Witnessed cardiac arrest (uncontrolled)											0	0.0							16	0.2
III/ Withdrawal of life-sustaining therapy (controlled)											11	1.0							116	1.8
IV/ Cardiac arrest while brain dead											0	0.0							0	0.0
Living organ donors	Number	РМР	Number	PMP	Numbe	r PMP	Number	РМР	Number	PMP	Number	PMP	Number	PMP	Number	РМР	Number	PMP	Number	РМР
Living Kidney donors: Number of men					0	0.0			4	3.3	14	1.3	29	5.0	1	0.8	14	2.5	173	2.7
Living Liver donors: Number of men					0	0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	10	0.2
Living Lung donors: Number of men					0	0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

					EURO	OPEAN	UNION C	OUNTR	IES									
Country	Germa	ny	Gree	:e	Hung	ary	Irela	nd	Ital	У	Latvi	ia	Lithua	nia	Luxemb	ourg	Malt	ta
Population (million inhabitants): UNFPA	82.3		11.1		9.7	7	4.8	3	59.	3	1.9		2.9		0.6		0.4	Ļ
						D	ONATION											
Actual deceased organ donors	Number	PMP	Number	PMP	Number	PMP	Number	РМР	Number	PMP	Number	РМР	Number	РМР	Number	РМР	Number	PMF
Actual deceased organ donors																		
-both DBD and DCD included-	955	11.6	45	4.1	168	17.3	81	16.9	1466	24.7	24	12.6	46	15.9	7	11.7	10	25.0
Actual deceased donors: Number of men	505	6.1	20	1.8	102	10.5	39	8.1	802	13.5	10	5.3	27	9.3	6	10.0	5	12.5
Actual deceased donors: Number of DD > 60 years	402	4.9	13	1.2	55	5.7	20	4.2	866	14.6	8	4.2	20	6.9	3	5.0	4	10.0
Actual donors after circulatory death –DCD–	0	0.0	0	0.0	0	0.0	4	0.8	57	1.0	1	0.5	0	0.0	0	0.0	0	0.0
II/ Witnessed cardiac arrest (uncontrolled)	-						0	0.0	24	0.4	0	0.0						
III/ Withdrawal of life-sustaining therapy (controlled)							4	0.8	32	0.5	0	0.0						
IV/ Cardiac arrest while brain dead							0	0.0	1	0.0	1	0.5						
Utilised deceased organ donors	Number	PMP	Number	РМР	Number	РМР	Number	РМР	Number	PMP	Number	РМР	Number	PMP	Number	РМР	Number	РМ
Utilised deceased organ donors																		
-both DBD and DCD included-	933	11.3	43	3.9	167	17.2	73	15.2	1371	23.1	22	11.6	45	15.5	7	11.7	10	25.0
Utilised deceased donors: Number of men	492	6.0	19	1.7	101	10.4	35	7.3	742	12.5	10	5.3	26	9.0	6	10.0	5	12.5
Utilised deceased donors: Number of DD > 60 years	387	4.7	13	1.2	55	5.7	16	3.3	785	13.2	6	3.2	19	6.6	3	5.0	4	10.0
Utilised donors after circulatory death -DCD-	0	0.0	0	0.0	0	0.0	3	0.6	47	0.8	1	0.5	0	0.0	0	0.0	0	0.0
II/ Witnessed cardiac arrest (uncontrolled)							0	0.0	18	0.3	0	0.0						
III/ Withdrawal of life-sustaining therapy (controlled)							3	0.6	28	0.5	0	0.0						
IV/ Cardiac arrest while brain dead							0	0.0	1	0.0	1	0.5						
Living organ donors	Number	PMP	Number	РМР	Number	РМР	Number	РМР	Number	РМР	Number	РМР	Number	РМР	Number	РМР	Number	PM
Living Kidney donors: Number of men			18	1.6	8	0.8	16	3.3	81	1.4	6	3.2	5	1.7			2	5.0
Living Liver donors: Number of men			0	0.0	0	0.0	0	0.0	10	0.2	0	0.0	0	0.0			0	0.0
Envirg Eiver donors. Humber of men																		

						DONA	TION ACT	ΙVITY										
					EUR	OPEAN	UNION C	OUNTR	IES									
Country	Netherl	ands	Polar	d	Portu	aal	Roma	nia	Slova	kia	Slove	nia	Spai	n	Swed	len	United K	ingdom
	17.		38.1		10.3	-	19.6		5.4		2.1		46.4		10.		66	-
Population (million inhabitants): UNFPA	17.	1	38.1		10.3				5.4	•	2.1		40.4	•	10.	U	00	.0
							ONATION											
Actual deceased organ donors	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP
Actual deceased organ donors																		
-both DBD and DCD included-	281	16.4	498	13.1	344	33.4	65	3.3	78	14.4	46	21.9	2241	48.3	191	19.1	1619	24.3
Actual deceased donors: Number of men	165	9.6	329	8.6	208	20.2	43	2.2	49	9.1	33	15.7	1344	29.0	107	10.7	879	13.2
Actual deceased donors: Number of DD > 60 years	125	7.3	113	3.0	187	18.2	20	1.0	19	3.5	26	12.4	1278	27.5	113	11.3	592	8.9
Actual donors after circulatory death -DCD-	164	9.6	4	0.1	28	2.7	0	0.0	0	0.0	0	0.0	629	13.6	10	1.0	619	9.3
II/ Witnessed cardiac arrest (uncontrolled)			4	0.1	28	2.7							72	1.6	0	0.0	0	0.0
III/ Withdrawal of life-sustaining therapy (controlled)			0	0.0	0	0.0							556	12.0	10	1.0	619	9.3
IV/ Cardiac arrest while brain dead			0	0.0	0	0.0							1	0.0	0	0.0	0	0.0
Utilised deceased organ donors																		
Utilised deceased organ donors																		
-both DBD and DCD included-	273	16.0	475	12.5	309	30.0	65	3.3	74	13.7	40	19.0	1925	41.5	182	18.2	1542	23.2
Utilised deceased donors: Number of men	159	9.3	311	8.2	186	18.1	43	2.2	48	8.9	30	14.3	1139	24.5	103	10.3	835	12.5
Utilised deceased donors: Number of DD > 60 years	118	6.9	97	2.5	161	15.6	20	1.0	16	3.0	21	10.0	1041	22.4	105	10.5	541	8.1
Utilised donors after circulatory death –DCD–	157	9.2	4	0.1	23	2.2	0	0.0	0	0.0	0	0.0	527	11.4	10	1.0	565	8.5
II/ Witnessed cardiac arrest (uncontrolled)			4	0.1	23	2.2							41	0.9	0	0.0	0	0.0
III/ Withdrawal of life-sustaining therapy (controlled)			0	0.0	0	0.0							485	10.5	10	1.0	565	8.5
IV/ Cardiac arrest while brain dead			0	0.0	0	0.0							1	0.0	0	0.0	0	0.0
Living organ donors																		
Living Kidney donors: Number of men			14	0.4	16	1.6			1	0.2			94	2.0	66	6.6	479	7.2
Living Liver donors: Number of men			8	0.2	1	0.1			0	0.0			8	0.2	1	0.1	10	0.2
Living Lung donors: Number of men			0	0.0	0	0.0	0	0.0	0	0.0			0	0.0	0	0.0	0	0.0

									ΓΙΟΝ ΑCTIVI														
							C	OTHE		S													
Country	Algeri	ia	Armer	nia	Austra	alia	Belar	us	Bosnia and Herzegovina	Cana	ida	Georg	jia	lcela	nd	Indi	a	Isra	ael	Kuwa	ait	Mala	ysia
Population (million inhabitants): UNFPA	42.0	,	2.9		24.	В	9.5		3.5	37.	0	3.9		0.3	:	1354	.1	8.	5	4.2	2	32	0
	1						1	D	ONATION	1				1				1		1		1	
Actual deceased organ donors	Number	РМР	Number	PMP	Number	РМР	Number	РМР	Number PMP	Number	PMP	Number	РМР	Number	РМР	Number	PMP	Numbe	r PMP	Number	PMP	Numbe	ar PM
Actual deceased organ donors -both DBD and DCD included-	0	0.0	0	0.0	554	22.3	238	25.1				0	0.0	10	33.3	875	0.7	113	13.3	12	2.9	7	0.2
Actual deceased donors: Number of men					325	13.1	90	9.5						7	23.3			67	7.9	10	2.4	4	0.1
Actual deceased donors: Number of DD > 60 years					167	6.7	20	2.1						3	10.0	143	0.1	45	5.3	1	0.2	0	0.0
Actual donors after circulatory death –DCD– II/ Witnessed cardiac arrest (uncontrolled) III/ Withdrawal of life–sustaining therapy (controlled) IV/ Cardiac arrest while brain dead					154	6.2	0	0.0						0	0.0	3	0.0	2 2 0 0	0.2 0.2 0.0 0.0	0	0.0	0	0.0
Utilised deceased organ donors	Number	РМР	Number	PMP	Number	PMP	Number	PMP	Number PMP	Number	РМР	Number	PMP	Number	PMP	Number	PMP	Numbe	r PMP	Number	PMP	Numbe	er PM
Utilised deceased organ donors -both DBD and DCD included-	0	0.0	0	0.0	531	21.4	238	25.1		763	20.6	0	0.0	10	33.3	712	0.5	110	12.9	10	2.4	7	0.2
Utilised deceased donors: Number of men					312	12.6	90	9.5						7	23.3			65	7.6	8	1.9	4	0.1
Utilised deceased donors: Number of DD > 60 years					150	6.0	20	2.1						3	10.0	115	0.1	42	4.9	1	0.2	0	0.0
Utilised donors after circulatory death –DCD– II/ Witnessed cardiac arrest (uncontrolled) III/ Withdrawal of life–sustaining therapy (controlled) IV/ Cardiac arrest while brain dead					145	5.8	0	0.0		227	6.1			0	0.0	3	0.0	2 2 0 0	0.2 0.2 0.0 0.0	0	0.0	0	0.0
Living organ donors	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Numbe	r PMP	Number	PMP	Numbe	er PM
Living Kidney donors: Number of men	94	2.2	4	1.4	99	4.0	2	0.2				10	2.6	4	13.3			127	14.9	40	9.5	25	0.
Living Liver donors: Number of men	4	0.1	0	0.0	0	0.0	0	0.0				9	2.3	0	0.0			11	1.3	0	0.0	1	0.0
Living Lung donors: Number of men	0	0.0	0	0.0	0	0.0	0	0.0				0	0.0	0	0.0			0	0.0	0	0.0	0	0.

DONATION ACTIVITY	

							(OTHE	R COUN	ITRIE	S													
Country	New Zea	aland	Norw	ay	Qata	ır	Republ Moldo	ic of	Russi Federa	an	Sau Arat		Suda	an	Switzer	rland	Syria Aral Reput	b	The R of Nor Maced	th	Turk	ey	Unit Stat of Am	tes
Population (million inhabitants): UNFPA	4.7		5.4		2.7		4.0		144.	.0	33.	6	41.	5	8.5	5	18.3	3	2.1	I	81.9	•	326	i.8
	1	'			1			D	ONATIC	ON									1					
Actual deceased organ donors	Number	РМР	Number	PMP	Number	РМР	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	РМР	Number	PMP	Number	PMP	Numbe	r PMP
Actual deceased organ donors -both DBD and DCD included-	62	13.2	104	19.6	7	2.6	10	2.4	646	4.5	96	2.9	0	0.0	158	18.6	0	0.0	1	0.5	598	7.3	10722	32.8
Actual deceased donors: Number of men	32	6.8	59	11.1	6	2.2	6	1.5	423	2.9	85	2.5			94	11.1					377	4.6	6497	19.9
Actual deceased donors: Number of DD > 60 years	20	4.3	54	10.2	0	0.0	4	1.0	68	0.5	6	0.2			80	9.4			0	0.0	203	2.5	1544	4.7
Actual donors after circulatory death -DCD- II/ Witnessed cardiac arrest (uncontrolled) III/ Withdrawal of life-sustaining therapy (controlled) IV/ Cardiac arrest while brain dead	9	1.9	0	0.0	0	0.0	0	0.0	37 26 0 9	0.3 0.2 0.0 0.1	0	0.0			32 0 32 0	3.8 0.0 3.8 0.0			0	0.0	0	0.0	2133 29 2104 0	6.5 0.1 6.4 0.0
Utilised deceased organ donors	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Numbe	r PMP
Utilised deceased organ donors -both DBD and DCD included-	58	12.3	100	18.9	6	2.2	8	2.0	639	4.4	94	2.8	0	0.0	154	18.1	0	0.0	1	0.5	560	6.8	10106	30.9
Utilised deceased donors: Number of men	30	6.4	56	10.6	5	1.9	4	1.0	417	2.9	83	2.5			91	10.7					356	4.3	6158	18.8
Utilised deceased donors: Number of DD > 60 years	17	3.6	50	9.4	0	0.0	3	0.7	68	0.5	6	0.2			77	9.1			0	0.0	184	2.2	1335	4.1
Utilised donors after circulatory death –DCD– II/ Witnessed cardiac arrest (uncontrolled) III/ Withdrawal of life–sustaining therapy (controlled) IV/ Cardiac arrest while brain dead	8	1.7	0	0.0	0	0.0	0	0.0	35 26 0 9	0.2 0.2 0.0 0.1	0	0.0			31 0 31 0	3.6 0.0 3.6 0.0			0	0.0	0	0.0	1862 22 1840 0	5.7 0.1 5.6 0.0
Living organ donors	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Numbe	er PMP
Living Kidney donors: Number of men	30	8.1	31	5.8	13	4.8	2	0.5	65	0.5			135	3.3							1981	24.2	2358	7.2
Living Liver donors: Number of men	0	0.0	0	0.0	3	1.1	3	0.7	77	0.5			0	0.0			0	0.0	0	0.0	724	8.8	180	0.6
Living Lung donors: Number of men	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

						D	ONATIO	N ACTI	VITY											
						LATIN	AMERIC	AN CO	UNTRIE	S										
Country	Argen	itina	Boli	via	Bı	azil	Chil	e	Color	nbia	Costa I	Rica	Cuba	1	Dominio Repub		Ecuad	lor	El Salva	ador
Population (million inhabitants): UNFPA	44.	7	11.	.2	21	0.9	18.	2	49	.5	5.0		11.5		10.9		16.9	•	6.4	Ļ
	1				1		DON	ATION			1		1				1		1	
Actual deceased organ donors	Number	РМР	Number	РМР	Numb	er PMP	Number	РМР	Number	PMP	Number	РМР	Number	PMP	Number	PMP	Number	РМР	Number	r PMP
Actual deceased organ donors																				
-both DBD and DCD included-	701	15.7	4	0.4	3529	16.7	119	6.5	398	8.0	35	7.0	130	11.3	9	0.8	133	7.9	0	0.0
Actual deceased donors: Number of men	279	6.2	2	0.2	2074	9.8			262	5.3	23	4.6	88	7.7	7	0.6	87	5.1		
Actual deceased donors: Number of DD > 60 years	131	2.9	0	0.0	415	2.0			36	0.7	6	1.2	16	1.4	2	0.2	12	0.7		
Actual donors after circulatory death –DCD– II/ Witnessed cardiac arrest (uncontrolled)	0	0.0	0	0.0	0	0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
III/ Withdrawal of life–sustaining therapy (controlled) IV/ Cardiac arrest while brain dead																				
Utilised deceased organ donors																				
Utilised deceased organ donor																				
-both DBD and DCD included-	643	14.4	4	0.4	3022	14.3	119	6.5	394	8.0	35	7.0	80	7.0	7	0.6	128	7.6	0	0.0
Utilised deceased donors: Number of men	386	8.6	2	0.2	1852	8.8			260	5.3	23	4.6	46	4.0	2	0.2	84	5.0		
Utilised deceased donors: Number of DD > 60 years	103	2.3	0	0.0	225	1.1			34	0.7	6	1.2	7	0.6	1	0.1	12	0.7		
Utilised donors after circulatory death -DCD-	0	0.0	0	0.0	0	0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
II/ Witnessed cardiac arrest (uncontrolled) III/ Withdrawal of life–sustaining therapy (controlled)																				
IV/ Cardiac arrest while brain dead																				
Living organ donors																				
Living Kidney donors: Number of men	207	4.6	35	3.1					60	1.2	13	2.6	9	0.8	24	2.2	11	0.7	22	3.4
Living Liver donors: Number of men	16	0.4	1	0.1					25	0.5	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Living Lung donors: Number of men	0	0.0	0	0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

					DONAT	ION ACTI	VITY										
				LAT	IN AME	RICAN CO	UNTRIE	S									
Country	Guater	nala	Honduras	Mex	co	Nicarag	lua	Panama	a	Paragua	v	Peru		Urugua	v	Venezue	ela
Population (million inhabitants): UNFPA	17.	2	9.4	130	8	6.3		4.2		6.9		32.6		3.5		32.4	
		-	2.4					7.2		0.5		52.0		5.5		52.4	
					D	ONATION											
Actual deceased organ donors	Number	PMP	Number PI	IP Number	РМР	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	РМР
Actual deceased organ donors																	
-both DBD and DCD included-	5	0.3		534	4.1	1	0.2	27	6.4	13	1.9	65	2.0	77	22.0	0	0.0
Actual deceased donors: Number of men	3	0.2		354	2.7	1	0.2	16	3.8	5	0.7	40	1.2	44	12.6		
Actual deceased donors: Number of DD > 60 years	0	0.0		47	0.4	0	0.0	1	0.2	0	0.0	4	0.1	10	2.9		
Actual donors after circulatory death -DCD-	0	0.0		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
II/ Witnessed cardiac arrest (uncontrolled)																	
III/ Withdrawal of life-sustaining therapy (controlled)																	
IV/ Cardiac arrest while brain dead																	
Utilised deceased organ donors																	
-																	
Utilised deceased organ donors -both DBD and DCD included-	5	0.3		518	4.0	1	0.2	27	6.4	13	1.9	62	1.9	76	21.7	0	0.0
Utilised deceased donors: Number of men	3	0.2		347	2.7	1	0.2	16	3.8	5	0.7	37	1.1	44	12.6		
Utilised deceased donors: Number of DD > 60 years	0	0.0		39	0.3	0	0.0	1	0.2	0	0.0	4	0.1	9	2.6		
Utilised donors after circulatory death –DCD–	5	0.0		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
II/ Witnessed cardiac arrest (uncontrolled) III/ Withdrawal of life-sustaining therapy (controlled)																	
IV/ Cardiac arrest while brain dead																	
Living organ donors																	
Living Kidney donors: Number of men	61	3.5		1034	7.9	6	1.0	5	1.2	9	1.3	15	0.5	5	1.4		
Living Liver donors: Number of men	0	0.0		12	0.1	0	0.0	0	0.0	0	0.0	0	0.0				
Living Lung donors: Number of men	0	0.0		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		

						TRAN	ISPLANT	ATION	ACTIVIT	Y										
						EURO	PEAN UN		OUNTRIE	S										
Country Population (million inhabitants): UNFPA	Aust 8.8		Belgi 11		Bulg 7.	.0	Croa 4.2 TRANSPL	2	Cypr 1.2		Czech Re 10.0		Denm 5.8		Estor 1.3		Finla 5.5		Fran 65.	
	Number	PMP	Number	РМР	Number		Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP
KIDNEY Total Tx -all combinations included- Kidney tx: Number of men Paediatric <18 years	414 294 14 344 35 334 10 70 68 2	47.0 33.4 1.6 39.1 4.0 38.0 1.1 8.0 7.7 0.2	531 341 14 474 98 474 0 57 56 1	46.2 29.7 1.2 41.2 8.5 41.2 0.0 5.0 4.9 0.1	25 20 0 20 0 20 0 5 5 0	3.6 2.9 0.0 2.9 0.0 2.9 0.0 0.7 0.7 0.7	183 0 178 0 178 0 5 5 5 0	43.6 0.0 42.4 0.0 42.4 0.0 1.2 1.2 1.2 0.0	19 14 0 4 15 15 0	15.8 11.7 0.0 3.3 12.5 12.5 0.0	508 348 15 461 22 454 7 47 47 40 7	47.9 32.8 1.4 43.5 2.1 42.8 0.7 4.4 3.8 0.7	236 153 8 159 0 158 1 77 76 1 0 1 0	40.7 26.4 1.4 27.4 0.0 27.2 0.2 13.3 13.1 0.2 0.0 0.2 0.0	58 34 2 54 0 54 0 4 4 0	44.6 26.2 1.5 41.5 0.0 41.5 0.0 3.1 3.1 0.0	238 145 15 206 0 206 0 32 32 32 0	43.3 26.4 2.7 37.5 0.0 37.5 0.0 5.8 5.8 0.0	3567 2240 95 3026 244 2988 38 541 541 0	54.7 34.4 1.5 46.4 3.7 45.8 0.6 8.3 8.3 0.0
LIVER Total Tx –all combinations included– Liver tx: Number of men Paediatric <18 years	182 134 12 4 0 7 8	20.7 15.2 1.4 0.5 0.0 0.8 0.9	308 217 42 9 0 33 73	26.8 18.9 3.7 0.8 0.0 2.9 6.3	13 0 4 0 2 0	1.9 0.0 0.6 0.0 0.0 0.3 0.0	133 0 0 1 0	31.7 0.0 0.0 0.2 0.0	0	0.0	216 125 13 11 0 0 1	20.4 11.8 1.2 1.0 0.0 0.0 0.1	43 12 5 0 0 0 0	7.4 2.1 0.9 0.0 0.0 0.0 0.0	10 7 0 0 0 0 0	7.7 5.4 0.0 0.0 0.0 0.0 0.0	66 28 8 0 0 0 0	12.0 5.1 1.5 0.0 0.0 0.0 0.0	1325 934 82 75 6 14 48	20.3 14.3 1.3 1.2 0.1 0.2 0.7
HEART Total Tx –all combinations included– Heart tx: Number of men Paediatric <18 years	65 52 7	7.4 5.9 0.8	76 2	6.6 0.2	4 4 0	0.6 0.6 0.0	37	8.8	0	0.0	74 53 2	7.0 5.0 0.2	26 21 1	4.5 3.6 0.2	0	0.0	47 31 9	8.5 5.6 1.6	459 309 34	7.0 4.7 0.5
HEART-LUNG Total Tx Paediatric <18 years	0	0.0	2 0	0.2 0.0	0	0.0	0	0.0	0	0.0	1 0	0.1 0.0	0	0.0	0	0.0	0	0.0	9 1	0.1 0.0
LUNG Total Tx -all combinations included- Lung Tx: Number of men Paediatric <18 years Single Tx Double Tx (heart-lung Tx included) Tx from DCD (double + single)	117 72 2 5 112 9	13.3 8.2 0.2 0.6 12.7 1.0	116 0 4 112 30	10.1 0.0 0.0 0.3 9.7 2.6	0	0.0	0	0.0	0	0.0	42 24 1 3 39 0	4.0 2.3 0.1 0.3 3.7 0.0	25 14 0 1 24 0	4.3 2.4 0.0 0.2 4.1 0.0	4 2 0 1 3 0	3.1 1.5 0.0 0.8 2.3 0.0	18 11 0 0 18 0	3.3 2.0 0.0 0.0 3.3 0.0	382 213 11 35 347 10	5.9 3.3 0.2 0.5 5.3 0.2
PANCREAS Total Tx –all combinations included– Pancreas Tx: Number of men Paediatric <18 years Pancreas Tx Alone Kidney – Pancreas Tx Tx from DCD	20 16 0 1 19 1	2.3 1.8 0.0 0.1 2.2 0.1	16 57 0 2 14 2	1.4 5.0 0.0 0.2 1.2 0.2	0	0.0	0	0.0	0	0.0	43 24 0 7 36 0	4.1 2.3 0.0 0.7 3.4 0.0	5 5 0 1 4 0	0.9 0.9 0.0 0.2 0.7 0.0	2 0 0 0 2 0	1.5 0.0 0.0 0.0 1.5 0.0	23 13 0 0 23 0	4.2 2.4 0.0 0.0 4.2 0.0	78 44 0 13 65 0	1.2 0.7 0.0 0.2 1.0 0.0
SMALL BOWEL Total Tx -all combinations included- Small bowel Tx: Number of men Paediatric <18 years Small bowel Tx Alone	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1 0 0 0	0.1 0.0 0.0 0.0	0	0.0	0	0.0	0	0.0	3 1 1 1	0.0 0.0 0.0 0.0
RECIPIENTS Total number of patients transplanted Patients transplanted: Number of men Paediatric <18 years Patients transplanted from living donors	772 548 29 77	87.7 62.3 3.3 8.8	1021 665 54 90	88.8 57.8 4.7 7.8	42 34 4 7	6.0 4.9 0.6 1.0	351 6	83.6 1.4	19 14 0 15	15.8 11.7 0.0 12.5	884 574 0 47	83.4 54.2 0.0 4.4	329 200 13 77	56.7 34.5 2.2 13.3	72 43 2 4	55.4 33.1 1.5 3.1	367 231 32 32	66.7 42.0 5.8 5.8	5591 213 555	85.8 3.3 8.5

					TRA	NSPLA	NTATION	ACTIVI	ТҮ									
					EUR	OPEAN	UNION C	OUNTR	IES									
Country Population (million inhabitants): UNFPA	Germ 82.		Greed 11.1		Hung 9.7		Irela 4.8		Ital 59.		Latvi 1.9		Lithua 2.9		Luxeml 0.6		Mal 0.4	
							SPLANTA			5								
	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	РМР
KIDNEY Total Tx -all combinations included- Kidney tx: Number of men Paediatric <18 years	2291 1436 107 1653 0 1635 18 638 629 9	27.8 17.4 1.3 20.1 0.0 19.9 0.2 7.8 7.6 0.1	141 100 2 72 0 72 0 69 69 0	12.7 9.0 0.2 6.5 0.0 6.5 0.0 6.2 6.2 0.0	335 209 15 290 0 290 0 45 45 0	34.5 21.5 1.5 29.9 0.0 29.9 0.0 4.6 4.6 0.0	167 116 7 127 6 120 1 40	34.8 24.2 1.5 26.5 1.3 25.0 0.2 8.3	2124 1383 75 1831 63 1705 126 293 275 18 15 3 0	35.8 23.3 1.3 30.9 1.1 28.8 2.1 4.9 4.6 0.3 0.3 0.1 0.0	53 34 0 39 1 39 0 14 11 3 2 1 0	$\begin{array}{c} 27.9 \\ 17.9 \\ 0.0 \\ 20.5 \\ 0.5 \\ 20.5 \\ 0.0 \\ 7.4 \\ 5.8 \\ 1.6 \\ 1.1 \\ 0.5 \\ 0.0 \end{array}$	84 47 2 73 0 72 1 11	29.0 16.2 0.7 25.2 0.0 24.8 0.3 3.8	0	0.0	19 16 0 15 0 15 0 4 4 0	47.5 40.0 0.0 37.5 0.0 37.5 0.0 10.0 10.0 10.0 0.0
LIVER Total Tx -all combinations included- Liver tx: Number of men Paediatric <18 years Split Tx Domino Tx Tx from living donors Tx from DCD	877 575 102 74 5 52 0	10.7 7.0 1.2 0.9 0.1 0.6 0.0	23 16 0 0 0 0 0	2.1 1.4 0.0 0.0 0.0 0.0 0.0	80 49 5 0 0 0	8.2 5.1 0.5 0.0 0.0 0.0 0.0	56 32 1 0 0 0	11.7 6.7 0.2 0.0 0.0 0.0 0.0	1246 931 91 64 0 25 34	21.0 15.7 1.5 1.1 0.0 0.4 0.6	6 6 0 0 0 6 0	3.2 3.2 0.0 0.0 0.0 3.2 0.0	19 14 0 0 0 0 0	6.6 4.8 0.0 0.0 0.0 0.0 0.0	0	0.0	0	0.0
HEART Total Tx –all combinations included– Heart tx: Number of men Paediatric <18 years	318 232 42	3.9 2.8 0.5	8 3 1	0.7 0.3 0.1	62 44 4	6.4 4.5 0.4	18 15 0	3.8 3.1 0.0	233 172 20	3.9 2.9 0.3	3 2 0	1.6 1.1 0.0	10 9 2	3.4 3.1 0.7	0	0.0	0	0.0
HEART-LUNG Total Tx Paediatric <18 years	2 0	0.0 0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LUNG Total Tx -all combinations included- Lung Tx: Number of men Paediatric <18 years Single Tx Double Tx (heart-lung Tx included) Tx from DCD (double + single)	375 199 14 54 321 0	4.6 2.4 0.2 0.7 3.9 0.0	0	0.0	23 9 1 0 23 0	2.4 0.9 0.1 0.0 2.4 0.0	28 21 0 16 12 0	5.8 4.4 0.0 3.3 2.5 0.0	144 98 10 19 125 3	2.4 1.7 0.2 0.3 2.1 0.1	0	0.0	0	0.0	0	0.0	0	0.0
PANCREAS Total Tx -all combinations included– Pancreas Tx: Number of men Paediatric <18 years Pancreas Tx Alone Kidney – Pancreas Tx Tx from DCD	95 47 1 6 84 0	1.2 0.6 0.0 0.1 1.0 0.0	0	0.0	5 4 0 0 5 0	0.5 0.4 0.0 0.0 0.5 0.0	5 2 0 5 0	1.0 0.4 0.0 0.0 1.0 0.0	41 23 0 9 32 0	0.7 0.4 0.0 0.2 0.5 0.0	1 0 0 1 0	0.5 0.0 0.0 0.0 0.5 0.0	0	0.0	0	0.0	0	0.0
SMALL BOWEL Total Tx –all combinations included– Small bowel Tx: Number of men Paediatric <18 years Small bowel Tx Alone	3 1 0	0.0 0.0 0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
RECIPIENTS Total number of patients transplanted Patients transplanted: Number of men Paediatric <18 years Patients transplanted from living donors	3830 2429 260 690	46.5 29.5 3.2 8.4	172 119 3 69	15.5 10.7 0.3 6.2	497 310 25 45	51.2 32.0 2.6 4.6	269 186 8 40	56.0 38.8 1.7 8.3	3675 2539 186 318	62.0 42.8 3.1 5.4	62 42 0 14	32.6 22.1 0.0 7.4	113 70 11	39.0 24.1 3.8	0 0 0 0	0.0 0.0 0.0 0.0	19 16 0 4	47.5 40.0 0.0 10.0

					TRA	NSPLA	NTATION	ACTIVI	ТҮ									
					EUR	OPEAN	UNION C	OUNTR	IES									
Country Population (million inhabitants): UNFPA	Nether 17.		Pola 38.1		Port 10.	3	Roma 19.	6	Slova 5.4		Slov 2.1	enia	Spa 46.		Swee 10		United K 66	
	1		1		1		SPLANTA		1		1		1		1		1	
KIDNEY Total Tx - all combinations included- Kidney tx: Number of men Paediatric <18 years Tx from DD - Tx from DCD - Single Tx - Double Tx Tx from living donors - Tx from urelated living donors	Number 998 648 28 488 296 480 8 510 421 89	58.4 37.9 1.6 28.5 17.3 28.1 0.5 29.8 24.6 5.2	Number 946 606 41 906 7 906 0 40 40 0	PMP 24.8 15.9 1.1 23.8 0.2 23.8 0.0 1.0 0.0	Number 502 321 9 443 46 409 34 59 53 6 6 6 6 0 0	PMP 48.7 31.2 0.9 43.0 4.5 39.7 3.3 5.7 5.1 0.6 0.6 0.0 0.0	Number 183 5 119 0 119 0 64 64 0	PMP 9.3 0.3 6.1 0.0 6.1 0.0 3.3 3.3 0.0	Number 146 88 2 135 0 135 0 111 11 0	PMP 27.0 16.3 0.4 25.0 0.0 25.0 0.0 2.0 2.0 0.0 0.0	Number 56 35 0 54 0 54 0 2 2 0	PMP 26.7 16.7 0.0 25.7 0.0 25.7 0.0 1.0 1.0 1.0 0.0	Number 3313 2130 79 3020 856 3013 7 293 275 18 13 5 0	PMP 71.4 45.9 1.7 65.1 18.4 64.9 0.2 6.3 5.9 0.4 0.3 0.1 0.0	Number 448 289 18 304 17 302 2 144 139 5 3 2 0	PMP 44.8 28.9 1.8 30.4 1.7 30.2 0.2 14.4 13.9 0.5 0.3 0.2 0.0	Number 3642 2286 139 2608 989 2579 29 1034 820 214 146 68 0	PMP 54.7 34.3 2.1 39.2 14.8 38.7 0.4 15.5 12.3 3.2 2.2 1.0 0.0
LIVER Total Tx -all combinations included- Liver tx: Number of men Paediatric <18 years Split Tx Domino Tx Tx from living donors Tx from DCD	195 127 27 7 0 12 69	11.4 7.4 1.6 0.4 0.0 0.7 4.0	316 182 32 0 0 22 0	8.3 4.8 0.8 0.0 0.0 0.0 0.6 0.0	232 163 9 1 12 1 0	22.5 15.8 0.9 0.1 1.2 0.1 0.0	69 2 0 11 0	3.5 0.1 0.0 0.0 0.6 0.0	37 22 0 0 0 0 0	6.9 4.1 0.0 0.0 0.0 0.0 0.0	27 16 0 0 0 0	12.9 7.6 0.0 0.0 0.0 0.0 0.0	1230 914 66 12 1 23 196	26.5 19.7 1.4 0.3 0.0 0.5 4.2	163 108 11 6 0 1 0	16.3 10.8 1.1 0.6 0.0 0.1 0.0	1068 662 105 96 1 19 194	16.0 9.9 1.6 1.4 0.0 0.3 2.9
HEART Total Tx –all combinations included– Heart tx: Number of men Paediatric <18 years	38 25 9	2.2 1.5 0.5	147 105 7	3.9 2.8 0.2	33 21 3	3.2 2.0 0.3	7	0.4 0.1	18 14 1	3.3 2.6 0.2	23 18 1	11.0 8.6 0.5	321 228 36	6.9 4.9 0.8	66 48 6	6.6 4.8 0.6	194 123 38	2.9 1.8 0.6
HEART-LUNG Total Tx Paediatric <18 years	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2 0	0.0 0.0	0	0.0	6 2	0.1 0.0
LUNG Total Tx –all combinations included– Lung Tx: Number of men Paediatric -118 years Single Tx Double Tx (heart–lung Tx included) Tx from DCD (double + single)	89 59 9 80 30	5.2 3.5 0.5 4.7 1.8	43 29 2 8 35 0	1.1 0.8 0.1 0.2 0.9 0.0	27 16 1 4 23 0	2.6 1.6 0.1 0.4 2.2 0.0	4 0 0 4 0	0.2 0.0 0.0 0.2 0.0	0	0.0	0	0.0	369 222 7 106 263 64	8.0 4.8 0.2 2.3 5.7 1.4	74 38 2 11 63 1	7.4 3.8 0.2 1.1 6.3 0.1	189 102 6 15 174 38	2.8 1.5 0.1 0.2 2.6 0.6
PANCREAS Total Tx -all combinations included- Pancreas Tx: Number of men Paediatric <18 years Pancreas Tx Alone Kidney - Pancreas Tx Tx from DCD	36 23 1 14 20 19	2.1 1.3 0.1 0.8 1.2 1.1	20 12 0 1 19 0	0.5 0.3 0.0 0.0 0.5 0.0	35 21 0 2 33 0	3.4 2.0 0.0 0.2 3.2 0.0	0	0.0	0	0.0	3 0 0 3 0	1.4 0.0 0.0 1.4 0.0	82 39 2 10 68 4	1.8 0.8 0.0 0.2 1.5 0.1	18 12 1 6 12 0	1.8 1.2 0.1 0.6 1.2 0.0	217 124 4 20 174 58	3.3 1.9 0.1 0.3 2.6 0.9
SMALL BOWEL Total Tx –all combinations included– Small bowel Tx: Number of men Paediatric <18 years Small bowel Tx Alone	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6 2 2 2	0.1 0.0 0.0 0.0	2 2 1 0	0.2 0.2 0.1 0.0	25 16 5 2	0.4 0.2 0.1 0.0
RECIPIENTS Total number of patients transplanted Patients transplanted: Number of men Paediatric <18 years Patients transplanted from living donors	1336 868 50 522	78.1 50.8 2.9 30.5	1447 917 82 62	38.0 24.1 2.2 1.6	783 512 22 60	76.0 49.7 2.1 5.8	263 9 75	13.4 0.5 3.8	201 124 3 11	37.2 23.0 0.6 2.0	106 69 1 2	50.5 32.9 0.5 1.0	5196 3462 188 316	112.0 74.6 4.1 6.8	753 483 36 145	75.3 48.3 3.6 14.5	5122 3190 283 1053	76.9 47.9 4.2 15.8

							TRAN	SPLAN		IVITY													
							(OTHEF		5													
Country	Alg	eria	Arme	nia	Austr	alia	Belai	rus	Bosnia and	Cana	da	Georg	gia	Icelar	d	India	a	Isra	ael	Kuv	vait	Mala	ysia
Population (million inhabitants): UNFPA	42	.0	2.9	,	24.	8	9.5	5	Herzegovina 3.5	37.0	D	3.9		0.3		1354.	.1	8.	5	4.	2	32	.0
	1						Т	RANS	PLANTATION											1			
	Number	PMP	Number	PMP	Numbe	r PMP	Numbe	r PMP	Number PMP	Number	PMP	Number	РМР	Number	РМР	Number	PMP	Number	r PMP	Number	PMP	Number	r PMP
KIDNEY Total Tx -all combinations included- Kidney tx: Number of men Paediatric <18 years	268 153 11 0 0 0 0 268 268 268 0	6.4 3.6 0.3 0.0 0.0 0.0 6.4 6.4 0.0	12 5 1 0 12 12 12 0	4.1 1.7 0.3 0.0 4.1 4.1 4.1 0.0	1135 715 45 897 249 872 25 238 192 46 40 6	45.8 28.8 1.8 36.2 10.0 35.2 1.0 9.6 7.7 1.9 1.6 0.2	356 170 21 350 0 350 0 6 6 0	37.5 17.9 2.2 36.8 0.0 36.8 0.0 0.6 0.6 0.0		1706 50 1219 357 1204 15 487 250 237	46.1 1.4 32.9 9.6 32.5 0.4 13.2 6.8 6.4	17 10 1 0 0 0 0 17	4.4 2.6 0.3 0.0 0.0 0.0 0.0 4.4	9 8 1 0 9 9 9 0	30.0 26.7 3.3 0.0 30.0 30.0 0.0	7936 50 1164 5 1111 53 6772 5205 1567	5.9 0.0 0.9 0.0 0.8 0.0 5.0 3.8 1.2	401 273 27 170 4 165 5 231 105 126 25 17 84	47.2 32.1 3.2 20.0 0.5 19.4 0.6 27.2 12.4 14.8 2.9 2.0 9.9	70 49 3 19 0 19 0 51 27 24 0 0 24	16.7 11.7 0.7 4.5 0.0 4.5 0.0 12.1 6.4 5.7 0.0 0.0 5.7	80 41 5 12 0 12 0 68 68 68 0	2.5 1.3 0.2 0.4 0.0 0.4 0.0 2.1 2.1 0.0
LIVER Total Tx –all combinations included– Liver tx: Number of men Paediatric <18 years Split Tx Domino Tx Tx from living donors Tx from DCD	7 4 0 0 0 7 0	0.2 0.1 0.0 0.0 0.0 0.2 0.0	0	0.0	320 203 43 0 0 21	12.9 8.2 1.7 0.0 0.0 0.8	80 47 7 0 0 6 0	8.4 4.9 0.7 0.0 0.0 0.6 0.0		536 42 8 69 41	14.5 1.1 0.2 1.9 1.1	13 9 0 0 13	3.3 2.3 0.0 0.0 3.3	0	0.0	1945 99 5 1 1313 0	1.4 0.1 0.0 0.0 1.0 0.0	117 73 20 4 0 17 0	13.8 8.6 2.4 0.5 0.0 2.0 0.0	4 3 0 0 0 0 0 0	1.0 0.7 0.0 0.0 0.0 0.0 0.0	4 1 0 0 0 1 0	0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
HEART Total Tx –all combinations included– Heart tx: Number of men Paediatric <18 years	0	0.0	0	0.0	128 87 11	5.2 3.5 0.4	41 32 0	4.3 3.4 0.0		193 22	5.2 0.6	0	0.0	0	0.0	241 17	0.2 0.0	26 14 2	3.1 1.6 0.2	0	0.0	1 0 0	0.0 0.0 0.0
HEART-LUNG Total Tx Paediatric <18 years	0	0.0			7 1	0.3 0.0	0	0.0				0	0.0			44 0	0.0 0.0	0	0.0	0	0.0	0	0.0
LUNG Total Tx -all combinations included- Lung Tx: Number of men Paediatric <18 years Single Tx Double Tx (heart-lung Tx included) Tx from DCD (double + single)	0	0.0	0	0.0	221 133 5 22 199 56	8.9 5.4 0.2 0.9 8.0 2.3	4 2 0 0 4 0	0.4 0.2 0.0 0.0 0.4 0.0		361 5 37 324 83	9.8 0.1 1.0 8.8 2.2	0	0.0	0	0.0	191 4 5 186 0	0.1 0.0 0.0 0.1 0.0	56 43 1 12 44 0	6.6 5.1 0.1 1.4 5.2 0.0	0	0.0	0	0.0
PANCREAS Total Tx –all combinations included– Pancreas Tx: Number of men Paediatric <18 years Pancreas Tx Alone Kidney – Pancreas Tx Tx from DCD	0	0.0	0	0.0	52 30 0 4 47 2	2.1 1.2 0.0 0.2 1.9 0.1	1 1 0 1 0	0.1 0.1 0.0 0.0 0.1 0.0		57 0 9 48 5	1.5 0.0 0.2 1.3 0.1	0	0.0	0	0.0	25 0 11 14 0	0.0 0.0 0.0 0.0 0.0	8 4 0 1 7 0	0.9 0.5 0.0 0.1 0.8 0.0	0	0.0	0	0.0
SMALL BOWEL Total Tx -all combinations included- Small bowel Tx: Number of men Paediatric <18 years Small bowel Tx Alone	0	0.0	0	0.0	1 1 1 0	0.0 0.0 0.0 0.0	0	0.0				0	0.0	0	0.0	2 0 0	0.0 0.0 0.0	1 0 0 1	0.1 0.0 0.0 0.1	0	0.0	0	0.0
RECIPIENTS Total number of patients transplanted Patients transplanted: Number of men Paediatric <18 years Patients transplanted from living donors	275 157 11 275	6.5 3.7 0.3 6.5	12 5 1 12	4.1 1.7 0.3 4.1	1780 454 62 236	71.8 18.3 2.5 9.5	482 252 28 12	50.7 26.5 2.9 1.3		2826 127 556	76.4 3.4 15.0	30 19 1 30	7.7 4.9 0.3 7.7	9 8 1 9	30.0 26.7 3.3 30.0	10282 170 8085	7.6 0.1 6.0	592 398 50 248	69.6 46.8 5.9 29.2	74 52 3 51	17.6 12.4 0.7 12.1	85 42 5 69	2.7 1.3 0.2 2.2

							TR	ANSP	LANTA	TION	ΑϹΤΙVΙΊ	ſY												
								ОТ	HER CO	DUNT	RIES													
Country	New Z	ealand	Nor	way	Qa	tar	Repub Mold			sian ation	Saudi A	rabia	Sud	an	Switze	rland	Syrian Repu		The R of No of Mace	rṫh	Turk	ey	Stat	ited es of erica
Population (million inhabitants): UNFPA	4.	7	5.	.4	2.	7	4.0	0	14	4.0	33.	.6	41.	.5	8.5	5	18.	3	2.1		81.	9		6.8
								TR	ANSPL	ANTAT	ION													
	Numbe	r PMP	Numbe	r PMP	Number	РМР	Number	РМР	Numbe	r PMP	Number	РМР	Number	РМР	Number	РМР	Number	РМР	Number	РМР	Number	РМР	Numbe	r PMP
KIDNEY Total Tx -all combinations included- Kidney tx: Number of men Paediatric <18 years	182 114 6 98 15 97 1 84 69 15	38.7 24.3 1.3 20.9 3.2 20.6 0.2 17.9 14.7 3.2	240 137 5 168 0 166 2 72 72 0	45.3 25.8 0.9 31.7 0.0 31.3 0.4 13.6 13.6 0.0	43 29 1 11 0 10 1 32 32 0	15.9 10.7 0.4 4.1 0.0 3.7 0.4 11.9 11.9 0.0	13 7 0 7 0 6 6 6 0	3.2 1.7 0.0 1.7 0.0 1.5 1.5 0.0	1361 754 86 1161 65 1161 0 200 200 0	9.5 5.2 0.6 8.1 0.5 8.1 0.0 1.4 1.4 0.0	1006 87 141 0 136 5 865 701 164 52 5 107	29.9 2.6 4.2 0.0 4.0 0.1 25.7 20.9 4.9 1.5 0.1 3.2	273 198 29 0 0 0 0 273 269 4 4 0 0	6.6 4.8 0.7 0.0 0.0 0.0 0.0 6.6 6.5 0.1 0.1 0.0 0.0	352 227 15 239 37 228 11 113	41.4 26.7 1.8 28.1 4.4 26.8 1.3 13.3	251 27 0 0 0 251 123 128 0 0 128	13.7 1.5 0.0 0.0 0.0 13.7 6.7 7.0 0.0 0.0 7.0	17 2 0 15 15 0	8.1 1.0 0.0 7.1 7.1 0.0	3874 2485 224 859 0 819 40 3015 2550 465 181 0 0	47.3 30.3 2.7 10.5 0.0 10.0 0.5 36.8 31.1 5.7 2.2 0.0 0.0	22003 1382 756 15561 3302 15245 316 6442 5121 1321 933 382 6	67.3 4.2 2.3 47.6 10.1 46.6 1.0 19.7 15.7 4.0 2.9 1.2 0.0
LIVER Total Tx -all combinations included- Liver tx: Number of men Paediatric <18 years Split Tx Domino Tx Tx from living donors Tx from DCD	49 27 8 9 0 2 1	10.4 5.7 1.7 1.9 0.0 0.4 0.2	95 57 13 6 0 1	17.9 10.8 2.5 1.1 0.0 0.2 0.0	8 5 0 0 0 3 0	3.0 1.9 0.0 0.0 0.0 1.1 0.0	11 8 5 0 0 5 0	2.7 2.0 1.2 0.0 0.0 1.2 0.0	505 247 133 22 0 163 0	3.5 1.7 0.9 0.2 0.0 1.1 0.0	270 102 12 1 207 0	8.0 3.0 0.4 0.0 6.2 0.0	0	0.0	156 112 10 0 7 21	18.4 13.2 1.4 1.2 0.0 0.8 2.5	0	0.0	0	0.0	1587 1041 265 22 6 1143 0	19.4 12.7 3.2 0.3 0.1 14.0 0.0	8250 5278 563 199 9 392 535	25.2 16.2 1.7 0.6 0.0 1.2 1.6
HEART Total Tx -all combinations included- Heart tx: Number of men Paediatric <18 years	20 14 2	4.3 3.0 0.4	29 15 5	5.5 2.8 0.9	0	0.0	0	0.0	285 248 9	2.0 1.7 0.1	27 20 4	0.8 0.6 0.1	0	0.0	50 36 6	5.9 4.2 0.7	0	0.0	0	0.0	91 66 17	1.1 0.8 0.2	3440 2397 473	10.5 7.3 1.4
HEART-LUNG Total Tx Paediatric <18 years	0	0.0	0	0.0	0	0.0	0	0.0	3 0	0.0 0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	32 5	0.1 0.0
LUNG Total Tx -all combinations included- Lung Tx: Number of men Paediatric <18 years Single Tx Double Tx (heart-lung Tx included) Tx from DCD (double + single)	28 16 0 1 27 2	6.0 3.4 0.0 0.2 5.7 0.4	30 17 1 0 30 0	5.7 3.2 0.2 0.0 5.7 0.0	0	0.0	0	0.0	28 19 2 3 25 0	0.2 0.1 0.0 0.0 0.2 0.0	35 21 3 2 33 0	1.0 0.6 0.1 0.1 1.0 0.0	0	0.0	42 29 1 2 40 4	4.9 3.4 0.1 0.2 4.7 0.5	0	0.0	0	0.0	43 31 0 0 43 0	0.5 0.4 0.0 0.0 0.5 0.0	2562 1531 40 640 1922 121	7.8 4.7 0.1 2.0 5.9 0.4
PANCREAS Total Tx -all combinations included- Pancreas Tx: Number of men Paediatric <18 years Pancreas Tx Alone Kidney – Pancreas Tx Tx from DCD	6 2 0 0 6 0	1.3 0.4 0.0 0.0 1.3 0.0	15 3 0 8 7 0	2.8 0.6 0.0 1.5 1.3 0.0	0	0.0	0	0.0	17 8 0 1 16 0	0.1 0.0 0.0 0.1 0.0	8 3 0 0 8 0	0.2 0.1 0.0 0.0 0.2 0.0	0	0.0	11 8 0 3 8 0	1.3 0.9 0.0 0.4 0.9 0.0	0	0.0	0	0.0	4 1 0 4 0 0	0.0 0.0 0.0 0.0 0.0 0.0	1027 614 32 191 836 25	3.1 1.9 0.1 0.6 2.6 0.1
SMALL BOWEL Total Tx -all combinations included- Small bowel Tx: Number of men Paediatric <18 years Small bowel Tx Alone	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4 2 0 4	0.1 0.1 0.0 0.1			0	0.0	0	0.0	0	0.0	0	0.0	104 60 37 37	0.3 0.2 0.1 0.1
RECIPIENTS Total number of patients transplanted Patients transplanted: Number of men Paediatric <18 years Patients transplanted from living donors	276 16 86	58.7 3.4 18.3	400 226 24 73.0	75.5 42.6 4.5 13.8	51 34 1 35	18.9 12.6 0.4 13.0	24 15 1 11	5.9 3.7 0.2 2.7	2177 1262 230 363	15.1 8.8 1.6 2.5	1341 195 1072	39.9 5.8 31.9	273 198 29 273	6.6 4.8 0.7 6.6	599 402 34 120	70.5 47.3 4.0 14.1	251 27 251	13.7 1.5 13.7	17 15	8.1 7.1	5599 3624 506 4164	68.4 44.2 6.2 50.8	35274 21825 1796 6842	107.9 66.8 5.5 20.9

						TRAN	SPLANT	ATION	ΑCTIVIT	(
						LATIN	AMERIC	AN CO	UNTRIES	5										
Country	Argen	tina	Boliv	/ia	Bra	azil	Chil	e	Colom	bia	Costa F	Rica	Cub	a	Domini		Ecuad	lor	El Salva	ador
Population (million inhabitants): UNFPA	44.	7	11.	2	21	0.9	18.	2	49.	5	5.0		11.	5	Repub 10.9		16.9	9	6.4	ł.
							TRANSPL	ANTA	TION											
KIDNEY	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	PMP	Number	РМР
Total Tx –all combinations included– Kidney tx: Number of men Paediatric <18 years Tx from DD - Tx from DCD - Single Tx - Double Tx Tx from living donors - Tx from related living donors - Tx from unrelated living donors Paired exchange or cross–over Non–directed altruistic or anonymous Directed altruistic	1475 850 155 1099 0 1099 0 376 376 0	33.0 19.0 3.5 24.6 0.0 24.6 0.0 8.4 8.4 0.0	76 36 4 8 0 8 0 68 68 68 0	6.8 3.0 0.4 0.7 0.0 0.7 0.0 6.1 6.1 0.0	5975 3621 337 4942 0 4932 10 1033 981 52	28.3 17.2 1.6 23.4 0.0 23.4 0.0 4.9 4.7 0.2	212	11.6	864 502 55 724 0 709 15 140 140 0	17.5 10.1 14.6 0.0 14.3 0.3 2.8 2.8 0.0	63 38 2 42 21	12.6 7.6 0.4 8.4 4.2	173 4 160 0 160 0 13 13 0	15.0 0.3 13.9 0.0 13.9 0.0 1.1 1.1 0.0	54 34 0 13 0 13 41 28 13	5.0 3.1 0.0 1.2 0.0 0.0 1.2 3.8 2.6 1.2	249 145 22 227 0 227 0 227 0 22 22 0	14.7 8.6 1.3 13.4 0.0 13.4 0.0 1.3 1.3 0.0	34 22 1 0 34	5.3 3.4 0.2 0.0
LIVER Total Tx -all combinations included- Liver tx: Number of men Paediatric <18 years Split Tx Domino Tx Tx from living donors Tx from DCD	473 276 97 55 0 41 0	10.6 6.2 2.2 1.2 0.0 0.9 0.0	1 0 0 0 1 0	0.1 0.0 0.0 0.0 0.0 0.1 0.0	2221 1491 239 6 6 175 0	10.5 7.1 1.1 0.0 0.0 0.8 0.0	87	4.8	251 132 71 0 50 0	5.1 2.7 1.4 0.0 1.0 0.0	27 14 6 1 0 2 0	5.4 2.8 1.2 0.2 0.0 0.4 0.0	13 1 0 0 1 0	1.1 0.1 0.0 0.0 0.1 0.0	3 3 0 0 0 0	0.3 0.3 0.0 0.0 0.0 0.0	29 20 2 0	1.7 1.2 0.1 0.0	0	0.0
HEART Total Tx –all combinations included– Heart tx: Number of men Paediatric <18 years	132 86 15	3.0 1.9 0.3	0	0.0	358 234 39	1.7 1.1 0.2	30	1.6	57 47 3	1.2 0.9 0.1	8 6 0	1.6 1.2 0.0	0	0.0	0	0.0	0	0.0	0	0.0
HEART-LUNG Total Tx Paediatric <18 years	1 0	0.0 0.0	0	0.0	0	0.0			0	0.0	2 0	0.4 0.0	0	0.0	0	0.0	0	0.0	0	0.0
LUNG Total Tx -all combinations included- Lung Tx: Number of men Paediatric <18 years Single Tx Double Tx (heart-lung Tx included) Tx from DCD (double + single)	44 26 4 19 25 0	1.0 0.6 0.1 0.4 0.6 0.0	0	0.0	121 65 12 46 73 0	0.6 0.3 0.1 0.2 0.3 0.0	13	0.7	17 5 1 7 10 0	0.3 0.1 0.0 0.1 0.2 0.0	2 0 0 2 0	0.4 0.0 0.0 0.0 0.4 0.0	0	0.0	0	0.0	1 0 0 1 0	0.1 0.0 0.0 0.0 0.1 0.0	0	0.0
PANCREAS Total Tx -all combinations included- Pancreas Tx: Number of men Paediatric <18 years Pancreas Tx Alone Kidney - Pancreas Tx Tx from DCD	89 32 0 5 84 0	2.0 0.7 0.0 0.1 1.9 0.0	0	0.0	150 62 0 44 106 0	0.7 0.3 0.0 0.2 0.5 0.0	7	0.4	10 4 0 2 8 0	0.2 0.1 0.0 0.0 0.2 0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SMALL BOWEL Total Tx -all combinations included- Small bowel Tx: Number of men Paediatric <18 years Small bowel Tx Alone	1 0 1 0	0.0 0.0 0.0 0.0	0	0.0	4 4 1 0	0.0 0.0 0.0 0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
RECIPIENTS Total number of patients transplanted Patients transplanted: Number of men Paediatric <18 years Patients transplanted from living donors	2102 1224 265 417	47.0 27.3 5.9 9.3	77 36 4 69	6.9 3.2 0.4 6.2	8642 3502 616 1192	41.0 16.6 2.9 5.7			1184 686 130 190	23.9 13.9 2.6 3.8	99 58 8 23	19.8 11.6 1.6 4.6	186 5 14	16.2 0.4 1.2	57 34 0 41	5.2 3.1 0.0 3.8	279 165 24 22	16.5 9.8 1.4 1.3	34 22 1 34	5.3 3.4 0.2 5.3

					TRA	NSPLA	NTATION	ACTIVI	ТҮ									
					LAT	IN AM	RICAN CO	DUNTRI	ES									
Country Population (million inhabitants): UNFPA	Guater 17.		Hondura 9.4	s	Mexi 130	.8	Nicara 6.3	-	Pana 4.2		Parag 6.9		Per 32.6		Urug 3.		Venez 32.	
	1						SPLANTA											
KIDNEY Total Tx –all combinations included– Kidney tx: Number of men Paediatric <18 years	Number 115 67 10 10 10 10 105 103 2	 PMP 6.7 3.9 0.6 0.0 0.6 0.0 0.6 0.0 6.1 6.0 0.1 	Number	PMP	Number 3081 1958 224 976 0 966 10 2105 1719 386	PMP 23.6 15.0 1.7 7.5 0.0 7.4 0.1 16.1 13.1 3.0	Number 16 1 0 1 0 15 15 0	PMP 2.5 0.2 0.0 0.2 0.0 2.4 2.4 2.4 0.0	Number 46 31 0 38 0 38 0 8 8 0	PMP 11.0 7.4 0.0 9.0 0.0 9.0 0.0 1.9 1.9 0.0	Number 41 33 4 25 0 16 16 16 0	 PMP 5.9 4.8 0.6 3.6 0.0 2.3 2.3 0.0 	Number 157 91 27 115 0 115 0 42 41 1	<pre>PMP 4.8 2.8 0.8 3.5 0.0 3.5 0.0 1.3 1.3 0.0</pre>	Number 161 100 7 148 0 13 13 0	PMP 46.0 28.6 2.0 42.3 0.0 3.7 3.7 0.0	Number 40 0 0 0 0 0 40	PMP 1.2 0.0 0.0 0.0 0.0 1.2
LIVER Total Tx –all combinations included– Liver tx: Number of men Paediatric <18 years Split Tx Domino Tx Tx from living donors Tx from DCD	0	0.0			241 138 37 0 17 0	1.8 1.1 0.3 0.0 0.1 0.0	0	0.0	16 11 0 0 0 0 0	3.8 2.6 0.0 0.0 0.0 0.0 0.0	3 0 0 0 0 0 0	0.4 0.0 0.0 0.0 0.0 0.0 0.0	45 26 13 3 0 5 0	1.4 0.8 0.4 0.1 0.0 0.2 0.0	25 13 3 0 0 2 0	7.1 3.7 0.9 0.0 0.0 0.6 0.0	0	0.0
HEART Total Tx –all combinations included– Heart tx: Number of men Paediatric <18 years	0	0.0			26 20 0	0.2 0.2 0.0	0	0.0	1 1 0	0.2 0.2 0.0	2 2 0	0.3 0.3 0.0	12 10 3	0.4 0.3 0.1	14 9 1	4.0 2.6 0.3	0	0.0
HEART-LUNG Total Tx Paediatric <18 years	0	0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LUNG Total Tx -all combinations included- Lung Tx: Number of men Paediatric <18 years Single Tx Double Tx (heart-lung Tx included) Tx from DCD (double + single)	0	0.0			3 3 0 2 1 0	0.0 0.0 0.0 0.0 0.0 0.0	0	0.0	0	0.0	0	0.0	4 2 0	0.1 0.1 0.0	5 2 0	1.4 0.6 0.0	0	0.0
PANCREAS Total Tx -all combinations included- Pancreas Tx: Number of men Paediatric <18 years Pancreas Tx Alone Kidney - Pancreas Tx Tx from DCD	0	0.0			1 1 0 0 0 0	0.0 0.0 0.0 0.0 0.0 0.0	0	0.0	0	0.0	0	0.0	2 2 0 0 2 0	0.1 0.1 0.0 0.0 0.1 0.0	0	0.0	0	0.0
SMALL BOWEL Total Tx -all combinations included- Small bowel Tx: Number of men Paediatric <18 years Small bowel Tx Alone	0	0.0			0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
RECIPIENTS Total number of patients transplanted Patients transplanted: Number of men Paediatric <18 years Patients transplanted from living donors	115 67 10 105	6.7 3.9 0.6 6.1					16 1 15	2.5 0.2 2.4	63 43 0 8	15.0 10.2 0.0 1.9	46 35 4 16	6.7 5.1 0.6 2.3	216 130 42 47	6.6 4.0 1.3 1.4	205 124 11 15	58.6 35.4 3.1 4.3	40 0 40	1.2 0.0 1.2

			WAITING L	IST						
		EUROP	EAN UNION	COUNTRIES						
Country Population (million inhabitants): UNFPA	Austria 8.8	Belgium 11.5	Bulgaria 7.0	Croatia 4.2	Cyprus 1.2	Czech Republic 10.6	Denmark 5.2	Estonia 1.3	Finland 5.5	France 65.2
KIDNEY										
N Tx CENTRES	5	8	3	4	1	7	3	1	1	44
Patients included on the WL for the first time in the course of 2018	508	607	148	171	12	480	276	46	273	5269
Total number of patients ever active on the WL during 2018	1036	1456	1052		62	799	881	111	787	19625
Patients awaiting for a transplant (only active candidates) on 31/12/2018	597	824	924	168	58	523	414	33	380	8065
Patients who died while on the WL during 2018	27	33	77	15	0	43	33	2	10	396
Patients on dialysIs on 31/12/2018			877	2500				410		
LIVER										
N Tx CENTRES	3	7	3	3	0	2	1	1	1	21
Patients included on the WL for the first time in the course of 2018	231	375	22	161	0	242	48	11	64	1883
Total number of patients ever active on the WL during 2018	299	576	68		0	105	80	15	77	3306
Patients awaiting for a transplant (only active candidates) on 31/12/2018	87	189	24	114	0	76	25	4	7	737
Patients who died while on the WL during 2018	20	35	13	30	0	10	3	1	0	193
HEART										
N TX CENTRES	3	7	2	2	0	2	2	0	1	24
Patients included on the WL for the first time in the course of 2018	68	99	31	62	0	87	31		42	626
Total number of patients ever active on the WL during 2018	137	202	60		0	138	52		85	941
Patients awaiting for a transplant (only active candidates) on 31/12/2018	60	111	28	38	0	82	14		27	256
Patients who died while on the WL during 2018	10	8	17	6	0	26	2		5	67
LUNG										
N Tx CENTRES	2	3	2	0	0	1	1	1	1	12
Patients included on the WL for the first time in the course of 2018	126	141	13	0	0	60	29	6	26	419
Total number of patients ever active on the WL during 2018	231	284	22	0	0	65	59	11	47	545
Patients awaiting for a transplant (only active candidates) on 31/12/2018	72	143	13	0	0	58	26	5	20	119
Patients who died while on the WL during 2018	9	6	7	0	0	15	3	0	6	14
PANCREAS										
N Tx CENTRES	3	8	1	1	0	1	1	1	1	12
Patients included on the WL for the first time in the course of 2018	21	34	0	7	0	50	8	4	28	103
Total number of patients ever active on the WL during 2018	31	95	11		0	49	15	6	43	339
Patients awaiting for a transplant (only active candidates) on 31/12/2018	10	57	11	11	0	33	7	2	15	106
Patients who died while on the WL during 2018	2	2	0	4	0	1	2	0	0	6
SMALL BOWEL										
N Tx CENTRES		10	1	1	0	1	0	0	1	5
Patients included on the WL for the first time in the course of 2018			0	0	0	3	0		0	2
Total number of patients ever active on the WL during 2018			0	0	0	2	0		0	6
Patients awaiting for a transplant (only active candidates) on 31/12/2018		6	0	0	0	1	0		0	2
Patients who died while on the WL during 2018			0	0	0	0	0		0	

			WAITING LIST						
		EUROPE	AN UNION CO	JNTRIES					
Country	Germany	Greece	Hungary	Ireland	Italy	Latvia	Lithuania	Luxembourg	Malta
Population (million inhabitants): UNFPA	82.3	11.1	9.7	4.8	59.3	1.9	2.9	0.6	0.4
KIDNEY									
N Tx CENTRES	38	5	4	1	40	1	2	0	1
Patients included on the WL for the first time in the course of 2018	2348	220	393	178	2330	59	99	0	10
Total number of patients ever active on the WL during 2018	10616	1354	1230	660	9059	82	201	0	92
Patients awaiting for a transplant (only active candidates) on 31/12/2018	7526	1246	818	429	6770	28	100	0	
Patients who died while on the WL during 2018	453	35	53	17	167	1	7	0	6
Patients on dialysIs on 31/12/2018		11843	6915	2124		650	1340	0	292
LIVER									
N Tx CENTRES	21	2	1	1	22	1	2	0	0
Patients included on the WL for the first time in the course of 2018	1177	70	81	63	1461	17	51	0	0
Total number of patients ever active on the WL during 2018	2387	218	181	98	2434	9	97	0	0
Patients awaiting for a transplant (only active candidates) on 31/12/2018	851	159	72	32	961	6	38	0	0
Patients who died while on the WL during 2018	289	21	12	6	129	3	22	0	0
HEART									
N Tx CENTRES	23	1	2	1	16	1	2	0	1
Patients included on the WL for the first time in the course of 2018	493	15	84	23	324	8	27	0	
Total number of patients ever active on the WL during 2018	1223	57	144	37	1047	8	70	0	
Patients awaiting for a transplant (only active candidates) on 31/12/2018	719	38	60	10	711	5	38	0	
Patients who died while on the WL during 2018	86	9	10	2	53	0	16	0	
LUNG									
N Tx CENTRES	15	0	1	1	11	0	1	0	0
Patients included on the WL for the first time in the course of 2018	391		30	43	214	0	4	0	0
Total number of patients ever active on the WL during 2018	799		42	85	562	0	14	0	0
Patients awaiting for a transplant (only active candidates) on 31/12/2018	314		10	32	362	0	6	0	0
Patients who died while on the WL during 2018	71		4	16	39	0	6	0	0
PANCREAS									
N Tx CENTRES	28	0	2	1	16	1	1	0	0
Patients included on the WL for the first time in the course of 2018	144		17	10	62		4	0	0
Total number of patients ever active on the WL during 2018	458		48	24	311	0	7	0	0
Patients awaiting for a transplant (only active candidates) on 31/12/2018	287		40	19	253	0	0	0	0
Patients who died while on the WL during 2018	36		0	1	0	0	0	0	0
SMALL BOWEL									
N Tx CENTRES	9	0	0		2	0	0	0	0
Patients included on the WL for the first time in the course of 2018			0	0	0	0		0	0
Total number of patients ever active on the WL during 2018			0	0	12	0		0	0
Patients awaiting for a transplant (only active candidates) on 31/12/2018	12		0	0	11	0		0	0
Patients who died while on the WL during 2018			0	0	0	0		0	0

		W	AITING LIST						
		EUROPEAN		ITRIES					
Country Population (million inhabitants): UNFPA	Netherlands 17.1	Poland 38.1	Portugal 10.3	Romania 19.6	Slovakia 5.4	Slovenia 2.1	Spain 46.4	Sweden 10.0	United Kingdom 66.6
KIDNEY									
N Tx CENTRES	10	21	8	5	4	1	40	4	24
Patients included on the WL for the first time in the course of 2018	1521	1178	323	523	154	79		408	2552
Total number of patients ever active on the WL during 2018	2194	2745	2342	5582	432	132	7246	1173	9072
Patients awaiting for a transplant (only active candidates) on 31/12/2018	741	1196	1968	5255	296	73	3933	423	5000
Patients who died while on the WL during 2018	66	73	41	13	29			31	283
Patients on dialysis on 31/12/2018		20000	13014	9900	3560		27629		2841
LIVER									
N Tx CENTRES	3	9	3	4	1	1	25	2	7
Patients included on the WL for the first time in the course of 2018	239	393	238	138	38	36	1374	168	334
Total number of patients ever active on the WL during 2018	372	626	323	610	64	54	1829	222	1692
Patients awaiting for a transplant (only active candidates) on 31/12/2018	127	158	113	573	22	19	386	42	407
Patients who died while on the WL during 2018	26	27	18	32	4	5	51	4	39
HEART									
N Tx CENTRES	3	6	4	3	1	1	16	2	7
Patients included on the WL for the first time in the course of 2018	57	326	47	29	24	39	363	75	159
Total number of patients ever active on the WL during 2018	164	946	71	214	51	81	475	113	603
Patients awaiting for a transplant (only active candidates) on 31/12/2018	121	453	27	15	33	48	126	31	309
Patients who died while on the WL during 2018	9	99	12	9	4	5	11	3	23
LUNG									
N Tx CENTRES	3	5	1	1	0		8	2	6
Patients included on the WL for the first time in the course of 2018	133	145	39	6	0		411	60	175
Total number of patients ever active on the WL during 2018	311	228	97	10	0		671	95	633
Patients awaiting for a transplant (only active candidates) on 31/12/2018	186	113	57	2	0		241	15	354
Patients who died while on the WL during 2018	12	22	6	0	0		25	0	63
PANCREAS									
N Tx CENTRES	2	1	2	0	1	1	13	4	10
Patients included on the WL for the first time in the course of 2018	42	44	33	0	0	3	107	26	163
Total number of patients ever active on the WL during 2018	89	107	77	0	0	5	210	38	478
Patients awaiting for a transplant (only active candidates) on 31/12/2018	41	47	28	0	0	1	98	16	185
Patients who died while on the WL during 2018	1	2	1	0	0		3	1	19
SMALL BOWEL									
N Tx CENTRES				0	0		3	1	4
Patients included on the WL for the first time in the course of 2018		1		0	0		4	2	0
Total number of patients ever active on the WL during 2018		2		0	0		16	3	41
Patients awaiting for a transplant (only active candidates) on 31/12/2018		1		0	0		9	1	10
Patients who died while on the WL during 2018		0		0	0		1	0	2

			WA	TING LIST								
			OTHEF		IES							
Country	Algeria	Armenia	Australia	Belarus	Bosnia and Herzegovina	Canada	Georgia	Iceland	India	Israel	Kuwait	Malaysia
Population (million inhabitants): UNFPA	42.0	2.9	24.8	9.5		37.0	3.9	0.3	1354.1	8.5	4.2	32.0
KIDNEY												
N Tx CENTRES	12	1	20	7		25	3	1	443	6	1	6
Patients included on the WL for the first time in the course of 2018			1014	395					6094	419	104	
Total number of patients ever active on the WL during 2018			1979	721					12758		389	
Patients awaiting for a transplant (only active candidates) on 31/12/2018			982	334		2016			8158	813	131	5147
Patients who died while on the WL during 2018			6	31		94			192	47	6	459
Patients on dialysls on 31/12/2018	23798		13412	3741			2645		11222	6687	2000	42350
LIVER												
N Tx CENTRES	3	0	8	1		9	2	0	147	3	1	2
Patients included on the WL for the first time in the course of 2018			361	109					3017	171	8	6
Total number of patients ever active on the WL during 2018			508	216					4173		8	9
Patients awaiting for a transplant (only active candidates) on 31/12/2018			136	124		377			1700	101	3	4
Patients who died while on the WL during 2018			6	12		81			456	32	1	1
HEART												
N Tx CENTRES	0	0	5	1		11	0	0	115	2	0	1
Patients included on the WL for the first time in the course of 2018			159	52					302	63	0	2
Total number of patients ever active on the WL during 2018			223	116					425		0	9
Patients awaiting for a transplant (only active candidates) on 31/12/2018			74	67		109			155	85	0	7
Patients who died while on the WL during 2018			8	8		9			22	14	0	1
LUNG												
N Tx CENTRES	0	0	5	2		6	0	0	59	1	0	1
Patients included on the WL for the first time in the course of 2018			258	5					57	106	0	4
Total number of patients ever active on the WL during 2018			345	41					75		0	7
Patients awaiting for a transplant (only active candidates) on 31/12/2018			97	35		221			16	109	0	3
Patients who died while on the WL during 2018			14	2		28			3	30	0	4
PANCREAS												
N Tx CENTRES	0	0	2	1		8	0	0	40	2	1	0
Patients included on the WL for the first time in the course of 2018			32	14					36		8	
Total number of patients ever active on the WL during 2018			103	77					48		5	
Patients awaiting for a transplant (only active candidates) on 31/12/2018			39	74		81			18	10	5	
Patients who died while on the WL during 2018			3	2					11		0	
SMALL BOWEL												
N TX CENTRES	0	0	1	1		3	0	0	18	1	0	0
Patients included on the WL for the first time in the course of 2018			0	0					1		0	
Total number of patients ever active on the WL during 2018			3	0					6		0	
Patients awaiting for a transplant (only active candidates) on 31/12/2018			1	0		0			0		0	
Patients who died while on the WL during 2018			0	0		0			0		0	

			W	AITING LIST								
			OTH	ER COUNTRI	ES							
Country	New Zealand	Norway	Qatar	Republic of Moldova	Russian Federation	Saudi Arabia	Sudan	Switzerland	Syrian Arab Republic	The Rep. of North Macedonia	Turkey America	United States of
Population (million inhabitants): UNFPA	4.7	5.4	2.7	4.0		33.6	41.5	8.5	18.3	2.1	81.9	326.8
KIDNEY												
N Tx CENTRES	4	1	1	1	49	18	7	6	6	1	78	237
Patients included on the WL for the first time in the course of 2018		258	42	13	1728	2650		394			6308	30726
Total number of patients ever active on the WL during 2018		771	108	51	6219	6750	216				28145	88595
Patients awaiting for a transplant (only active candidates) on 31/12/2018		343	54	32	4815	4850	30	478			20877	60901
Patients who died while on the WL during 2018		16	1	1	57			25			1939	3934
Patients on dialysls on 31/12/2018	2949		905	660	45000	19214	9525	400			63349	726331
LIVER												
N Tx CENTRES		1	1	1	28	6		3	1	0	49	147
Patients included on the WL for the first time in the course of 2018		97	12	22	579	285		209			2182	11766
Total number of patients ever active on the WL during 2018		142	16	110	1830	570					3424	23695
Patients awaiting for a transplant (only active candidates) on 31/12/2018		32	6	91	1171	300		88			1774	10666
Patients who died while on the WL during 2018		6	2	8	154			29			380	1164
HEART												
N Tx CENTRES		1	0	0	18	2		3	0	0	15	140
Patients included on the WL for the first time in the course of 2018		32		0	397	81		60			475	4293
Total number of patients ever active on the WL during 2018		48		3	823	120					1156	7648
Patients awaiting for a transplant (only active candidates) on 31/12/2018		11		3	490	93		46			946	2891
Patients who died while on the WL during 2018		0		0	48			12			199	316
LUNG												
N Tx CENTRES		1	0	0	3	2		2	0	0	5	71
Patients included on the WL for the first time in the course of 2018		37			35	50		43			81	3016
Total number of patients ever active on the WL during 2018		80			77	75					84	4363
Patients awaiting for a transplant (only active candidates) on 31/12/2018		41			34	37		24			48	1230
Patients who died while on the WL during 2018		7			15			4			36	213
PANCREAS												
N Tx CENTRES		1	0	0	6	2		2	0	0	8	135
Patients included on the WL for the first time in the course of 2018		9			33	18		18			23	1308
Total number of patients ever active on the WL during 2018		37			153	35					170	2432
Patients awaiting for a transplant (only active candidates) on 31/12/2018		13			132	27		19			166	1041
Patients who died while on the WL during 2018		0			4			6			2	112
SMALL BOWEL												
N Tx CENTRES		0	0	0	0	1		2	0	0	5	20
Patients included on the WL for the first time in the course of 2018		0			0	2		0			4	115
Total number of patients ever active on the WL during 2018		0			0	4		0			4	263
Patients awaiting for a transplant (only active candidates) on 31/12/2018		0			0	2		0			1	159
Patients who died while on the WL during 2018		0			0			0			3	14

			WAITIN	G LIST						
		LATI	N AMERICA		RIES					
Country Population (million inhabitants): UNFPA	Argentina 44.7	Bolivia 11.2	Brazil 210.9	Chile 18.2	Colombia 49.5	Costa Rica 5.0	Cuba 11.5	Dominican Republic 10.9	Ecuador 16.9	El Salvador 6.4
KIDNEY										
N Tx CENTRES	58	10	191		25	7	9	8	8	
Patients included on the WL for the first time in the course of 2018	2177		12631		1484	50	100	53	420	
Total number of patients ever active on the WL during 2018	8310		33201		5166		450	255	592	
Patients awaiting for a transplant (only active candidates) on 31/12/2018	5834		22736		2576	250	382	207	400	
Patients who died while on the WL during 2018	514		1402		93	32		4	14	
Patients on dialysls on 31/12/2018	30053		108468		26952	226	3200	4197	12367	
LIVER										
N Tx CENTRES	37	1	85		11	4	3	1	2	
Patients included on the WL for the first time in the course of 2018	834		3847		307	20	10	13	55	
Total number of patients ever active on the WL during 2018	2101		5112		726		32	42	58	
Patients awaiting for a transplant (only active candidates) on 31/12/2018	1195		1112		138	21	30	33	15	
Patients who died while on the WL during 2018	192		814		24	10		8	11	
HEART										
N Tx CENTRES	25	0	64		7	1	1	2	1	
Patients included on the WL for the first time in the course of 2018	204		566		85	10	3	0	0	
Total number of patients ever active on the WL during 2018	330		843		179		5	0	0	
Patients awaiting for a transplant (only active candidates) on 31/12/2018	120		270		22	0	4	0	0	
Patients who died while on the WL during 2018	40		110		9			0	0	
LUNG										
N Tx CENTRES	8	0	9		4	1	0	0	1	
Patients included on the WL for the first time in the course of 2018	137		177		46	4	0	0	1	
Total number of patients ever active on the WL during 2018	336		366		102	4	0	0	1	
Patients awaiting for a transplant (only active candidates) on 31/12/2018	233		175		32	2	0	0	1	
Patients who died while on the WL during 2018	38		36		7		0	0	0	
PANCREAS										
N Tx CENTRES	16	0	22		5	1	0	1	0	
Patients included on the WL for the first time in the course of 2018	9		312		4		0	0	0	
Total number of patients ever active on the WL during 2018	14		855		5		0	0	0	
Patients awaiting for a transplant (only active candidates) on 31/12/2018	11		438		3		0	0	0	
Patients who died while on the WL during 2018	0		63		0		0	0	0	
SMALL BOWEL										
N Tx CENTRES	2	0	3		4	1	0	0	0	
Patients included on the WL for the first time in the course of 2018	1		7		2		0	0	0	
Total number of patients ever active on the WL during 2018	11		9		2		0	0	0	
Patients awaiting for a transplant (only active candidates) on 31/12/2018	9		7		1		0	0	0	
Patients who died while on the WL during 2018	0		0		0		0	0	0	

WAITING LIST LATIN AMERICAN COUNTRIES Guatemala Honduras Country Mexico Nicaragua Panama Paraguay Peru Uruguay Venezuela 17.2 4.2 **Population (million inhabitants): UNFPA** 130.8 6.9 326.0 3.5 32.4 KIDNEY **N Tx CENTRES** Patients included on the WL for the first time in the course of 2018 Total number of patients ever active on the WL during 2018 Patients awaiting for a transplant (only active candidates) on 31/12/2018 Patients who died while on the WL during 2018 Patients on dialysls on 31/12/2018 LIVER **N Tx CENTRES** Patients included on the WL for the first time in the course of 2018 Total number of patients ever active on the WL during 2018 Patients awaiting for a transplant (only active candidates) on 31/12/2018 Patients who died while on the WL during 2018 HEART **N Tx CENTRES** Patients included on the WL for the first time in the course of 2018 Total number of patients ever active on the WL during 2018 Patients awaiting for a transplant (only active candidates) on 31/12/2018 Patients who died while on the WL during 2018 LUNG **N Tx CENTRES** Patients included on the WL for the first time in the course of 2018 Total number of patients ever active on the WL during 2018 Patients awaiting for a transplant (only active candidates) on 31/12/2018 Patients who died while on the WL during 2018 PANCREAS N Tx CENTRES Patients included on the WL for the first time in the course of 2018 Total number of patients ever active on the WL during 2018 Patients awaiting for a transplant (only active candidates) on 31/12/2018 Patients who died while on the WL during 2018 SMALL BOWEL N Tx CENTRES Patients included on the WL for the first time in the course of 2018 Total number of patients ever active on the WL during 2018 Patients awaiting for a transplant (only active candidates) on 31/12/2018 Patients who died while on the WL during 2018

International Data on Tissues and Haematopoietic Stem Cell Donation and Transplantation Activity. Year 2018



Preliminary European Figures on Tissue & Cell (HPC) Donation and Transplantation Activities, documents produced by the "EUROCET - European Network of Competent Authorities for Tissues and Cells" (2018)



Data provided by National Competent Authorities:

EUROPE

Austria

Belgium

Bulgaria Maya Serafimova Yordan Peev

Cyprus

Czech Republic Eva Křemenová

Germany Dagmar Dörmann

Denmark

Estonia Pille Säälik

Spain Jorge Gayoso Bibiana Ramos Marina Álvarez

Finland Anne Vaskunlahti

France Katia Bruneau

Greece

Croatia Milena Ivanković

Hungary János Sajtos

Ireland

Italy Fiorenza Bariani Letizia Lombardini Liliam Santilli

Lithuania Justina Davainytė

Luxembourg Martine Debacker

Latvia leva Bekere **The Republic of Moldova** Igor Codreanu Tatiana Timbalari

The Rep. of North Macedonia

Malta Patricia Galea

Netherlands Frank van Linden

Norway

Poland

Portugal Paulo Severino

Romania

Sweden Nina Lundmark Tobiasregistret

Slovenia

Slovakia Magdaléna Krátka Daniel Kuba

Switzerland Barbara Schärer

Turkey

United Kingdom Rita Barallon Robert Watson

LATIN AMERICA

Argentina Sergio Madera

Bolivia

Brazil Daniela Ferreira Salomao Thais Lucena de Oliveira

Chile Juan E. Sánchez

Colombia Edwin A. Cárdenas Adriana Segura Yazmin R. Arias **Costa Rica** César A. Gamboa Martha Romero Roselyn Serrano

Cuba M. Antonio Enamorado

Dominican Republic Fernando R. Morales Alexander Altman

Ecuador Mauricio Heredia

El Salvador Raúl Palomo

Guatemala Salvador López Rudolf García-Gallont

Honduras

Mexico J. Salvador Aburto José André Madrigal

Nicaragua Mabel I. Sandoval

Panama Cesar J. Cuero Camilo Chong

Paraguay Gustavo A. Melgarejo Marcelo Martínez

Peru Juan A. Almeyda

Uruguay Milka Bengochea

Venezuela Evelyn Alonzo

Data recorded & prepared by: EUROCET - European Network of Competent Authorities for Tissues and Cells -Team (www.eurocet.org)

European Network of Competent Authorities for Tissues and Cells

Glossary (Tissues)

Α

- Adipose tissue: Connective tissue in which fat is stored and which has the cells distended by droplets of fat.
- **Amniotic membrane**: The innermost layer of the placental membrane; it surrounds the foetus during pregnancy.
- **Autologous:** Refers to tissues or cells removed from and applied in the same individual.

В

- **Blood vessels:** A tube in the body carrying blood to (veins) or from (arteries) the heart.
- **Bone:** The hard, rigid, mineralised form of connective tissue constituting most of the skeleton of vertebrates and composed primarily of calcium salts. There are two types of osseous tissue that form bones: cortical bone (the compact bone of the shaft of a bone that surrounds the marrow cavity) and cancellous or trabecular bone (typically occurs at the ends of long bones, proximal to joints and within the interior of vertebrae). Cancellous bone is highly vascular and frequently contains bone marrow.
- **Bone filling material:** Cancellous (spongy type of bone with a very high surface area found at the ends of long bones) or Corticocancellous bone which has been chopped, shaped or ground to chips, cubes, granules or powder.

С

- **Cancellous bone chips**: Spongy (cancellous) bone cut in pieces, chopped or shaped to chips or cubes of various sizes.
- **Cardiovascular:** Relating to the heart or vessels carrying blood.
- **Competent authority** (or health authority/regulatory authority/regulatory agency): the body which has been delegated with the responsibility for ensuring that tissue and cell donation, banking and human application are appropriately promoted, regulated and monitored in the interests of donor and patient safety and public transparency on a national or regional basis by their government.
- **Cornea:** The transparent anterior part of the outer fibrous coat of the eye. A collagenous tissue bounded by an outer stratified epithelium and an inner monolayer of endothelial cells. The major refractive component of the eye.
- **Cortical strut:** A small shaped piece of compact bone mainly from the femur or tibia used in structural grafting, such as rings, pins etc.

Cortico cancellous bone chips: Bone containing both compact and spongy part cut into pieces, chopped or shaped to chips or cubes of varying sizes.

Craniectomy: The surgical removal of a portion of the skull.

D

- **Deceased donor:** A person declared to be dead according to established medical criteria and from whom cells, tissues or organs have been recovered for the purpose of human application.
- Deceased heart-beating donor (DBD) (Donor after Brain Death): A donor who is declared dead based on the irreversible loss of neurological functions. Also known as heart-beating donor.
- Deceased non-heart beating donor (DCD) (Donor after Cardiac Death): A donor who is declared dead and diagnosed by means of cardiopulmonary criteria.
- **Distribution**: Transportation and delivery of cells or tissues intended for human application.
- **Donation**: Donating human tissues or cells intended for human applications.
- **Donor**: Every human source, whether living or deceased of human cells or tissues.

Е

Export: Act of transporting a tissue or cell intended for human application to another country where it is to be processed further or used directly.

F

- Fascia: A layer of fibrous connective tissue that surrounds muscles, groups of muscles, blood vessels and nerves, which binds some structures together while permitting others to slide smoothly over each other.
- **Femoral arteries superficial:** The section of femoral artery from the bifurcation of the common femoral artery with the profunda femoris artery to the popliteral artery.
- **Femoral head:** Ball shaped proximal head of the femur (thigh bone) forming ball and socket joint with the os coxae (hip bone)

Η

Heart valve: One of the four structures within the heart that prevent backflow of blood by opening and closing with each heartbeat. They include two semilunar valves (aortic and pulmonary), the mitral (or bicuspid) valve, and the tricuspid valve. They permit blood flow in only one direction.

Human application: The use of tissues or cells on or in a human recipient.

Human tissues and cells for human application: Material containing or consisting of human tissues and/or cells intended for implantation, transplantation, infusion, or transfer into a human recipient.

- **Import:** The act of bringing tissues or cells into one country from another for the purpose of human application or further processing.
- **Importing tissue establishment:** A tissue bank or a unit of a hospital or another body established within the EU which is a party to a contractual agreement with a third country supplier for the import into the EU of tissues and cells coming from a third country and intended for human application.

L

- **Ligament:** A tough band of fibrous connective tissue that connects bone to bone.
- **Living donor:** A living person from whom cells or tissues have been removed for the purpose of human application.

Μ

- **Menisci:** The cartilage cushions found in the knee joint between the femur and tibia.
- **Musculoskeletal:** Tissues that are part of the skeleton and muscular system, including muscles, bones, cartilage, tendons and ligaments, which function in the support and movement of the body.

Ν

- Number of tissues discarded: The number of tissues and/or cells that have been discarded.
- Number of tissues distributed: the total number transported or delivered to a clinical unit (as Article 3 (k) of Directive 2004/23/EC defines: Distribution "means transportation and delivery of tissues or cells intended for human applications" (Article 3 (k) Directive 2004/23/EC), whereas 'human application' is defined in the same article as follows: "means the use of tissues or cells on or in a human recipient and extracorporeal applications'.)
- Number of tissues processed: Article 3(g) of Directive 2004/23/EC defines processing as 'all operations involved in the preparation, manipulation, preservation and packaging of tissues or cells intended for human

applications'. This term refers to tissues and cells processed in TEs but not necessarily distributed.

- Number of tissue procured: The number of donated tissue made available through the process of procurement.
- Number of recipients for each type of tissue: The total number of patients who had at least one unit of tissues or cells applied during the year concerned in a given country. It is acknowledged that not all Member States currently collect data on the total number of patients treated with each type of tissue or cells.

0

Ocular tissue: Corneas and Scleras.

Other tissue: All human tissues for human application that does not have a dedicated row on the form.

Ρ

- **Pancreas:** A large lobulated gland that in humans lies in front of the upper lumbar vertebrae and behind the stomach and is somewhat hammer-shaped and firmly attached anteriorly to the curve of the duodenum with which it communicates through one or more pancreatic ducts.
- **Pancreatic islets:** Any of the groups of small slightly granular endocrine cells that form anastomosing trabeculae among the tubules and alveoli of the pancreas and secrete insulin and glucagon.
- **Parathyroid:** Any of the usually four small endocrine glands that are adjacent to or embedded in the thyroid gland, are composed of irregularly arranged secretory epithelial cells lying in a stroma rich in capillaries, and produce parathyroid hormone.
- **Placenta:** An organ that connects the developing foetus to the uterine wall to allow nutrient uptake, waste elimination and gas exchange via the mother's blood supply.
- **Processing:** All operations involved in the preparation, manipulation, preservation, storage and packaging of tissues or cells intended for human application.

R

Recipient: Person to whom human tissues, cells or reproductive cells and embryos are applied.

Retrieval or Recovery: See Number of tissue procured.

S

Sclera: Fibrous white outer coat of the eye.

Skin: Thin layer of tissue forming the natural outer covering of the human body. Skin is composed of two primary

layers: the epidermis and dermis. These layers are separated by a thin sheet of fibres, the 'basement membrane'. Keratinocytes constitute 95% of the epidermis. The dermis provides tensile strength and elasticity to the skin through an extracellular matrix composed of collagen fibrils, microfibrils, and elastic fibres, embedded in proteoglycans.

- **Skin meshed:** Strips of skin graft less than 1mm in depth cut into a lattice structure to increase surface area.
- **Storage:** Means maintaining the product under appropriate controlled conditions until distribution.

Т

- **Tendon**: A tough band of fibrous connective tissue that usually connects muscle to bone and which can withstand tension.
- **Tissue**: All constituent parts of the human body formed by cells.
- **Tissue establishment:** A tissue bank or a unit of a hospital or another body where activities of processing,

preservation, storage or distribution of human tissues and cells are undertaken. It may also be responsible for procurement and/or testing of tissues and cells.

- **Tissue donation (effective):** When tissue intended for human application is retrieved from a human body.
- **Transplantation/implantation/grafting:** Transfer (engraftment) of human tissues or cells from a donor to a recipient with the aim of restoring function(s) in the body.

U

Unique donation number: The unique number attributed to a specific donation of tissues and cells in line with the system in place in each Member State for allocating such numbers, as further specified in Annex VII to Commission Directive (EU) 2015/565.

W

Whole bone: Whole or pieces of bone which remain as a piece rather than being ground down.

European Network of Competent Authorities for Tissues and Cells

Glossary (Haematopoietic Stem Cells)

Α

- Allogeneic use: Cells removed from one person and applied to another.
- Autologous use: Cells removed from and applied in the same person.

В

- **Banking:** Processing, preservation, storage and distribution of cells for human application or other purposes, including research and training.
- **Bone marrow:** Tissue at the centre of large bones. It is the place where new blood cells are produced. Bone marrow contains two types of stem cell: haematopoietic (which can produce blood cells) and stromal (which can produce fat, cartilage and bone). In this collection: as a source of haematopoietic stem cells or mesenchymal stem cells.

С

- **Cells**: Means individual human cells or a collection of human cells when not bound by any form of connective tissue.
- **Collection:** Any procedure for procuring a cellular therapy product regardless of technique or source (synonym: harvest).
- **Competent authority** (or health authority/regulatory authority/regulatory agency): the body which has been delegated with the responsibility for ensuring that tissue and cell donation, banking and human application are appropriately promoted, regulated and monitored in the interests of donor and patient safety and public transparency on a national or regional basis by their government.
- **Cord blood:** Blood collected from placental vessels and umbilical cord blood vessels after the umbilical cord is clamped and/or severed as a source of haematopoietic progenitor cells.
- **Cord blood bank:** An organisation responsible for donor management and the collection, processing, testing, cryopreservation, storage, listing, reservation, release, and distribution of cord blood units.
- **Cryopreservation:** Preservation and storage of viable tissues and cells (including gametes and embryos) to preserve viability, either by freezing or vitrification, or alternatively (to extend their viable life) by low-temperature storage.

D

- **Distribution:** Transportation and delivery of tissues or cells intended for human applications.
- **Donation**: Donating human tissues or cells intended for human applications.
- **Donation centre:** An organisation responsible for donor recruitment, consenting, testing, management and the collection of donor personal, genetic, medical data.
- **Donor**: Every human source, whether living or deceased of human cells.
- **Donor registry:** An organisation responsible for coordinating the search for haematopoietic stem cells from donors (including cord blood) unrelated to the potential recipient.

Н

- HPC transplant centre: A medical facility where a patient (recipient) receives a transplant (graft) with HSC from an unrelated donor or from an umbilical cord blood unit. The TC oversees the immediate medical treatment and provides long-term follow-up of the recipient. The search unit undertakes the search for an unrelated donor for specific patients using criteria defined and documented by the TC. This entity may be contained within a TC or may be separate from the TC. If separate, the search unit may coordinate searches for one or several TCs. In the standards, reference to a TC should be interpreted as a TC and/or a search unit as appropriate. Transplant centres/search units seeking an international donor work through the registry in their country.
- Haematopoietic progenitor cells (HPC): Primitive haematopoietic cells capable of self-renewal as well as maturation into any of the haematopoietic lineages, including committed and lineage-restricted progenitor cells, unless otherwise specified and regardless of tissue source. Also referred to as 'haematopoietic stem cells.
- Human application: The use of tissues or cells on or in a human recipient.
- Human tissues and cells for human application: Material containing or consisting of human tissues and/or cells intended for implantation, transplantation, infusion, or transfer into a human recipient.

Number of cells distributed: The total number transported or delivered to a clinical unit (as Article 3 (k) of Directive 2004/23/EC define:. Distribution "means transportation and delivery of tissues or cells intended for human applications" (Article 3 (k) Directive 2004/23/EC), whereas 'human application' is defined in the same article as follows: "means the use of tissues or cells on or in a human recipient and extracorporeal applications'.)

0

Organisation responsible for human application: means a healthcare establishment or a unit of a hospital or another body which carries out human application of human tissues and cells

Ρ

- **Peripheral blood:** In this collection: HSC haematopoietic stem cells collected in peripheral blood by apheresis.
- **Potential donor:** Any person who has no medical contraindications for organ, tissue or cell donation and who meets the definition of a deceased heartbeating donor, deceased non-heartbeating donor or living donor.
- **Procurement organisation:** Means a health care establishment or a unit of a hospital or another body that undertakes the procurement of human tissues and cells and that may not be accredited, designated, authorised or licensed as a tissue establishment.

- **Recipient:** Person to whom human tissues, cells or reproductive cells and embryos are applied.
- **Related:** Existence of a genetic relationship between donor and recipient.

S

Search performed: Number of searches for compatibility performed in the marrow registry.

T.

- Transplantation/implantation/grafting:Transfer(engraftment) of human tissues or cells from a donorto a recipient with the aim of restoring function(s) inthe body.
- **Transplant centre:** See Organisation responsible for human application.

U

- **Unique donation number:** The unique number attributed to a specific donation of tissues and cells in line with the system in place in each Member State for allocating such numbers, as further specified in Annex VII to Commission Directive (EU) 2015/565.
- **Unrelated:** Where there exists no genetic relationship between donor and recipient.

PRELIMINARY DATA ON TISSUES - YEAR 2018

					E	UROPEAN	UNION C	OUNTRIES	5							
Country		Austria	Belgium	Bulgaria	Croatia	Cyprus	Czech	Denmark	Estonia	Finland	France	Germany	Greece	Hungary	Ireland	Italy
Population (Source: eurosto	nt)	8.822.267	11.398.589	7.050.034	4.105.493	864.236	Republic 10.610.055	5.781.190	1.319.133	5.513.130	66.926.166	82.792.351	10.741.165	9.778.371	4.830.392	60.483.97
TYPE OF TISSUE	TYPE OF DATA	NO DATA	NO DATA			NO DATA		NO DATA					NO DATA		NO DATA	
CORNEA	N of tissue donations			68	273		517		23	218	5.599	NA		NA		8.765
	Tissue donation PMP			9,6	66,5		48,7		17,4	39,5	83,7	NA		NA		144,9
	N of tissue retrieved			133	540		1.059		46	340	11.145	11.824		317		17.385
	N tissue processed (units)			0	546		330		56	340	5.897	11.510		317		
	N tissue distributed nationally (units)			119	340		590		54	273	5.448	7.995		255		6.808
	N tissue imported (units)			3	13		0		0	46	24	848		255		0.000
	N tissue exported (units)			0	0		101		0	2	158	64		0		619
	N of tissues transplanted			119	353		724		NA	273	4.812	NA		262		015
	N of patients transplanted			111	338		724		58	NA	4.437	NA		249		
	N of transplant procedures			119	353		724		NA	NA	UK	NA		262		5.945
SKIN	N of tissue donations			79	1		91		8	23	323	NA		NA		348
	Tissue donation PMP			11,2	0,2		8,6		6,1	4,2	4,8	0,0		NA		5,8
	N of tissue retrieved (cm ²)			125.425	42		127.960		NE	138.402	640.496	26.009		50		915.311
	N tissue processed (units)			14	15		1.303		43	1.189	1.247	120.255		210		
	N tissue distributed															
	nationally (units)			0	21		136		22	1.230	900	260.456		210		3.814
	N tissue imported (units)			0	13		0		0	NE	0	83.000		0		
	N tissue exported (units)			0	0		0		0	NE	35.735 360.003	8.134		0		
	N of tissues transplanted N of patients transplanted			0	28 5		1.343 432		NA 4	1.230 17	205	NA NA		210 210		
	N of transplant procedures			0	14		1.343		4 NA	NA	UK	NA		210		1.717
HEART VALVE	N of tissue donations			0	5		102		NE	42	333	NA		NA		230
HEART VALVE	Tissue donation PMP			0,0	5 1,2		103 9,7		NE	42 7,6	5,0	NA 0,0		NA		3,8
	N of tissue retrieved			0,0	8		182		NE	95	762	708		27		3,8 494
	N tissue processed (units)			0	8		182		NE	95	174	386		27		777
	N tissue distributed			0	0		102			20		500		27		
	nationally (units)			0	8		136		NE	111	230	152		21		208
	N tissue imported (units)			0	0		0		NE	NE	57	1		0		1
	N tissue exported (units)			0	0		0		NE	NE	67	37		0		
	N of tissues transplanted			0	7		127		NA	111	230	NA		21		
	N of patients transplanted			0	8		125		NE	NA	230	NA		21		
	N of transplant procedures			0	8		127		NA	NA	UK	NA		21		
BLOOD VESSEL	N of tissue donations			0	б		12		28	17	11.015	NA		NA		425
	Tissue donation PMP			0,0	1,5		1,1		21,2	3,1	164,6	0,0		NA		7,0
	N of tissue retrieved			0	14		21		39	48	11.688	198		136		691
	N tissue processed (units)			0	14		16		70	43	3.400	218		136		
	N tissue distributed			0	4		13		37	29	3.389	74		107		393
	nationally (units) N tissue imported (units)			0	4		0		37	29 NE	50	74 1		0		393
	N tissue exported (units)			0	0		0		0	NE	39	0		0		
	N of tissues transplanted			0	5		13		NA	29	3.389	NA		242		
	N of patients transplanted			0	3		12		35	NA	1.994	NA		137		
	N of transplant procedures			0	3		12		NA	NA	UK	NA		137		226
MUSCULOSKELETAL	N of tissue donations			2.788	173		1.520		95	816	27.434	NA		NA		3.597
MOJCOLOJILLEIAL	Tissue donation PMP			395,5	42,1		143,3		72,0	148,0	409,9	0,0		NA		59,5
	N of tissue retrieved			5.700	251		5.145		105	1.210	27.868	21.688		1.672		7278
	N tissue processed (units)			203	251		3.439		471	1.210	24.002	55.541		6.920		. 2. 0
	N tissue distributed															
	nationally (units)			250	184		1.958		274	NA	66.461	71.235		6.769		116.558
	N tissue imported (units)			0	7		96		51	NE	774	4.599		0		
	N tissue exported (units)			0	0		2.268		51	NE	8.190	17.340		0		38
	N of tissues transplanted			176	181		3.437		NA	NA	66.461	NA		161		
	N of patients transplanted			146	142		3.391		186	NA	47.772	NA		158		
	N of transplant procedures			152	147		3.409		NA	NA	UK	NA		159		7.583

					PRELIM	NARY DA	TA ON TIS	SUES - YE	AR 2018							
					E	EUROPEAN		OUNTRIES	5							
Country		Austria	Belgium	Bulgaria	Croatia	Cyprus	Czech	Denmark	Estonia	Finland	France	Germany	Greece	Hungary	Ireland	Italy
Population (Source: eurostat)		8.822.267	11.398.589	7.050.034	4.105.493	864.236	Republic 10.610.055	5.781.190	1.319.133	5.513.130	66.926.166	82.792.351	10.741.165	9.778.371	4.830.392	60.483.973
TYPE OF TISSUE	TYPE OF DATA	NO DATA	NO DATA			NO DATA		NO DATA					NO DATA		NO DATA	
PLACENTA/AMNIOTIC																
MEMBRANES	N of tissue donations			16	2		704		4	6	241	NA		NA		317
	Tissue donation PMP N of tissue retrieved			2,3 16	0,5 2		66,4 704		3,0 4	1,1 6	3,6 241	0,0 188		NA 0		5,2 317
	N tissue processed (units)			45	106		8.378		157	251	2.834	6.845		155		517
	N tissue distributed			15	100		0.070		157	201	2.051	0.010		155		
	nationally (units)			39	133		780		65	216	3.182	4.052		126		4.383
	N tissue imported (units)			0	0		0		0	138	0	9		0		
	N tissue exported (units) N of tissues transplanted			0 310	0 134		601 1.420		0 NA	14 NA	172 3.182	114 NA		0 119		
	N of patients transplanted			202	134		224		NA 45	NA	2.744	NA		66		
	N of transplant procedures			307	134		1.420		NA	NA	UK	NA		75		855
	N. Get al. et			0	<u>_</u>		10		NE	•	<i>c.</i>					50
PANCREAS/PANCREATIC ISLETS	N of tissue donations Tissue donation PMP			0 0,0	0 0,0		10 0,9		NE NE	0 0,0	51 0,8	NA 0,0		NA NA		59 1,0
	N of tissue retrieved			0	0		10		3	0	51	0		0		59
	N tissue processed (units)			0	0		10		NE	0	UK	0		0		59
	N tissue distributed															
	nationally (units)			0	0		10		NE	0	UK	0		0		14
	N tissue imported (units) N tissue exported (units)			0	0		0		NE NE	NE NE	UK UK	0		0 0		
	N of tissues transplanted			0	õ		10		NA	0	UK	ŇA		õ		
	N of patients transplanted			0	0		10		NE	0	UK	NA		0		
	N of transplant procedures			0	0		10		NA	0	UK	NA		0		11
ADIPOSE TISSUE	N of tissue donations			2	0		27		NE	1	NA	NA		NA		NA
	Tissue donation PMP			0,3	0,0		2,5		NE	0,2	NA	0,0		NA		NA
	N of tissue retrieved			2 0	0		27 21		NE NE	1 1	UK UK	0		0 0		NA NA
	N tissue processed (units) N tissue distributed			0	0		21		INE	I	UK	0		0		INA
	nationally (units)			0	0		21		NE	NA	UK	0		0		NA
	N tissue imported (units)			0	0		0		NE	NE	UK	0		0		
	N tissue exported (units)			0	0		0		NE	NE	UK	0		0		
	N of tissues transplanted			0	0		18		NA	NA NA	UK UK	NA		0		
	N of patients transplanted N of transplant procedures			0 0	0		18 18		NE NA	NA	UK	NA NA		0 0		NA
					-											
PARATHYROID	N of tissue donations Tissue donation PMP			0 0,0	0 0,0		0 0,0		NE NE	NE NE	NA NA	NA 0,0		NA NA		13 0,2
	N of tissue retrieved			0	0		0		NE	NE	0	0		0		13
	N tissue processed (units)			0	0		0		NE	NE	0	0		0		13
	N tissue distributed															
	nationally (units) N tissue imported (units)			0	0		0		NE NE	NE NE	0	0		0 0		0
	N tissue imported (units) N tissue exported (units)			0	0		0		NE	NE	0	0		0		
	N of tissues transplanted			0	Ő		õ		NA	0	Ő	ŇA		õ		
	N of patients transplanted			0	0		0		NE	0	0	NA		0		
	N of transplant procedures			0	0		0		NA	0	UK	NA		0		
AUTOLOGOUS CRANIECTOMY PIECES	N of tissue retrieved			0	0		95		NE	9	338	0		0		664
OTHER TISSUE	N of tissue donations			31	0		410		NE	NE	NA	NA		NA		NA
	Tissue donation PMP N of tissue retrieved			4,4 31	0,0 0		38,6 413		NE NE	NE NE	NA UK	0,0 3.735		NA 14		NA NA
	N tissue processed (units)			0	0		324		NE	NE	UK	4.613		14		NA
	N tissue distributed															
	nationally (units)			0	5		142		NE	NE	UK	2.230		9		NA
	N tissue imported (units)			0	0		128		NE	22	UK	11		0		
	N tissue exported (units)			0	0 4		0		NE NA	NE NA	UK UK	4 NA		0		
	N of tissues transplanted N of patients transplanted			0	4		18 18		NA NE	NA NA	UK UK	NA NA		26 26		

<table-container> Image: state in the im</table-container>						PREL	IMINARY I	DATA ON	TISSUES -	YEAR 20	18							
Packanetore Pac						EURO		ON COUN	TRIES							ОТН	ER COUNT	RIES
NetworkNotable<	Country		Latvia	Lithuania	Luxembourg	Malta	Netherlands	Poland	Portugal	Romania	Slovakia	Slovenia	Spain	Sweden		Norway		Switzerland
CORNA No. 6.2 2.00 5.00 100 2.07 2	Population (Source: eurostat	t)	1.934.379	2.808.901	602.005	475.701	17.181.084	37.976.687	10.291.027	19.530.631	5.443.120	2.066.880	46.658.447	10.120.242		5.295.619		8.484.130
Image: And out of the problem is and out of the probl	TYPE OF TISSUE	TYPE OF DATA						NO DATA		NO DATA		NO DATA				NO DATA		
Image: sectore of the sectore of th	CORNEA												3.574					
Image process of all																		
Instruction		N of tissue retrieved	40		NA	6												
Image: Statistic problem Solution Solut			40	50	NA	0	4.405		1.039		236		6.620	1.374	6.798		27	759
Inside microare NA 0 PA 0 PA 0 PA 0 PA 0 PA 0 PA			54	45	NA	0	1 720		969		169		4.402	1.050	4 752		27	290
Instrume engender Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. Notice engender Networks No. No. Notice engender Networks No. No. Notice engender Networks No. No. No. No. No. No. No. No. No. No.																		
Image: Series intermediation NA 42 NA 0 141 92 181 181 44.90 167 167 172 173 174 175 174 175 174 <th< td=""><td></td><td></td><td></td><td>-</td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>				-		-												
Indepandent baringhound NA 6 NA 0 1200				-		-			-						-			
Index to the transfer proceed of the transfer proceed of the transfer process of transfer																		
Induct optimized matrixed																		
Induct optimized matrixed	CIVINI	N of discus describes	NE		NIA	0	267		0		0		257		512		6	NE
Image definition No. UK NA 0 1/29/27 0 0 56/27 1/27 <	SKIN								-		-							
N issue processed unity N issue dividual N issue dividual N issue dividual N issue imported unity N of suest transplant N of suest transplant N issue imported unity N of suest transplant N of suest transplant N issue imported unity N of suest transplant N of suest transplant N of suest transplant N issue imported unity N of suest transplant N of suest transplant N issue imported unity N of suest transplant N of suest transplant N issue imported unity N of suest transplant N of suest transplant N issue imported unity N of suest transplant N of suest transplant N issue imported unity N issue																		
Instance		N tissue processed (units)																
Intisue monore during Net No divisions transplant of tissue transplant of			NE		NA	0	1 6 2 6		25		60		266 592	177	4164		120	NE
Interse Name																		
Index Note Strate No. No. No. Store Store <th< td=""><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>						-												
No fostents transplanded Normalisar processing in the source domain Nor fissue									-									
No finasue processed units NE NE NR NA 0 1000000000000000000000000000000000000																		
Index and only in this we chow only in the this we chow only in the this we chow only in this we chow the this we chow only in this we chow the this we chow only in this we chow the this we									-									
Index and only in this we chow only in the this we chow only in the this we chow only in this we chow the this we chow only in this we chow the this we chow only in this we chow the this we		N - f times de setiene	NE	NE		0	217		22		4		220	161	(20)		0	11
N of tissue entrived NE NE NA 0 299 46 5 411 245 630 0 0 0 0 N tissue process (units) NE NE NA 0 844 66 5 411 227 704 0.0 0 0 N tissue inproted (units) NE NE NA 0 25 0 NA 1 1 129 NE 26 N of tissue scapated (units) NE NE NA 0 114 5 2 65 207 788 0 25 N of tissue transplanted NE NE NA 0 144 5 2 1 18 33 3 2 7 33 2 7 7 18 0 2 7 7 14 0 0 2 14 0 0 2 33 3 2 7 7 7 7 7	HEART VALVE																	
N issue processed (units) NE NE NA 0 434 66 5 410 3.77 7.8 5.70 0.0 0 N issue inported (units) NE NA 0 97 5 2.2 197 7.5 52.9 0 0 0 0.8 2.6 0.8 N.8 0.2 0.0 N.8 2.6 0.0 N.8 0.0 <td></td>																		
Nissee distributed Nissee distributed No No So So So So No No No No No No No So So So No											-							
Nisue incorted (units) NE NR NA 0 25 0 NA 1 1 1 1 10 10 NE		N tissue distributed																
N tissue exported (units) N of tissue transplanted N of tissue transplanted N of tissue transplanted N of tissue exported (units) N E N A 0 114 5 2 61 198 NA 0 25 BLOOD VESSEL N of tissue frame/and to transplanted N of tansplant procedure N E N R N A 0 114 5 2 N A 18 N A 0 25 BLOOD VESSEL N of tissue donation FMP N E N E N A 0 16 0 0 33 22 53 1,4 0,8 N of tissue donation FMP N E N E N A 0 16 0 0 33 22 53 1,4 0,8 N tissue processed (units) N E N E N A 0 16 0 0 24877 12 96 0 0 55 N tissue exponted (units) N E N E N A 0 42 0 0 100 12 17.4 0 55 N						-			-		-		197					
N of tissue transplanted N of patient stransplanted N of transplant proceduresN E NEN E NAN A011452265207788025BLOOD VESSEL N Of transplant proceduresN of transplant proceduresN EN EN A0114521N A198NA025BLOOD VESSELN of tissue donations Tissue donation N of tissue retrieved N Sitesue proceduresN EN EN B000003372933357N Of tissue retrieved N Sitesue procedures N Sitesue proceduresN EN EN E0000337293332270N Of tissue retrieved N Sitesue proceduresN EN EN E104200024.877129600035N Sitesue procedures N Sitesue proceduresN EN EN E11030NA140NA17N E55N Sitesue procedures N of tissue proceduresN EN EN E00018012174055N Of tissue procedures N of tissue proceduresN EN A0420018012174055N Sitese procedures N of tissue proceduresN EN A0167544112401.556.076122935N Sites						-			-				111	-				
N of patients transplanted N of transplant proceduresN E N EN E N EN A N0114 145 S21010198NA N025BLOOD VESSELN of tissue donations N fissue donation PMP N of tissue transplanted N tissue donation PMP N EN EN A N E01600.00.03.99.25.35.31.40.8N of tissue etriceved N tissue gorcessed (units) N tissue etriceved N EN EN E11042000.024.871.296000N of tassue etriceved N tissue etriceved N tissue etriceved N tissue etriceved N tissue etriceved N of tassue etriceved N of tissue etriceved N EN EN E11042.000NA10NA7N EN EN EN of tassue etriceved N of patients transplanted N of tissue etriceved N of tissue etriceved N of tissue etriceved N of tissue etriceved N etriceved N EN EN A042.00018110N A7N EN EN EMUSCULOSKELETAL N fitssue donation FMP N tissue etriceved N of tissue etriceved N of tissue etriceved N of tissue etriceved N of tissue etriceved N fitssue etriceved N of tissue etriceved N of tissue etriceved N of tiss									-									
No fransplant proceduresNENENA01452NA198NA0025BLOOD VESSELN of tissue donationsNENENA01600337225333227N of tissue donation PMPNENENA05000033722933227N of tissue groensed (units)NENENENA050003372233227N tissue groot d(units)NENENE110420033722332400N tissue groot d(units)NENENE11042001801271600N of tissue sangulated (units)NENENE110320NA10NA7NENENENENE110320NA10NA7NE				=		-			-		-						-	
BLOOD VESSEL No No 16 0 0 184 93 353 5 7 BLOOD VESSEL No f tissue donation PMP NE NE NA 0,0 0,9 0,0 0,0 3,9 9,2 5,3 1,4 0,8 N of tissue retrieved NE NA 0 5 0 0 337 229 333 22 7 N tissue processed (units) NE NE NA 0 16 0 0 19,855 229 414 0 0 N tissue processed (units) NE NE 11 0 3 0 NA 140 NA 7 NE 7 N tissue stransplanted NE NA 0 20 0 NA 21 NA 7 NE 7 N of tissue stransplanted NE NA 0 43 0 0 NA 10 NA 0 55 M of																		
Tissue donation PMPNENENENA0,00,90,00,03,99,25,31,40,8N of tissue processed (units)NENENA050030729353229353229220235229235229235229235229235229235229235229235229235229235229235229235229235229235229235229235229235229235229235229235236236236236236236236236236236235236236236235236236236235236																	_	_
N of tissue retrievedN EN A050033729333227N tissue distributedN tissue distributedNN016001985522941400N tissue distributedN EN E110420024.8771296000N tissue distributedN EN EN E110420024.8771296000N tissue exported (units)N EN EN A0200N A20N A7N EN E55N of tissue stransplantedN EN A0420013110N A055N of tissue stransplantedN EN A0420013110N A055N of tissue stransplant proceduresN EN A04300013110N A055N of tissue stransplantedN AN A0167544112430157560763229349N of tissue stransplantedN A0196755178321.84717546.0447229N of tissue stransplantedN A019675481.021.84717546.0447229N of tissue stransplantedN A019675717.84 <td< td=""><td>BLOOD VESSEL</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	BLOOD VESSEL								-		-							
N issue grocessed (units) N issue distributed nationally (units)NENENI0160019.855229414000N issue distributed nationally (units)NENE110420024.8771296000N issue grooted (units)NENENE11030NA140NA17NE55N issue grooted (units)NENENENA0200NA2013012174055N of tissue stransplantedNENENA04300013110NA055N of tansplant procedureNENA0430001311556.07632296MUSCULOSKELETALN of tissue drantion PMP10,3320NA01675,2178321.8471,7546.07632296N of tissue drantion PMP10,3320NA0196725.21,78321.8471,7546.07632299N tissue distributed N tissue distributed N tissue distributed N tissue distributed N tissue distributed N tissue distributed N tissue distributed333053301,2914465821,9111.0547.599475NAN tissue distributed N tissue inspronted (units)004,35903,7499 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																		
N tissue distributed nationally (units) NE NE 11 0 42 0 0 24.877 12 96 0 0 0 N tissue imported (units) NE NE 11 0 3 0 NA 1407 NA 97 NE 0 0 0 N tissue imported (units) NE NE NA 0 20 0 NA 291 NA 7 NE 5 N of tissue stransplanted NE NE NA 0 432 0 0 131 10 NA 0 55 N of tissue donation S NE NE NA 0 42 0 0 NA 0 55 N of tissue donation PM 103 32.0 NA 0 167 54 411 240 1.575 6.076 32 296 N of tissue donation PM 103 32.0 NA 0 1.967 55 1.783									-		-							
nationally (units) NE NE 11 0 42 0 0 24.877 12 96 0 0 N tissue imported (units) NE NE 11 0 3 0 NA 140 NA 77 NE 57 N tissue exported (units) NE NE NA 0 0 NA 291 NA 7 NE 57 N of tissue stransplanted NE NE NA 0 43 0 0 180 12 174 0 55 N of patients transplant procedures NE NA 0 42 0 0 NA 0 55 N of tissue donations 20 90 NA 0 43 0 0 NA 0 32 2430 1575 6.076 32 266 Tissue donation PMP 10,3 32,0 NA 0,0 9,7 5,2 81,0 51.87 6.074 32,99 </td <td></td> <td></td> <td>NL</td> <td>INL</td> <td>11/1</td> <td>0</td> <td>10</td> <td></td> <td>0</td> <td></td> <td>0</td> <td></td> <td>19.000</td> <td>229</td> <td>414</td> <td></td> <td>0</td> <td>0</td>			NL	INL	11/1	0	10		0		0		19.000	229	414		0	0
N tissue imported (units) NE NE NE N1 0 3 0 NA 140 NA 17 NE S5 N tissue exported (units) NE NE NA 0 200 0 NA 291 NA 7 NE NE NE NE NA 0 43 0 0 0 131 10 NA 0 55 N of transplant procedures NE NA 0 42 0 0 NA 10 NA 0 55 N of transplant procedures NE NA 0 42 0 0 NA 10 NA 0 55 MUSCULOSKELETAL N of tissue donations 20 90 NA 0 167 54 441 2430 1.575 6.076 32 296 Tissue donation PMP 10,3 32,0 NA 0 1.967 255 1.783 2.866 2.029 3.108			NE	NF	11	0	42		0		0		24 877	12	96		0	0
N tissue exported (units)NENENENA0200NA0200NA291NA7NENE7N of tissue stransplantedNENENA0430018012174055N of tissue stransplantedNENENA0420018110NA055N of transplant proceduresNENENA043000NA10NA055MUSCULOSKELETALN of tissue donations2090NA0167544412.4301.5756.07632296Tissue donation PMP10.332.0NA0.09.775.281.052.1155.691.79.034.9N of tissue retrieved4040NA01.9672551.7832.662.020.643559.9N tissue processed (units)9590NA01.02914462.18471.5746.0447.22.96N tissue imported (units)4330553010.2914465821.9111.05427.599475NAN tissue exported (units)004.359037.4990212361043.752NE0N tissue transplantedNA32NA052.8820051724.7611.017									0		-							
No fissues transplanted N of patients transplanted N of transplant proceduresNE NENE NENA NA NA0430000180 012174 10055 0055 55MUSCULOSKELETAL MUSCULOSKELETALNo fissue donations No fissue donation PMP No fissue donation PMP No0NA0167 16754441 243024301.575 15,660,7632 90,72296 90,72No fissue donation PMP No fissue retrieved N of tissue processed (units) N tissue processed (units) N tissue imported (units)30 90NA01.967 90,83722551.783 4662.1382.666 2.0292.029 3.1083.08 355355 9393No tissue expressed (units) N tissue imported (units)43 9030 90533 903.122446 912.138 922.666 922.029 913.108 933.092 93753 9393No tissue exported (units) N tissue exported (units) N of patients transplanted N of patients transplanted N A32NA 906.732314 9020166 90,91730,902NE 9343 9343 94446 942.138 94043.752NE 9443 9443 9443 94446 942.138 941.664 9430,902NE 9443 9443 9443 94446 942.138 941.664 9430,902NE 9443 9443 94						-			-									
N of patients transplanted N of transplant proceduresNE NENE NENA NA042 43000131 010NA NA055 055MUSCULOSKELETALN of tissue donations Tissue donation PMP N of tissue retrieved N of tissue retrieved 400NA0167 10,3544412,430 52,11,575 15,66,076 91,732 90,034,99 34,99N of tissue retrieved N tissue processed (units) N tissue imported (units)433055301,967 10,291255 4461,783 21,8471,754 1,7546,044 6,04472 72 299 3,108299 3,108N tissue imported (units) N tissue imported (units)4330553010,2914465821,911 2,1081,054 2,75992,7599 4,754,75 4,33NA 4,33N tissue imported (units) N tissue exported (units)004,91206,7331201,6630,902NE 4,3594,3 4,359N tissue exported (units) N tissue exported (units)004,35903,74490212361 4,00043,752NE 4,7510N of tissues transplanted N of tissues transplanted N of subset transplanted N d30NA05,28827031919,1421,0171,0171,0171,0191,0192,011N tissue distributed N of patients transplanted N of subset transplanted NA <td></td>																		
N of transplant procedures NE NE NA 0 43 0 0 NA 10 NA 0 55 MUSCULOSKELETAL N of tissue donations Tissue donation PMP 10,3 32,0 NA 0,0 9,7 5,2 81,0 52,1 155,6 91,7 9,0 34,9 N of tissue retrieved 40 40 NA 0 1,967 255 1,783 21,847 1,754 6,044 72 299 N tissue processed (units) 95 90 NA 0 6,372 446 2,138 2,666 2,029 3,108 355 9,3 N tissue distributed - <						-			-		-							
Tissue donation PMP 10,3 32,0 NA 0,0 9,7 5,2 81,0 52,1 155,6 91,7 9,0 34,9 N of tissue retrieved 40 40 NA 0 1,967 255 1,783 21,847 1,754 6,044 72 299 N tissue processed (units) 9 9 NA 0 6,372 466 2.080 2.066 2.029 3.10 30 39 N tissue distributed						-			-		-							
Tissue donation PMP 10,3 32,0 NA 0,0 9,7 5,2 81,0 52,1 155,6 91,7 9,0 34,9 N of tissue retrieved 40 40 NA 0 1,967 255 1,783 21,847 1,754 6,044 72 299 N tissue processed (units) 9 9 NA 0 6,372 466 2.080 2.066 2.029 3.10 30 39 N tissue distributed	MUSCULOSKEI ETAI	N of tissue donations	20	90	NA	0	167		54		441		2.430	1.575	6.076		32	296
N of tissue retrieved 40 NA 0 1,967 255 1.783 21.847 1.754 6.044 72 299 N tissue processed (units) 95 90 NA 0 6.372 446 2.138 2.666 2.029 3.108 355 93 N tissue distributed																		
N tissue processed (units) 95 90 NA 0 6.372 446 2.138 2.666 2.029 3.108 355 93 N tissue distributed - </td <td></td>																		
N tissue distributed A3 30 553 0 10.291 446 582 1.911 1.054 27.599 475 NA N tissue imported (units) 0 0 4.912 0 673 31 2 0 166 30.902 NE 43 N tissue exported (units) 0 4.359 0 37.449 0 212 361 0 43.752 NE 0 N tissue exported (units) 0 4.359 0 5.613 400 517 24.761 1.017 28.890 419 245 N of patients transplanted NA 30 NA 0 5.288 270 319 19.142 1.021 NA 129 237																		
nationally (units)4330553010.2914465821.9111.05427.599475NAN tissue imported (units)004.9120673312016630.902NE43N tissue exported (units)04.359037.4490212361043.752NE9N of tissue stransplantedNA32NA05.61340051724.7611.01728.5041924.50N of patients transplantedNA30NA05.28827031919.1421.021NA129237																		
N tissue imported (units) 0 4.912 0 673 31 2 0 166 30.902 NE 43 N tissue exported (units) 0 4.359 0 37.449 0 212 361 0 43.752 NE 9 N of tissues transplanted NA 32 NA 0 5.613 400 517 24.761 1.017 28.89 419 24.761 N of patients transplanted NA 30 NA 0 5.288 270 319 19.142 1.021 NA 129 237			43	30	553	0	10.291		446		582		1.911	1.054	27.599		475	NA
N of tissues transplanted NA 32 NA 0 5.613 400 517 24.761 1.017 28.890 419 245 N of patients transplanted NA 30 NA 0 5.288 270 319 19.142 1.021 NA 129 237			0	0	4.912	0	673		31		2		0	166	30.902			43
N of patients transplanted NA 30 NA 0 5.288 270 319 19.142 1.021 NA 129 237		N tissue exported (units)	0	0	4.359	0	37.449		0		212		361	0	43.752		NE	0
						0												
N of transplant procedures NA 30 NA 0 5.613 365 343 NA 1.002 NA 129 237																		
		N of transplant procedures	NA	30	NA	0	5.613		365		343		NA	1.002	NA		129	237

					FURO	PEAN UNIC		TRIFS							ОТН	ER COUNT	
Country		Latvia	Lithuania	Luxembourg	Malta	Netherlands		Portugal	Romania	Slovakia	Slovenia	Spain	Sweden	United	Norway	Republic	Switzerland
Population (Source: eurostat)		1.934.379	2.808.901	602.005	475.701	17.181.084	37.976.687	-	19.530.631		2.066.880	•	10.120.242	Kingdom 66.273.576	5.295.619	Of Moldova 3.547.539	8.484.130
•	TYPE OF DATA						NO DATA		NO DATA		NO DATA				NO DATA		
PLACENTA/AMNIOTIC MEMBRANES	N of tissue donations	8	2	NA	0	1		17		64		92	3	0		10	10
	Tissue donation PMP	4,1	0,7	NA	0,0	0,1		1,7		11,8		2,0	0,3	0,0		2,8	1,2
	N of tissue retrieved	8	2	NA	0	1		17		64		2.459	379	0		10	10
	N tissue processed (units)	NE	UK	NA	0	1		261		304		NA	424	98		102	129
	N tissue distributed																
	nationally (units)	NE	UK	NA	0	200		228		377		NA	312	2.096		74	22
	N tissue imported (units)	NE	0	NA	0	0		0		NA		NA	NA	266		NE	27
	N tissue exported (units)	NE	0	NA	0	702		0		NA		NA	NA	772		NE	0
	N of tissues transplanted	NE	2	NA	0	118		230		378		NA	317	2.224		74	134
	N of patients transplanted	NE	33	NA	0	114		183		261		NA	299	NA		50	115
	N of transplant procedures	NE	33	NA	0	118		210		309		NA	304	NA		68	115
PANCREAS/PANCREATIC ISLETS		NE	NE	NA	0	279		NA		0		NA	46	NA		NE	5
	Tissue donation PMP	NE	NE	NA	0,0	16,2		NA		0,0		NA	4,5	NE		NE	0,6
	N of tissue retrieved	NE	NE	NA	0	47		NA		0		NA	46	NA		NE	5
	N tissue processed (units)	NE	NE	NA	0	47		NA		0		NA	46	122		NE	39
	N tissue distributed																
	nationally (units)	NE	NE	NA	0	13		NA		0		NA	21	43		NE	NA
	N tissue imported (units)	NE	NE	NA	0	0		NA		NA		NA	NA	0		NE	29
	N tissue exported (units)	NE	NE	NA	0	0		NA		NA		NA	2	0		NE	23
	N of tissues transplanted	NE	NE	NA	0	12		NA		0		NA	23	34		NE	6
	N of patients transplanted	NE	NE	NA	0	9		NA		0		NA	3	NA		NE	6
	N of transplant procedures	NE	NE	NA	0	12		NA		0		NA	23	NA		NE	6
ADIPOSE TISSUE	N of tissue donations	NE	33	NA	0	0		NA		89		NA	NE	529		0	NE
	Tissue donation PMP	NE	117,5	NA	0,0	0,0		NA		163,5		NA	NE	79,8		0,0	0,0
	N of tissue retrieved	NE	33	NA	0	0		NA		89		NA	NE	529		0	NE
	N tissue processed (units)	NE	33	NA	0	0		NA		87		NA	NE	63		0	NE
	N tissue distributed																
	nationally (units)	NE	32	NA	0	0		NA		84		NA	NE	221		0	NE
	N tissue imported (units)	NE	0	NA	0	0		NA		NA		NA	NE	2		NE	NE
	N tissue exported (units)	NE	0	NA	0	0		NA		NA		NA	NE	2		NE	NE
	N of tissues transplanted	NA	32	NA	0	0		NA		84		NA	NE	294		0	NE
	N of patients transplanted	NA	19	NA	0	0		NA		84		NA	NE	NA		0	NE
	N of transplant procedures	NA	133	NA	0	0		NA		84		NA	NE	NA		0	NE
PARATHYROID	N of tissue donations	NE	NE NE	NA	0	0		NA		0		NA	NE	NA		NE NE	NE
	Tissue donation PMP	NE NE	NE	NA NA	0,0	0,0		NA		0,0		NA NA	NE NE	NA		NE	0,0 NE
	N of tissue retrieved				0	0		NA		0				0			
	N tissue processed (units)	NE	NE	NA	0	0		NA		0		NA	NE	NA		NE	NE
	N tissue distributed nationally (units)	NE	NE	NA	0	0		NA		0		NA	NE	NA		NE	NE
		NE	NE	NA	0	0		NA		NA		NA	NE	NA		NE	NE
	N tissue imported (units) N tissue exported (units)	NE	NE	NA	0	0		NA		NA		NA	NE	NA		NE	NE
	N of tissues transplanted	NE	NE	NA	0	0		NA		0		NA	NE	NA		NE	NE
	N of patients transplanted	NE	NE	NA	0	0		NA		0		NA	NE	NA		NE	NE
	N of transplant procedures	NE	NE	NA	0	0		NA		0		NA	NE	NA		NE	NE
AUTOLOGOUS CRANIECTOMY PIECES	N of tissue retrieved	NE	50	NA	0	82		NA		162		NA	215	32		4	NE
																•	
OTHER TISSUE	N of tissue donations	197	NE	NA	0	5		0		1.644		NA	0	2.749		1	NE
	Tissue donation PMP	101,8	NE	NA	0,0	0,3		0,0		302,0		NA	0,0	41,5		0,3	0,0
	N of tissue retrieved	197	NE	NA	0	0		0		1.644		NA	0	2.749		3	NE
	N tissue processed (units)	8	NE	NA	0	80				1.545		NA	0	13.428		0	NE
	N tissue distributed																
	nationally (units)	0	NE	NA	0	1.236		0		209		NA	0	15.698		0	NE
	N tissue imported (units)	0	NE	NA	0	12		0		678		NA	0	13.264		NE	NE
	N tissue exported (units)	0	NE	NA	0	0		0		116		NA	0	34.739		NE	NE
	N of tissues transplanted	NA	NE	NA	0	41		0		214		NA	0	1.124		0	NE
	N of patients transplanted	NA	NE	NA	0	41		0		148		NA	0	NA		0	NE
	N of transplant procedures	NA	NE	NA	0	41		0		200		NA	0	NA		0	NE

PRELIMINARY DATA ON TISSUES - YEAR 2018

						LATIN	AMER	CAN COUN	TRIES									
Country		Argentina	Brazil	Chile	Colombia	Costa Rica	Cuba	Dominican R.	Ecuador	El Salvador	Guatemala	Mexico	Nicaragua	Panama	Paraguay	Peru	Uruguay	Venezue
Population (Source: UNFPA 2018 - Million)	A, state of world population,	44,7	210,9	18,2	49,5	5,0	11,5	10,9	16,9	6,4	17,2	130,8	6,3	4,2	6,9	32,6	3,5	32,4
TYPE OF TISSUE	TYPE OF DATA	NO DATA		NO DATA			NO DA	ΓA		NO DATA			NO DATA			NO DAT	Ą	NO DAT
CORNEA	N of tissue donations		34.447		1.388	149		0	320		208	4.546		2	126		88	
connex	Tissue donation PMP		163,3		28,0	29,8		0,0	18,9		12,1	34,8		0,5	18,3		25,1	
	N of tissue retrieved		30.735		2.831	206		0	292		208	4.544		2	116		201	
	N of tissues transplanted		14.788		2.672	206		0			183	4.311		2	116			
	N of patients transplanted							0			183	4.311		2	116		187	
	N of transplant procedures		14.788			206		0	286		183	4.311		2	116		201	
BLOOD VESSEL	N of tissue donations		0		8	5		0	7		0	0		0	0		22	
	Tissue donation PMP		0,0		0,2	1,0		0,0	0,4		0,0	0,0		0,0	0,0		6,3	
	N of tissue retrieved		0		10	18		0	6		0	0		0	0		22	
	N of tissues transplanted		Ū		37	18		0	Ū		0	Ū		0	0			
	N of patients transplanted					18		0			0			0	0		17	
	N of transplant procedures							0	0		0			0	0		22	
HEART VALVE	N of tissue donations		239		34	5		0	0		0	0		0	0		0	
	Tissue donation PMP		1,1		0,7	1,0		0,0	0,0		0,0	0,0		0,0	0,0		0,0	
	N of tissue retrieved		429		33	1,0		0,0	0,0		0,0	32		0,0	0,0		0,0	
	N of tissues transplanted		163		37	17		0	Ū		0	4		0	0		0	
	N of patients transplanted		105		57	17		0			0	4		0	0		0	
	N of transplant procedures		163			17		0	0		0	4		0	0		0	
MUSCULOSKELETAL	N of tissue donations		1.105		881	57		0	350		0	459		0	0		36	
MUSCULUSKELETAL	Tissue donation PMP		5,2		17,8	57 11,4		0,0	350 20,7		0,0	459 3,5		0,0	0,0		30 10,3	
	N of tissue retrieved		5,2 17.676		17,8	11,4		0,0	20,7 326		0,0	3,5 477		0,0	0,0		10,5 36	
						147			320		0	4//		0	0		30	
	N of tissues transplanted N of patients transplanted		12.848		16.020	147		0 0			0			0	0		120	
	N of transplant procedures		12.848			147		0	292		0			0	0		412	
PLACENTA/AMNIOTIC MEMBRANE	N of tissue donations		0		84	32		0	7		0			0	0		91	
MEMORANE	Tissue donation PMP		0,0		84 1,7	32 6,4		0,0	7 0,4		0,0	0,0		0,0	0,0		91 26,0	
	N of tissue retrieved		0,0		83	6,4 54		0,0	0,4 251		0,0	0,0		0,0	0,0		26,0 91	
	N of tissues transplanted		0		65 465	54		0	201		0			0	0		21	
	N of patients transplanted		0		405			0			0			0	0		51	
	N of transplant procedures		0			54		0	263		0			0	0		266	
SKIN	N of tissue donations		627		84	8		0	7		0	0		0	0		17	
SIGIN	Tissue donation PMP		3,0		84 1,7	8 1,6		0,0	7 0,4		0,0	0,0		0,0	0,0		4,9	
	N of tissue retrieved		3,0 121.176		498	1,6 0		0,0 0	0,4 161		0,0 0	0,0		0,0	0,0 0		4,9 33.000	
	N of tissues transplanted		83.559		498 564	0 31		0	101		0	0		0	0		33.000	
	N of patients transplanted		03.333		507	51		0			0			0	0		24	
	N of transplant procedures		83.559			31		0	179		0			0	0		772	
OTUEDC					2										0			
OTHERS	N of tissue donations		0		0	0		0	6		0	0		0	0		0	
	Tissue donation PMP		0,0		0,0	0,0		0,0	0,4		0,0	0,0		0,0	0,0		0,0	
	N of tissue retrieved		0		9	0		0	4		0	0		0	0		0	
	N of tissues transplanted		0		9			0			0			0	0			
	N of patients transplanted		0					0			0			0	0			
	N of transplant procedures		0			NA		0	7		0			0	0			

			PRELIN	IINARY D	ATA ON	HPC CE	LS - YEA	R 2018								
				EUROP	EAN UNI	ON COU	NTRIES									
Country		Austria	Belgium	Bulgaria	Croatia	Cyprus	Czech Republic	Denmark	Estonia	Finland	France	Germany	Greece	Hungary	Ireland	Italy
Population (Source: eurostat)		8.822.267	11.398.589	7.050.034	4.105.493	864.236	10.610.055	5.781.190	1.319.133	5.513.130	66.926.166	82.792.351	10.741.165	9.778.371	4.830.392	60.483.9
CATEGORY OF <data< td=""><td>TYPE OF DATA</td><td>NO DATA</td><td>NO DATA</td><td></td><td></td><td>NO DATA</td><td></td><td>NO DATA</td><td></td><td></td><td></td><td></td><td>NO DATA</td><td></td><td>NO DATA</td><td></td></data<>	TYPE OF DATA	NO DATA	NO DATA			NO DATA		NO DATA					NO DATA		NO DATA	
POTENTIAL DONATIONS AND																
SEARCHING IN THE NATIONAL REGISTRIES	N of potential donors at 31.12			NA	56.201		115.997		NA	48.141	290.342	UK		NA		416.852
	N of cord blood units at 31.12			NA	3.502		6.707		0	NA	36.651	UK		NA		36.370
	N of searches requested			NA	505		48.991		NA	NA	28.472	UK		NA		3.055
	N of unrelated donations			NA	50		201		NA	NA	1.145	NA		NA		897
DONATIONS	N of donations - Autologous			2.519	570		1.100		57	NA	3.576	4.530		539		4.618
	N of donations - Allogenic			122	1.086		290		3	505	1.266	8.418		123		12.590
	N of donations - Allogenic, related			42	49		103		3	NA	988	1.037		122		1.328
	N of donations - Allogenic, unrelated			80	1.037		187		0	NA	278	7.381		1		11.262
BANKING OF CORD BLOOD	N of unrelated cord blood unitss collected			80	1.014		15		0	0	615	733		0		10.661
	N of unrelated cord blood unitss distributed			0	0		4		0	4	119	0		0		38
	N of related cord blood unitss collected			2.421	11		585		0	NE	NA	25		4.373		150
	N of related cord blood unitss distributed			0	0		0		0	NE	NA	0		2		4
TRANSPLANT	N of transplants - Autologous			98	190		463		55	NA	3.316	4.540		307		3.310
	N of patients transplanted - Autologous			93	131		364		NA	245	3.183	3.757		232		2.628
	N of transplants - Allogenic			64	80		266		23	NA	1.946	3.450		172		1.881
	N of patients transplanted - Allogenic			64	74		248		NA	131	1.905	3.267		158		1.796
	N of transplants - Allogenic, related			42	34		90		3	NA	991	1.017		80		1.020
	N of patients transplanted - Allogenic, related			42	31		83		NA	NA	NA	943		73		948
	N of transplants - Allogenic, unrelated			22	46		176		20	NA	955	2.433		92		861
	N of patients transplanted - Allogenic, unrelated			22	43		165		NA	NA	NA	2.324		85		848

			PRELI	MINARY D	ATA ON	HPC CELL	. S -
				EURO	PEAN UI		JNT
Latvia	Lithuania	Luxombourg	Malta	Nothorlands	Poland	Portugal	

- YEAR 2018

Country Population (Font: Eurostat) CATEGORY OF DATA TYPE OF DATA POTENTIAL DONATIONS AND SEARCHING IN THE NATIONAL REGISTRIES N of potential donors at 31.12 N of cord blood units at 31.12 N of searches request N of unrelated donations DONATIONS N of donations - Autologous N of donations - Allog related N of unrelated cord blood unitss collected N of unrelated cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Allogenic N of patients transpla Allogenic N of patients transpla Allogenic N of patients transpla	UK s UK	Lithuania 179 2.808.901		Malta 475.701	Netherlands 17.181.084	Poland 37.976.687	Portugal 10.291.027	Romania 19.530.631	Slovakia	Slovenia	Spain	Sweden	Unitsed Kingdom	Norway	Republic of Moldova	Switzerland
CATEGORY OF DATA TYPE OF DATA POTENTIAL DONATIONS AND SEARCHING IN THE NATIONAL REGISTRIES N of potential donors at 31.12 N of cord blood units at 31.12 N of searches request N of unrelated donations - Autologous N of donations - Allog related N of donations - Allog unrelated BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of related cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of patients transplats - Allogenic N of patients transpla	s UK s UK			475.701	17.181.084	37.976.687	10.291.027	19 530 631					Ringuoin			
POTENTIAL DONATIONS AND SEARCHING IN THE NATIONAL REGISTRIES N of potential donors at 31.12 N of cord blood units at 31.12 N of searches request N of unrelated donat DONATIONS N of donations - Autologous N of donations - Allog related N of donations - Allog nurelated N of donations - Allog related N of donations - Allog unrelated N of donations - Allog unrelated N of unrelated cord blood unitss collect N of unrelated cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Allogenic N of patients transpla	UK s UK	12.159	NO DATA					19.550.051	5.443.120	2.066.880	46.658.447	10.120.242	66.273.576	5.295.619	3.547.539	8.484.130
AND SEARCHING IN THE NATIONAL REGISTRIES N of potential donors at 31.12 N of cord blood units at 31.12 N of searches request N of unrelated donat DONATIONS N of donations - Autologous N of donations - Alloy related N of donations - Alloy unrelated N of related cord blood unitss collect N of unrelated cord blood unitss collected N of related cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of patients transpla Allogenic	UK s UK	12.159				NO DATA		NO DATA		NO DATA				NO DATA		
at 31.12 N of cord blood units at 31.12 N of searches request N of unrelated donat DONATIONS N of donations - Autologous N of donations - Allog related N of donations - Allog related N of donations - Allog unrelated N of donations - Allog unrelated N of donations - Allog related N of donations - Allog unrelated N of related cord blood unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of patients transpla Allogenic	UK s UK	12,159														
N of cord blood units at 31.12 N of searches requests N of unrelated donat DONATIONS N of donations - Autologous N of donations - Allog N of donations - Allog N of donations - Allog related BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of transplants - Allogenic Autologous N of transplants - Allogenic N of transplants - Allogenic	s UK			NE	273.426		403.832		17.549		373.196	NA	NA		NE	129.472
N of searches request N of unrelated donations - Autologous N of donations - Allog Image: N of donations - Allog N of donations - Allog Image: N of unrelated cord Image: N of unrelated cord Image: N of unrelated cord blood Image: N of related cord blood Image: N of patients transplate Autologous N of transplants - Allogenic N of patients transplat Allogenic		.2		NL	273.420		403.032		17.545		575.190	NA NA	114			123.472
N of unrelated donations DONATIONS N of donations - Autologous N of donations - Allog N of donations - Allog N of donations - Allog related N of donations - Allog BANKING OF Unrelated cord CORD BLOOD N of unrelated cord blood unitss collect N of related cord blood unitss collected N of related cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of transplants - Allogenic N of patients transpla Allogenic N of patients transpla	ted UK	1.664		NE	4.663		9.376		1.798		64.526	NA	NA		NE	4.771
DONATIONS N of donations - Autologous N of donations - Allog N of donations - Allog N of donations - Allog related N of donations - Allog unrelated BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss collected N of related cord blood unitss collected N of related cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of patients transpla Allogenic N of patients transpla		NA		NE	648		2.526		25.294		909	301	NA		NE	425
Autologous N of donations - Allog N of donations - Allog related N of donations - Allog unrelated N of donations - Allog unrelated CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss collect N of related cord bloo unitss collected N of related cord bloo unitss collected N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of patients transpla Allogenic	tions UK	NA		NE	449		136		51		731	NA	NA		NE	NA
N of donations - Allog N of donations - Allog related N of donations - Allog unrelated BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss distributed N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic																
N of donations - Allog related N of donations - Allog unrelated BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss distributed N of related cord bloo unitss collected N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic	UK	NA		NE	3.548		495		3.371		2.084	664	7.622		NE	533
related N of donations - Allog unrelated BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of related cord blood unitss distrib N of related cord blood unitss collected N of related cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic N of patients transpla	genic 263	NA		NE	339		1.200		196		919	691	25.653		NE	171
BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss distrib N of related cord blood unitss collected N of related cord bloo unitss collected N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of patients transpla Allogenic N of patients transpla	igenic,															
Unrelated BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss collected N of related cord bloo unitss collected N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of patients transpla Allogenic N of patients transpla	263	NA		NE	202		77		64		795	178	12.315		NE	107
BANKING OF CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss distrib N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of pransplants - Allogenic N of patients transpla Allogenic	igenic,															
CORD BLOOD N of unrelated cord blood unitss collect N of unrelated cord blood unitss distrib N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic	0	NA		NE	137		1.123		132		124	513	13.338		NE	64
blood unitss collect N of unrelated cord blood unitss distrib N of related cord blood unitss collected N of related cord blood unitss collected N of related cord blood unitss distributed TRANSPLANT N of transplants - Autologous N of transplants - Altologous N of transplants - Allogenic N of patients transpla Allogenic																
N of unrelated cord blood unitss distrik N of related cord bloounitss collected N of related cord bloounitss collected N of related cord bloounitss distributed TRANSPLANT N of transplants - Autologous N of patients transplats - Altologous N of transplants - Allogenic N of patients transplats - Allogenic																
blood unitss distrik N of related cord bloo unitss collected N of related cord bloo unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic	cted 0	NE		NE	111		1.041		117		954	317	11.008		NE	109
TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic N																
TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic	buted 0	NE		NE	74		0		6		178	3	NA		NE	3
N of related cord blog unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic N of patients transpla	od															
Unitss distributed TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic Allogenic	265	95		125	1		3		16		NA	63	11.357		NE	NA
TRANSPLANT N of transplants - Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic	ood															
Autologous N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic	0	0		NE	1		0		0		0	0	NA		NE	NA
N of patients transpla Autologous N of transplants - Allogenic N of patients transpla Allogenic																
Autologous N of transplants - Allogenic N of patients transpla Allogenic	UK	138		NE	3.756		378		166		2.084	528	NA		33	526
N of transplants - Allogenic N of patients transpla Allogenic	anted -															
Allogenic N of patients transpla Allogenic	UK	NA		NE	1.094		361		135		0	505	NA		32	404
N of patients transpla Allogenic																
Allogenic	UK	74		NE	827		159		77		1.294	301	NA		NE	256
-	anted -															
NL of two works	UK	NA		NE	758		154		66		0	294	NA		NE	212
N of transplants -																
Allogenic, related	UK	21		NE	253		68		30		795	110	NA		NE	114
N of patients transpla																
Allogenic, related	1.07	NA		NE	230		68		24		0	104	NA		NE	142
N of transplants -	UK															
Allogenic, unrelate		53		NE	574		91		47		499	191	NA		NE	91
N of patients transpla	ed UK															
Allogenic, unrelate	ed UK anted -	NA		NE	528		86		42		0	190	NA		NE	121

				PRE	LIMINARY	DATA OI	THPC (CELLS - YE	AR 2018								
					LAT	IN AMERIC	AN CO	UNTRIES									
Country		Argentina	Brazil	Chile	Colombia	Costa Rica	Cuba	Dominicana	Ecuador	Guatemala	Mexico	Nicaragua	Panama	Paraguay	Peru	Uruguay	Venezuel
Population (Source: UNFPA, 2018 - Million)	state of world population,	44,7	210,9	18,2	49,5	5,0	11,5	10,9	16,9	17,2	130,8	6,3	4,2	6,9	32,6	3,5	32,4
CATEGORY OF DATA	TYPE OF DATA	NO DATA		NO DATA			NO DATA	Ą				NO DATA			NO DATA		NO DATA
POTENTIAL DONATION AND SEARCHING IN THE NATIONAL REGISTRIES	N of potential donors at 31.12		4.783.465		0	NA		0	35	0	0		0	0		1.230	
	N of cord blood units at 31.12		15.373		0	NA		0	0	0	0		0	0		0	
	N of searches requested		14.477		0	NA		0	0	0	0		0	0		26	
BANKING OF CORD BLOOD	N of unrelated cord blood unitss at 31.12		15.030		0	0		0	1.186	0	0		0	0		0	
	N of related cord blood unitss at 31.12		0		0	0		0	0	0	0		0	0		0	
TRANSPLANT	N of transplants - Autologous		1.294		471	15		0	25	0	0		31	17		89	
	N of patients transplanted - Autologous		0		471			0	0	0	0		31	17		0	
	N of transplants - Allogenic		1.000		423	64		0	10	0	0		0	1		32	
	N of patients transplanted - Allogenic		367		423	0		0	0	0	0		0	1		32	
	N of transplants - Allogenic, related		621		201	64		0	10	0	0		0	1		28	
	N of patients transplanted - Allogenic, related	i	0		201	0		0	0	0	0		0	1		4	
	N of transplants - Allogenic, unrelated		379		222			0	0	0	0		0	0		28	
	N of patients transplanted - Allogenic, unrelate	d	367		222	0		0	0	0	0		0	0		4	

Council of Europe Reference Documents. Year 2018



Illicit and Unethical Activities with Human Tissues and Cells: Addressing the Need for the Elaboration of an International Legal Instrument to Protect Donors and Recipients

as adopted following the 22nd meeting of the European Committee on Organ Transplantation (CD-P-TO) on 12 October 2018

Official document PA/PH/TO (17) 12 DEF

1. Introduction

Biomedical innovation has led in recent years to an increase in the use of human cells, tissues and cellor tissue-based products. Today these human substances, including musculoskeletal, cardiovascular and ocular tissues, haematopoietic progenitor cells, gametes and embryos, are routinely used for medical purposes, therapy and research. A consequence of this growth is that the processing and distribution of tissues and cells of human origin has progressively become an "industry" in some settings and donated human material treated as a commodity [1].

Despite considerable efforts by the European Commission, the number of human tissues and cells that are used for human application in the European Union (EU) healthcare setting can only be estimated. In a survey of EU competent authorities, more than 2.1 million human tissue and cell products were reported to have been distributed for medical use in 2015 [2]. It is unclear from these data whether these are only allogeneic products, or if tissues and cells for autologous use are also included in the reports from the member states (MS). Furthermore, information on the volume of tissue products imported into the EU from third countries or exported outside of the EU is not systematically collected.

From surveys of relevant professional societies in the field and estimates by the European Commission, the total number of tissues and cells used for human application can be broken down into the rough annual figures described in Table 1.

This burgeoning field is in some cases highly profitable. In some countries, a progressive transformation of initially not-for-profit activities into for-profit activities in the tissues and cells field (e.g. cornea [3], bone, gametes [4]) has been described, with the potential risk of not complying with the essential principle that *"the human body and its parts shall not give rise, as such, to financial*

Table 1. Estimated annual volume of clinical use of human tissues in the European Union ² .									
Human substance	Estimated volume*								
Corneas	35 000								
Heart valves/cardiovascular tissue	5 000								
Haematopoietic stem cells (including cord blood)	57 000								
Musculoskeletal tissue	190 000–250 000								
Skin	14 000								
Medically assisted reproduction (including partner donation)	700 000-800 000								
* In products /transplants /implants									

* In products/transplants/implants

gain". Thus, profit rather than medical need may be the motivating factor for the procurement of tissues and cells. Furthermore, the availability of donors (both living and deceased) is often a limiting factor for the procurement of tissue and cells, thus source materials are often scarce. Due to this scarcity and the potential financial profits, the risk of illicit and unethical activities involving human tissues and cells can be considered a realistic threat.

Much has been written about trafficking in human organs and human trafficking for the purpose of organ removal [5]. Reports of human exploitation for organ removal and its consequences have been widely reported in the literature [6]. Resolutions, Conventions and professional declarations and statements against these crimes have been adopted by the international community and national laws have been enacted or reinforced in many countries to not only prohibit, but also criminalise the trade in human organs. In contrast, limited attention has been paid to illicit and unethical activities associated with the procurement and clinical use of other substances of human origin, such as tissues and cells. This is perhaps because society is less familiar with tissue and cell transplantation compared with organ transplantation, although the latter happens far less frequently. Moreover, there is no international agreement on what represents illicit and unethical activities with human tissues and cells, and there is no consensus on which of these practices should be criminalised.

Various ethical and safety-related scandals have been reported, such as procurement without consent or authorisation, inadequate testing, inaccurate or false donor files, irresponsible allocation and illegal trade. Hearings, lawsuits, convictions, resignations and closures of tissue establishments have followed. Mediatised cases such as the "France Hypophyse scandal" [7], the "New York body-snatching ring" [8] and the "Alder Hey organ retention scandal" [9] drew public attention and called into question the adequacy of the regulatory framework that governed the human cell, tissue and cellularand tissue-based product industry [10].

Furthermore, there are activities that, in addition to their illicit and unethical component, could seriously jeopardise the quality and safety of tissues and cells and thus the recipient's safety. This is the case when excessive reimbursement for donation is given (e.g. in a third country) that could be an incentive for the donor not to disclose relevant information related to certain health risks, or when cell-based experimental treatments are promoted or performed without any clinically demonstrated safety and efficacy.

Regrettably, knowledge about the true extent of these illicit and unethical activities with tissues and cells remains limited [11]. Little information is available from official sources, with figures and trends mostly the result of estimates and rumours. Unsubstantiated reports often appear in the media, such as those describing the existence of undercover networks of brokers, technicians and physicians in various countries. There are probably more cases, but many may go unreported due to fear on the part of the victims/donors and silence on the part of those directly involved in these illicit but lucrative activities. Furthermore, when detected, there are significant disparities from country to country in the management of suspected activities in this context. Inspectors and enforcement officers lack specific training on how to deal with, identify and handle cases of suspected or confirmed illicit activities related to tissues and cells [12].

In view of this evidence, it becomes clear that a definition of "Trafficking in Human Tissues and Cells" should be agreed upon at international level with the involvement of all the relevant stakeholders. Furthermore, the Council of Europe could play a leading role in elaborating an international legal instrument setting out this definition and the measures to prevent such trafficking and protect the victims, as well as the criminal-law measures to punish the crime. Such initiative would follow the elaboration of the Convention against trafficking in human organs, which was adopted by the Committee of Ministers of the Council of Europe in July 2014, and represented the first legal document providing an internationally agreed upon definition of trafficking in human organs, and identifying activities that ratifying states must criminalise [11, 13]. During the preparation of the Convention, ad-hoc Committee of Experts on Trafficking in Human Organs, Tissues and Cells (PC-TO) acknowledged the need to develop an Additional Protocol on Tissues and Cells in the future. This need was further stressed by the Committee on Organ Transplantation of the Council of Europe (CD-P-TO) and the Council of Europe Committee on Social Affairs, Health and Sustainable Development of the Parliamentary Assembly [14].

2. Objectives

With this paper, the CD-P-TO aims to raise awareness among Council of Europe decision-making bodies of the necessity to explore the need for an additional protocol to define, prevent and combat illicit activities in the chain of donation to clinical application of human tissue and cells, and to protect donors and recipients.

The present document outlines the issues related to illicit and unethical activities with tissues and cells. In particular, it is intended to provide: i) a review of the existing international legal framework that regulates practices in the field of tissues and cells; ii) a compilation of the available evidence with regard to the dimension and features of illicit and unethical activities involving tissues and cells; iii) a description of the consequences of such practices from the public health and other perspectives; iv) based on the above, a discussion on the need to develop additional international legal tools against unethical practices in the field of human tissues and cells.

In summary, our intention is to use the conclusions and recommendations reached by the CD-P-TO and summarised in this project as food for thought for the Council of Europe decision-making bodies. We are convinced that this study will make us stronger in our fight against illicit activities involving tissues and cells of human origin.

3. International standards in the field of tissues and cells

3.1 World Health Organization

The World Health Organization (WHO), through its 2010 *Guiding Principles on Human Cell, Tissue and Organ Transplantation*, sets out standards for the donation, procurement, clinical use and equitable distribution of human tissues and cells [15]. Although not legally binding, the WHO Guiding Principles have profoundly impacted upon national legislation and professional codes of practice. The fundamental principles laid down include:

 Consent requirements: the living donor must provide duly informed, specific and free consent to the removal of tissues and cells. The Guiding Principles also call for the prohibition of the removal of tissues and cells from living minors, although exceptions may be permissible under national law in the case of regenerative tissues, provided that the minor is duly protected. In the case of the deceased donor, consent for the removal of tissues and cells must be obtained as required by national law, only where there is no reason to believe that the deceased person objected to such removal. Consent may be explicit ("opt in") or presumed ("opt out") depending on the existing legal requirements within a given jurisdiction. Where explicit consent has been given and recorded, for example in a donor registry, such consent may be withdrawn at any time before the procurement. Procurement on the basis of presumed consent cannot proceed where the donor has recorded or otherwise made known an objection to deceased donation.

- Prohibition of financial gain: the principle of unpaid donation and the prohibition of financial gain from the human body and its parts is established in the WHO principles. Living donors may be reimbursed for reasonable and verifiable expenses and loss of earnings directly related to the donation, but countries should define the conditions under which such compensation is justified, always avoiding financial incentives or benefits in kind to living donors or deceased donor families. Procurement must be carried out on a non-profit basis. Similarly, WHO allows the payment of professional fees for the services rendered in connection with the donation, procurement and clinical use of human tissues and cells. The prohibition of advertising the need for, or the availability of, human tissues and cells with a view to offering or seeking financial gain or comparable advantage is also set down.
- Allocation: the allocation of tissues and cells should be guided by clinical criteria and ethical norms, not financial or other considerations. Allocation rules, defined by appropriately constituted committees, should be equitable, externally justified and transparent.
- Self-sufficiency: countries should strive to achieve self-sufficiency in human tissues for patient treatment by endorsing donation of tissues and cells and thus removing the incentive for unethical practices involving tissue and cells of human origin.
- Altruistic donation: solidarity between donors and recipients should be advocated without financial gain.
- Equal access to grafts: allocation of human tissues and access to treatment should be based on clinical need only.
- Efficacy, safety and quality: WHO sets out the need to ensure traceability and vigilance systems and to

assess the outcomes of recipients of these substances of human origin and of living donors.

3.2 Council of Europe

The Council of Europe Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (Oviedo convention) and its Additional Protocol concerning Transplantation of Organs and Tissues of Human Origin detail some of the essential principles related to the donation of organs and tissue that have been agreed upon [16, 17]. This Convention has been ratified by 29 Council of Europe MS that are hence bound by this treaty.

The fundamental principles laid down by the Oviedo Convention include:

- Organ and tissue removal from living donors: removal of organs or tissue from living persons for clinical use may only by carried out when there is no other therapeutic alternative or organ/tissue available from deceased persons. The necessary consent as provided for under Article 5 must have been given expressly and specifically either in written form or before an official body (Article 19).
- Protection of persons not able to consent: the Convention prohibits the removal of organs or tissues from persons not able to provide valid consent (Article 20).
- Prohibition of financial gain: the human body and its parts shall not, as such, give rise to financial gain (Article 21).
- Disposal of a removed part of the human body: the use of parts of the human body must be restricted to that for which specific information and consent was given (Article 22).

The above principles are complemented by those in the Additional Protocol concerning Transplantation of Organs and Tissues of Human Origin as follows [17]:

- Professional standards and safety: the Protocol stresses the need to conform to professional obligations and standards (Article 4) and further expands on the need to minimise disease transmission or other harm to recipients (Article 6).
- Consent requirements: an organ or tissue may be removed from a living donor only after the person

concerned has given free, informed and specific consent to it either in written form or before an official body (Article 13). As regards deceased donation, it is stipulated that organs or tissues shall not be removed from the body of a deceased person unless consent or authorisation required by law has been obtained. The removal shall not be carried out if the deceased person had objected to it (Article 17).

- Prohibition of financial gain: it is stated that "the human body and its parts shall not, as such, give rise to financial gain or comparable advantage". The text goes on to say that the prohibition of financial gain does not prevent: (i) compensation of living donors for loss of earnings and reimbursement of any other justifiable expenses caused by the removal or by the related medical examinations; (ii) compensation in the case of undue damage resulting from the removal of organs, tissues or cells; (iii) the payment of a justifiable fee for medical or related technical services rendered in connection with the donation (Article 21).
- Organ and tissue trafficking: organ and tissue trafficking are expressly prohibited (Article 22). It must be noted that, while the Council of Europe has developed an international definition of practices that are consistent with trafficking in human organs [13], it has not performed the same exercise in the field of human tissues and cells.

To provide guidance to MS on the implementation of the principle of the prohibition of financial gain as laid down in Article 21 of the Oviedo Convention, a guide was adopted in 2017 – *Guide for the implementation of the principle of prohibition of financial gain with respect to the human body and its parts, as such, from living or deceased donors* – which provides clarification on key notions relevant to the above-mentioned principles and examples of what are considered as "altruistic focused measures" [18].

3.3 European Union

The *Charter of Fundamental Rights* of the EU should be highlighted, notably the principle set out in Article 3(2)(c), which states that the prohibition on making the human body and its parts as such a source of financial gain must be respected [19]. As mentioned above, this principle is also enshrined in Article 21 of the *Convention on Human Rights and Biomedicine* [16], and in the *WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation* [16].

The European Commission has issued the following EU Cell and Tissue Directives: 2004/23/EC [20]; 2006/17/EC [21]; 2006/86/EC [22] and 2015/565/566/EC [23]. These directives were designed to ensure harmonised and high standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human cells and tissues, to facilitate their cross-border movements and to ensure availability in the EU. If MS cannot achieve self-sufficiency, for example because of the scale of the issue or the effects of the potential measures, this can be done at Union level. This means that the Union is allowed to adopt measures in accordance with the principle of subsidiary as set out in Article 5 of the Lisbon Treaty¹.

These Directives apply to tissues and cells, including haematopoietic peripheral blood, umbilicalcord blood and bone marrow stem cells, reproductive cells (oocytes, sperm), foetal tissues and cells and adult and embryonic stem cells.

Under *Directive 2004/23/EC* [20], MS must establish an accreditation system for tissue establishments and ensure that appropriate control measures are in place for the procurement of human tissues and cells. Furthermore, MS must organise inspections and control measures, which have to be carried out by officials representing the competent authority, to ensure that tissue establishments comply with the provisions under the EU Directives. The officials involved in inspections and control measures must be appropriately qualified and receive adequate training.

The EU Directives do not, however, describe the penalties that can be imposed in cases of infringement of the national provisions adopted under the EU Directives. MS are obliged to lay down national rules on penalties with regard to breaches of compliance with the EU Directives, penalties that must be effective, proportionate and dissuasive. There is no general overview available of the penalties that the different MS have adopted to ensure compliance with the EU Directives, because of the freedom given to the MS in choosing a legal framework. However, it is known that not all MS have implemented criminal legislation for cases of infringement of the relevant legislation on the quality and safety of tissues and the protection of donors' rights.

To support MS implement a legal framework to combat illicit activities involving tissues and cells, an Inspection

guide for Competent Authorities was published in 2011– *Guidance on the detection and investigation of suspected illegal and/or fraudulent activity (IFA) related to tissues and cells* [24] to provide guidance to European Union (EU) Competent Authorities for detecting / identifying, investigating, managing and communicating such activities.

3.4 Professional societies

The Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, originally adopted in June 1964, is a set of ethical principles regarding human experimentation developed for the medical community by the World Medical Association (WMA). [25] It is widely regarded as the cornerstone document on human research ethics. The Declaration developed the ten principles first stated in the Nuremberg Code [26], and tied them to the Declaration of Geneva (1948), a statement of physicians' ethical duties [27]. Subsequently, in 2012, the WMA also adopted a Statement On Organ And Tissue Donation [28].

The Barcelona Principles: An Agreement on the use of human donated tissue for ocular transplantation, research, and future technologies is an international consensus document, developed by the eye bank and ophthalmic communities under the leadership of the Global Alliance of Eye Bank Associations (GAEBA), to inform on the management of altruistic and voluntary ocular tissue donations, their subsequent utility within ophthalmology and research, their retention as a public resource for the shared benefit of all, and their accessibility by waiting recipients [29]. This document is the result of global sector engagement over a 12-month period that aims at providing leadership, guidance and recommendations that inform and support sound policy, sector wide strategic planning and implementation at local, national, regional, and international levels.

4. Dimension and characteristics of unethical activities involving human tissues and cells

Little research has been performed to investigate the extent of illicit and unethical activities with human cells and tissues in Europe and worldwide. Most of the information comes from case reports, investigating authorities such as the police or health departments and from articles published in the press.

¹ Under the principle of subsidiarity, in areas which do not fall within its exclusive competence, the Union shall act only if and insofar as the objectives of the proposed action cannot be sufficiently achieved by the Member States, either at central level or at regional and local level, but can rather, by reason of the scale or effects of the proposed action, be better achieved at Union level.

When illicit and unethical activities involve donors, they frequently relate to recently deceased persons. Tissues may have been sold for the purpose of research or clinical use without the authorisation required in the corresponding jurisdiction, or with falsified papers. Illicitly obtained tissues from one deceased person can reach up to 90 tissue recipients.

When recipients are victims of such practices, cases involve the use of illicitly and/or unsafely procured grafts, but also unethical medical practices such as unauthorised indications or medical treatments without any evidence of efficacy that may cause harm to patients [30]. The latter, however, are primarily violations of laws on practicing medicine and professional medical standards and cannot be prevented simply by regulating the quality and safety of tissues and cells for clinical use.

For the purpose of this document, we define illicit practices in the field of human tissue and cells as any practice performed in violation of one or more legal requirements or guiding principles, as set down in international legally binding instruments (see **Section 3**) that are related to the donation and/or human application of tissue and cells of human origin (see **Table 2**).

4.1 Results from the SOHO V&S project

In 2011, a report on illicit activities involving tissues and cells was prepared as part of an EUfunded project entitled "Vigilance and Surveillance of Substances of Human Origin (SOHO V&S)"² [13]. This report aimed at providing EU MS Competent Authorities responsible for tissues and cells with guidance on detecting/identifying, investigating, managing and communicating such activities.

In order to evaluate the experience with illicit activities related to tissues and cells, a questionnaire was developed as part of this project. The questionnaire was submitted to EU Competent Authorities, as well as to several other third countries, during 2010. The scope of the questionnaire was *Directive 2004/23/EC* on tissues and cells used in transplantation and assisted reproduction.

The questionnaire elicited 26 responses from 22 EU MS, 3 European non-EU countries (at the time Croatia had not yet joined the EU) and 1 non-European country³.

An analysis of all the responses showed that many questionnaires were incomplete due to the fact that MS had limited insight into the matter. Some findings, however, could be highlighted:

- The majority of countries had legislation in place related to illicit activities, which was applicable to human tissue and cells. Those who did not have any legislation in place indicated that they considered it necessary or were working on it.
- Twelve countries indicated having had actual experience with illicit activities over the previous 5 years. In addition, 15 countries had experienced misleading and unsubstantiated claims related to the beneficial effects of cell and tissue transplants.
- Eighteen countries had reported these incidents to other agencies and/or the general public.
- Seventeen cases of illicit were reported which dealt with gametes (sperm, oocytes, embryos), cord blood/tissue and bones/musculoskeletal tissue. Of these, nine were confirmed as constituting illicit activities and the others were still under investigation at the time the questionnaire was being completed. Most of the illicit activities had occurred during the procurement/donation stage of the process.
- Sanctions were imposed where cases of illicit activities had been identified, but it is notable that criminal and administrative sanctions are under the sovereignty of each MS and not EU institutions. Non-harmonised legislation in this regard means that an activity that is criminalised in one MS might not be so in another jurisdiction.

4.2 Interpol survey

At the request of the French Health Authority, a similar survey was developed by Interpol for Law Enforcement Agencies in 2012. In total, representatives from 43 countries completed this survey, most of them from policy-making agencies. One third of the respondents (14) reported cases of illicit with tissues and cells. These reports were based not only on questionnaires, but also on the Interpol database, scientific literature and other open sources. Only 50% of the respondents found legislation in their country sufficient in these matters.

² Grant Agreement Number: 20091110. Funded under the EU Second Programme of Community Action in the Field of Health.

³ Belgium, Croatia, Cyprus, Czech Republic, Denmark, Germany, Estonia, Iceland, Spain, Finland, France, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovenia, Sweden, United Kingdom, United States of America..

The types of tissue and cells subjected to illicit activities in these reports were bone (including demineralised bone), tendons and ligaments, ocular tissues (corneas and sclera), skin, human placenta, cord blood for autologous use and gametes.

4.3 Case reports

One of the most cautionary examples of a large-scale fraud is the case of Biomedical Tissue Services Ltd (BTS), where intentional misconduct with tissue donors turned out to be highly lucrative and led to a risk of harm to

Table 2. Areas of potential unethical activities in the field of	f tissues and cells.
Violation	Related legislation/principles
 Procurement of tissue/cells without free, specific and informed consent (living donor) or without the authorisation required in a given jurisdiction, for the purpose of: Clinical use Research Further processing as innovative therapies (e.g. in the EU, following under the regulatory frameworks of medical devices or advanced therapy medicinal products) Use of surgical residues without free, specific and informed consent 	 Directive 2004/23/EC (Article 13) Council of Europe recommendation (2006)4 Convention on Human Rights and Biomedicine and additional protocols (CETS 168,186,195,203)
Violation of body integrity beyond the necessity to procure tissue or cells	 Council of Europe recommendation (2016)6 Convention on Human Rights and Biomedicine and additional protocols (CETS 168,186,195,203)
Unlicensed storage, processing, distribution, testing	 Directive 2004/23/EC (Article 6) Directive 2006/86/EC (Articles 3 and 4)
Breach of legal requirements for traceability, donor evaluation, testing, processing, storage and distribution	 Directive 2004/23/EC (Article 8) Directive 2015/565/EC (Article 1, sub paragraph 2)
Excessive reimbursement or compensation of living donors or a third party in return for the donation of human tissues or cells	 Directive 2004/23/EC (Article 12) Council of Europe Convention on Human Rights and Biomedicine (Article 21) Additional Protocol on transplantation of organs and tissues of human origin (Article 21)
Distribution of unauthorised tissue and cell products (e.g. from unlicensed tissue establishments, illegal imports, brokers)	 Directive 2004/23/EC (Articles 6 and 9(3)) Directive 2015/566/EC (Article 3)
Promotion of tissueand cell-based experimental treatments without evidence of safety and/or efficacy	 WHO Guiding Principle 10 Additional Protocol to the Convention on Human Rights and Biomedicine concerning Transplantation of Organs and Tissues of Human Origin (Articles 4 and 6)

patients. Between 2002 and 2005, BTS distributed tens of thousands of illegally obtained and improperly processed tissues throughout the world. BTS acquired tissues from cooperative funeral homes in the New Jersey area without any authorisation, and produced false death certificates and infectious disease test results. The Food and Drug Administration (FDA) estimated that 13,000 patients had ultimately received tissues processed by BTS. Not all hospitals kept records of which tissues had been implanted and in which patients, so the impact on recipients' health remains largely unknown.

The FDA responded to the BTS scandal by strengthening the regulations governing tissue procurement. However, within a year, another organisation supplying improperly obtained and processed tissues, and using an almost identical *modus operandi*, was discovered to be operating in North Carolina, under the name Donor Referral Services [31].

In Europe, similar practices have been brought to the European Court of Human Rights: the removal of tissue from a deceased man's body without the knowledge or consent of his wife amounted to degrading treatment [32]. The applicant was a Latvian woman whose husband had died in a car accident. After the autopsy had taken place, it emerged that tissue had been removed from the body prior to the funeral without her knowledge or consent. Under a State-approved agreement, the tissue had been sent to a pharmaceutical company in Germany to be modified into bio implants. During the course of the investigation, it was established that in 1999 tissues had been removed from 152 people; in 2000, from 151 people; in 2001, from 127 people; and in 2002, from 65 people. In exchange for the supply of tissue to the company in Germany, the forensic centre involved had organised the purchase of various items of medical equipment, instruments, technology and computers for medical institutions in Latvia.

The Court underlined that, in the special field of organ and tissue transplantation, it had been recognised that the human body had to be treated with respect even after death. Indeed, international treaties, including the *Convention on Human Rights and Biomedicine* and its *Additional Protocol on Transplantation* [16, 17], were drafted to protect the dignity, identity and integrity of "everyone" who had been born, whether at the time living or dead. The Court stressed that respect for human dignity formed part of the very essence of the European Convention.

Between 2009 and 2012, concerns were raised about illegally obtained tissues in forensic institutes in Ukraine;

these were intended for the German and US markets and processed by for-profit tissue processors in both countries [33]. Although relatives of the deceased accused the forensic institutes of falsifying consent forms and/or obtaining more tissue than originally agreed upon, the police investigation could not substantiate illegal activities according to Ukrainian law. The processors stopped acquiring human tissue from Ukraine after negative publicity.

Recently, the financial gains made by abortion clinics as a result of selling foetal waste material for research purposes have come under public scrutiny. Although these practices have been going on for decades, ownership of the remains of the foetus and the necessity for consent from the mother has not been regulated in several European countries and therefore these practices continue despite the fact that in other countries they are considered to be a violation of principles and legal requirements.

Practices at some European sperm banks have also come under scrutiny. Among them, the direct sale of sperm samples to women for home insemination. In addition, because several MS prohibit anonymous gamete donation (with the purpose of protecting the right of the child to know its parent), distribution of anonymous sperm to some countries is considered illegal.

Stem cell therapy brings a new challenge to the field because of the fraudulent practice of offering cures for almost every known disease using stem cells from different sources (autologous, embryonic, allogenic), sometimes obtained and implanted without fulfilling any legal or quality requirements, and in all cases without any evidence of efficacy of these treatments [34].

5. Potential and actual consequences of unethical activities from the perspectives of society and public health

5.1 Risks for recipients

The most important risk for recipients of tissues or cells obtained through illicit and unethical activities is the lack of control of the quality and safety of the tissue or cell products. Risk are increased by incorrect donor histories, doubtful procurement circumstances, incomplete documentation and traceability, inadequate processing, storage and labelling and lack of vigilance and recall options. The consequences may be diverse but can potentially seriously jeopardise the clinical outcome of the patient. As is the case with organ trafficking, and in particular due to less stringent acceptance criteria, there is an enhanced risk of viral, bacterial or fungal infections transmitted via grafts procured in the context of illicit and unethical practices. In the past, several diseases have been transmitted via tissues and human cells: bone allografts have transmitted hepatitis viruses, tuberculosis and human immunodeficiency virus (HIV-1) [35]. Corneas have transmitted rabies, herpes simplex viruses, bacteria and fungi. Heart valves have been implicated in transmitting tuberculosis and hepatitis B. HIV-1 and cytomegalovirus seroconversion have been reported in patients receiving skin from seropositive donors. Creutzfeldt-Jacob disease has been transmitted by dura and pericardium transplants and several bacteria, such as Treponema, have been transferred through tissue. There are also potential dangers associated with stem cell therapy, such as malignant transformation of the implanted cells [36].

When illicit and unethical practices occur in the form of financial inducement to donors (or their families), there may be a risk of potential living donors not adequately considering and evaluating the potential risks related to the donation procedure or of donors or their families not disclosing relevant medical or behavioural information that would, under normal circumstances, preclude donation. This can also motivate intermediaries to withhold information for fear of losing fees.

While it cannot be stated that these complications are more frequent or particularly severe in the context of illicit and unethical practices with tissues and cells, inappropriate donor (and recipient) selection and substandard practices applied to the procurement, processing and allocation of human tissues and cells are more likely to result in harm to patients.

Desperation may lead patients to search for alternative treatment options for a substantial number of diseases. In this context, advances in the field of stem cell therapies have been accompanied by the promotion of the clinical use of tissues and cells of human origin with no scientific evidence in terms of efficacy and safety. On occasion, patients travel outside of their country of origin in search of these "miraculous" treatments that violate fundamental ethical principles and quality and safety standards (this is the so-called stem cell tourism).

5.2 Consequences for donors or next of kin

The procurement of tissue and cells without consent, or with consent based on insufficient information, may

cause severe psychological stress to the living donor and/or deceased donors' families. In particular, the idea that parts of the body "live on" elsewhere, or that the body of the deceased has been violated, often for financial gain, can cause trauma for donors (e.g. repeated and uncontrolled oocyte donation) and their next of kin.

Excessive damage to the deceased body, in the case of unprofessional procurement of tissue, may cause stress during the funeral and leave a permanent stain on relatives' memories of the donor. Other medical considerations include inadequate care and treatment of living donors after procurement of tissue or cells, including donation-related complications. Linked to the lack of appropriate clinical follow up, there is a possible absence of full traceability from donors to recipients and vice versa, as well as failure to record and report serious adverse events and reactions.

5.3 Consequences for the healthcare system

Successful tissue and cell donation and transplantation programs depend on public trust and support. The confidence of the general public in the donation system for tissue and cell products, in a context where the principle of voluntary unpaid donation is legally endorsed, is already threatened by the fact that certain human products are distributed via commercially used channels for pharmaceuticals and medical devices. Furthermore, the public has been shocked on several occasions by incidences of illicit medical practices where unfounded cures were promised by applying human materials.

Against this background, illicit and unethical practices pose an even bigger threat to public trust and support. Not only will scandals related to such practices cause a drop in confidence in all types of donor-derived products, but it will also result in a reluctance to donate bodily materials at all.

Ultimately this will affect the availability of tissue and cell grafts, and jeopardise the availability of organ and blood donors as well.

It is worth noting that desperate patients (as is the case with organ transplantation) who would like to find a solution for their disease are easy prey for illicit and unethical practices with human tissues and cells.

In the end, when financial gain plays a role, the allocation of human tissues and cells according to clinical needs no longer takes priority and this introduces inequality in access to treatment. Patients who benefit will tend to be those who can afford to pay. In addition to financial incentives to donate, there may be coercion, fraud and abuse of donors, as well as long-term medical, social and financial harm to living donors.

Finally, the risk of transmitting infections or other diseases with tissue or cells obtained through illicit and unethical practices does not only endanger the recipients, but may also affect others that are in contact with the recipients thus constituting a serious public health threat.

6. Conclusions

- The volume of tissue and cell donation and transplantation activities in Europe is substantial and the sector is developing fast, being subject to technological innovations and increasing commercial interest.
- The scarcity of donor material and the potential for financial gain from human tissues and cells for human application may encourage illicit activities. Although some cases of have come to light, the true dimension of the problem remains unknown in the absence of systematic and coordinated efforts to define and monitor these practices (last inventory in 2015).
- Illicit activities with tissue and cells may pose a risk to the individual health of both the donor and the recipient, by causing harm through unnecessary procurement procedures, facilitating the transmission of diseases (which also poses a risk to public health) or applying therapies that have not been tested in terms of safety and quality for the individual.
- Illicit activities may jeopardise public trust and willingness to altruistically donate tissue and cells and therefore limit the availability of these essential healthcare provisions for patients.
- The confidence of the general public in the donation system may be undermined by unethical but very lucrative medicinal procedures, in which treatments with tissues and cells offer unproven cures.
- The existing international legal framework provides ample provisions to ensure good practices and the quality and safety of tissues and cells, e.g. by specifying consent and authorisation requirements, prohibiting financial gain and creating the obligation of sanctions/penalties in cases of violation of such provisions. These provisions and sanctions, however, have not yet been implemented in all European

countries and most of those found to be violating these requirements have not been subject to sanctions.

Despite the existing legal framework, the interpretation of what constitutes illicit practices differs between countries; this may result in tissueand cell-related activities being acceptable in one country while illegal in a neighbouring one. Moreover, there is no international agreement on which illicit practices are of such severity – because they violate fundamental human rights and freedoms, such as that of selfdetermination, dignity and integrity and/or because they pose important threats to public health - that they should be subject to criminalisation and made consistent with trafficking in tissues and cells. International agreement and coordinated efforts against trafficking in human tissues and cells are imperative in this field where transnational activity is frequent.

7. Recommendations

- 1. The principle of the prohibition of making financial gain with the human body or its parts should be the paramount consideration in relation to the donation of tissues and cells of human origin. All national legislations concerning the donation and human application of tissues and cells should conform to this principle.
- The definition and interpretation of what constitute illicit activities, as well as the need for adequate sanctions against these practices, should be agreed at international level. In particular, international agreement should be reached on which illicit activities involving human tissue and cells are of such severity

 because they imply the violation of fundamental principles and/or pose important threats to public health – that they should be criminalised.
- Collaboration between international organisations, as well as national and international law enforcement agencies, such as Interpol and Europol, are indispensable where illicit practices are detected or suspected at an international level or where is the potential to have international consequences.
- 4. Cooperation among customs authorities, law enforcement agencies and Health Authorities should be strengthened, particularly during ongoing investigations. To coordinate the identification and management of suspected cases, clearly defined roles, training and education for all involved parties

and adequate resources should be set in place.

- Donors and recipients of tissues and cells, and the general public, should be informed of donors' rights and the legal context of donating, processing and distributing human materials for medical and research purposes, including (acceptable) commercial involvement.
- Healthcare professionals should continue to promote standards for ethical practices in the field of tissues and cells. Professional societies should have a leading role in the development and dissemination of such professional codes of ethics.
- 7. It is essential to start collecting reliable data on illicit activities involving human tissues and cells. There is limited knowledge of the scale of the problem since little and fragmentary information about the number of trafficked tissues and cells and victims of illicit practices is available from official sources. This hinders both the quantification of illicit practices and also their gualitative description. The data should be disaggregated by sex in order to assess whether and to what extent the processes disproportionately affect women and girls. States should make efforts in terms of data collection in relation to illicit practices and commission an international body to systematically monitor and report international data and exchange good practices for the prevention and prosecution of such activities.

References

- Pirnay JP, Vanderkelen A, Ectors N, Delloye C, Dufrane D, Baudoux E, et al. Beware of the commercialization of human cells and tissues: situation in the European Union. Cell Tissue Bank 2012;13(3): 487-498.
- Summary of the 2016 annual reporting of serious adverse reactions and events for tissue and cells. Available at: https://ec.europa.eu/health/sites/health/files/blood_tissues _organs/docs/2016_sare_tc_summar y_en.pdf, accessed in September 2018.
- 3. Mannis MJ, Sugar J. Is this the future of eye banking? Cornea 2018; 37; 811-812.
- Sperm donation: a lucrative and growing industry. Financial Times. Available at: https://accessed in September 2018.
- Danovitch GM, Chapman J, Capron AM, Levin A, Abbud-Filho M, Al Mousawi M, et al. Organ trafficking and transplant tourism: the role of global professional ethical standards-the 2008 Declaration of Istanbul. Transplantation 2013; 95: 1306-1312.
- López-Fraga M, Domínguez-Gil B, Capron AM, Van Assche K, Martin D, Cozzi E, Delmonico FL. A needed Convention against trafficking in human organs. Lancet 2014; 383(9936): 2187-2189.

- 7. Spurgeon B. French doctors are tried for treating children with infected growth hormone. BMJ 2008; 336: 348-349.
- 8. Waltz E. The body snatchers. Nat Med 2006;12:487-488.
- 9. Redfern M, Keeling JW, Powell E. The Royal Liverpool children's inquiry report. London: HMSO; 2001.
- 10. Collins S. Tissue Banks: Is the Federal Government's Oversight Adequate? Hearing before the Committee on Governmental Affairs. Washington: US Senate Diane Pub Co; 2001.
- Explanatory Report to the Council of Europe Convention against Trafficking in Human Organs. Available at: https://wcd.coe.int/ViewDoc.jsp?Ref=CM%282013%2979& Language=lanEnglish&Ver=addfinal&Sit e=COE&BackColorInternet=DBDCF2&BackColorIntranet=F DC864&BackColorLogged=FDC864, accessed in September 2018.
- The detection and investigation of suspected illegal and/or fraudulent activity (IFA) related to tissues and cells

 Survey Report. SOHO V&S Project, Deliverable 7 (2011).
 Available at: https://webgate.ec.europa.eu/chafea_pdb/assets/files/pdb /20091110/20091110_d07_oth_en_ps. pdf, accessed in September 2018.
- Council of Europe Convention against Trafficking in Human Organs. Available at: https://wcd.coe.int/ViewDoc.jsp?Ref=CM/Del/Dec%282014 %291205/10.3&Language=lanEnglish& Ver=app10&Site=COE&BackColorInternet=DBDCF2&BackC olorIntranet=FDC864&BackColorLogged =FDC864, accessed in September 2018.
- 14. Combatting trafficking in human tissues and cells. Motion for a recommendation tabled by the Committee on Social Affairs, Health and Sustainable Development. Available at: pace.net/tools/pdf.aspx?doc=aHR0cDovL2Fzc2VtYmx5Lm NvZS5pbnQvbncveG1sL1hSZWYvWDJILURXLWV4dHIuYXN wP2ZpbGVpZD0yMzkyOSZsYW5nPUVO&xsl=aHR0cDovL3 NIbWFudGljcGFjZS5uZXQvWHNsdC9QZGYvWFJIZi1XRC1B VC1YTUwyUERGLnhzbA==&xsltparams=ZmlsZWlkPTIzOT5, accessed in September 2018.
- 15. WHO Guiding Principles On Human Cell, Tissue and Organ Transplantation. Available at: accessed in September 2018.
- 16. Convention for the protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (ETS No. 164). Available at: https:// accessed in September 2018.
- 17. Additional Protocol to the Convention on Human Rights and Biomedicine concerning Transplantation of Organs and Tissues of Human Origin (ETS No. 186). Available at: https://accessed in September2018.
- Guide for the implementation of the principle of prohibition of financial gain with respect to the human body and its parts from living or deceased donors. Available at: https://rm.coe.int/guidefinancialgain/16807bfc9a, accessed in September 2018.
- 19. Charter of Fundamental Rights of the European Union. Available at:accessed in September 2018.
- 20. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Available at: https://eurlex.europa.eu/legalcontent/EN/TXT/?uri=CELEX%3A32004L 0023, accessed in September 2018.

- 21. Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells (Text with EEA relevance). Available at: https://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=CELEX:32006L0017, accessed in September 2018.
- 22. Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells (Text with EEA relevance). Available at: https://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=CELEX:32006L0086, accessed in September 2018.
- 23. Commission Directive (EU) 2015/565 of 8 April 2015 amending Directive 2006/86/EC as regards certain technical requirements for the coding of human tissues and cells Text with EEA relevance. Available at: https://eurlex.europa.eu/legalcontent/EN/TXT/?uri=uriserv:OJ.L_.2015 .093.01.0043.01.ENG, accessed in September 2018.
- 24. Guidance on the detection and investigation of suspected illegal and/or fraudulent activity (IFA) related to tissues and cells. SOHO V&S Project (2011). Access restricted to National Competent Authorities for Tissues and Cells, but a summary of the recommendations may be found in Chapter 9 of the following document: accessed in September 2018.

- 25. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available at: httww.w research-involving-human-subjects/, accessed in September 2018.
- 26. The Nuremberg Code. Available at: https://history.nih.gov/research/downloads/nuremberg.pd f, accessed in September 2018.
- 27. Declaration of Geneva. Available at: https://www.ethics/declaration-of-geneva/, accessed in September 2018.
- 28. WMA Statement on Organ and Tissue Donation. Available at: httpsw.w post/wma-statement-on-organ-and-tissue-donation/, accessed in September 2018.
- 29. The Barcelona Principles. Available at: content/uploads/2018/05/GAEBA-2018-The-Barcelona-Principles-FINAL.pdf, accessed in September 2018.
- 30. Barclay, E. Stem-cell experts raise concerns about medical tourism. Lancet 2009; 379: 883-884.
- Centers for Disease Control and Prevention (CDC). Brief report: investigation into recalled human tissue for transplantation—United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2006; 55(20): 564-566.
- 32. 32. Court ECHR 005 (2015)/13.01.2015.
- 33. International Consortium of Investigative Journalists "Skin and Bone". Available at: https://www.accessed in September 2018.
- 34. Kiatpongsan S, Sipp D. Monitoring and regulating offshore stem cell clinics. Science 2009; 323(5921): 1564-1565.
- 35. Notify Library. Available at: accessed in September 2018.
- 36. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donorderived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009 Feb 17;6(2):e1000029

An	nex 1. Questionnaire to compile information on experience of illegal and fraudulent and cells.	activities with tissues
1.	Please provide the number of suspected IFA cases related to tissues and cells your CA/MS has been involved in the last 5 years	
2.	What, in your opinion, are the strengths and weaknesses of the IFA management system in your MS? Please summarise. strengths: weaknesses:	🗌 Yes 🗌 No
3.	Do you have any experience in dealing with misleading advertising in the use of tissues and cells (i.e. unsubstantiated claims)? If Yes , please summarise	🗌 Yes 🗌 No
4.	Do you have procedures to communicate suspected IFA cases to other agencies/the public? If Yes , please summarise	🗌 Yes 🗌 No
5.	Have you had any experience with a "virtual" tissue establishment that is involved in import/export? If Yes , please summarise	🗌 Yes 🗌 No

Annex 2. Examples of cas	es relat	ed to consent matters.	
Case	Year	Reason for case	Decision/settlement
Beleno v. Tex. Dept. of State Health Servs., No. SA-09-CA-188-FB, United States District Court for the Western District of Texas	2009	Parents sued state for use of leftover blood samples that were collected for new-born blood screening and were used in research for which parents had not given consent.	Case settled out of court. State destroyed all existing leftover specimens.
Adams v. King County, 192 P. 3d 891 (Wa. 2008)	2008	Organ donor's organs were sent to medical research institute for research. Family sued, contending that donor's consent was limited to transplantation.	Court held that family had a claim based on their interest in proper treatment of body; not a property interest.
Washington University v. Catalona, 490 F 3d 667 (8th Cir. 2007)	2007	Washington University refused to relinquish custody of tissue obtained for research purposes when one of the investigators (and some of the donors) requested that the samples be transferred to another institution.	Court held that donors made a gift of their samples and did not retain a right to direct that they be transferred elsewhere.
Havasupai Tribe v. Arizona State University, Case No. CV2005013190, Superior Court of Arizona, Maricopa County	2004	Native American tribe filed lawsuit claiming samples given to local universities for diabetes research were used for studies on inbreeding, schizophrenia, metabolic diseases, alcoholism and population migration.	Case settled out of court. The University of Arizona's Board of Regents to pay \$700,000 to the tribe members, provide other forms of assistance to the impoverished Havasupai and return the blood samples.
Greenberg v. Miami Children's Hospital Research Institute, 264 F. Suppl. 2d, 1064 (SD Fl. 2003)	2003	Plaintiffs donated samples for research which led to development of new diagnostic test. Plaintiffs sued after learning that research institution was licensing the test.	Patients have no property right in tissue voluntarily donated for medical research.
Application nº 61243/08 by Dzintra ELBERTE v Latvia	2001	After the autopsy had taken place, it emerged that tissue had been removed from the body prior to the funeral without his wife knowledge or consent. More cases were discovered later.	Although relatives of the deceased accused the forensic institutes of falsifying consent forms and/or obtaining more tissue than originally agreed upon, the police investigation could not substantiate IFA according to Ukrainian law
Mansaw v. Midwest Organ Bank, 1998 U.S. Dist. LEXUS 10307 (W.D. Mo. 1998)	1998	Father sued for rights to control the removal of tissue and organs from his deceased son's body.	Court acknowledged father's property interest, but held that it was minimal.

Annex 2. Examples of cases related to consent matters. (cont.)				
Case	Year	Reason for case	Decision/settlement	
Moore v. Regents of University of California, 793 P.2d 479 (Cal. 1990)	1990	Patient's cells were used for research without his knowledge or consent. Patient sued after learning that research institution had developed cell line and realised economic benefit.	Court held that patient did not have property right in excised tissue, but could pursue a breach of fiduciary duty claim.	
York v. Jones, 717 F. Suppl. 421 (E.D. Va. 1989)	1989	Couple signed agreement regarding procedures for freezing their fertilised eggs, and permitting use for research if they no longer desired to initiate a pregnancy. Later the couple sought to have the prezygote transferred to another medical school for implantation.	Court ruled that the relationship was that of bailee/bailor and the couple did have property rights and could repossess the prezygote.	

Signatures & Ratifications of the Council of Europe Convention against Trafficking in Human Organs

Signatures

AND

 \leq

Armenia	24/01/2018
Austria	25/03/2015
Belgium	25/03/2015
Costa Rica*	16/04/2018
Greece	25/03/2015
Ireland	
Italy	25/03/2015
Luxembourg	
Russian Federation	
Spain	
Switzerland	10/11/2016
Turkey	25/03/2015
Ukraine	11/09/2017
United Kingdom	25/03/2015

Ratifications

Albania	06/06/2016
Croatia	16/05/2019
Czech Republic	21/09/2017
Latvia	09/07/2019
Malta	07/11/2017
Montenegro	05/02/2019
Norway	12/09/2017
Portugal	08/11/2018
Republic of Moldova	21/06/2017




Signature Ratification

Entry info force 01/03/2018

* Non-member states of the Council of Europe

seg. . . . , j



HEALTH MATTERS: INFORMATION BOOKLETS FOR THE GENERAL PUBLIC



Members of the European Committee (Partial Agreement) on Organ Transplantation (CD-P-TO) at (08.04.2019)

Secretariat LÓPEZ FRAGA Marta I OMFRO Mar MARCO Jaime SANCHEZ Ahlem Chair DOMÍNGUEZ-GIL Beatriz Vice-Chair KAMIŃSKI Artur Members AUSTRIA FRITZ Stephanie BRIX-ZULEGER Martina **ZUCKERMANN** Andreas WOREL Nina BELGIUM COLENBIE Luc **BULGARIA** ILIEV Dimitar AVRAMOVA Boryana CROATIA **BUSIC** Mirela ANUSIC JURICIC Martina GOLUBIC CEPULIC CYPRUS MICHAEL Nicolaos CZECH REPUBLIC ADAMEC Miloš DENMARK **ILKJAER** Lars **FSTONIA** DMITRIEV Peeter KAARE Ain FINLAND MAKISALO Heikki FRANCE **ARRABAL Samuel** SAINTE-MARIE Isabelle GERMANY SIEPMANN Claudia RAHMEL Axel TONJES Ralf Reinhard GREECE **BOLETIS** Ioannis HUNGARY **MIHALY Sandor ICELAND HEIMISDOTTIR Jorlaug IRFI AND** EGAN Jim SHERIDAN Gerard ITALY **CARDILLO** Massima COZZI Emanuele PORTA Eliana **CARELLA** Claudia **MORRESI** Assunta LATVIA JUSINSKIS Janis **BORMOTOVS** Jurijs LITHUANIA **BUZIUVIENNE** Audrone LUXEMBURG **REMY Philippe** MALTA ZARB ADAMI Joseph ABELA Carmel CALLEJA Paul MONTENEGRO **RATKOVIC Marina** NORWAY **HAGNESS** Morten POI AND CZERWINSKI Jaroslaw PORTUGAL BOLOTINHA Catarina PIRES DA SILVA Ana **REPUBLIC OF MOLDOVA** CODREANU Igor TIMBALARI Tatiana ROMANIA

LESAN Andrei DRAGOMIRISTEANU Aurora

SERBIA LONCAR Zlatibor **SLOVAK REPUBLIC DEDINSKA** Ivana **SLOVENIA** AVSEC Danica SPAIN GAYOSO CRUZ Jorge PEREZ BLANCO Alicia SWEDEN STROM Helena SWITZERLAND IMMER Franz VOLZ Alexandra THE NETHERLANDS HAASE-KROMWIJK Bernadette **BOKHORST Arlinke** TURKEY **UNSAL Ilker** ATES Utku UKRAINE NIKONENKO Oleksandr NYKONENKO Andriy UNITED KINGDOM FORSYTHE John Observers ARMENIA SARKISSIAN Ashot **DAGHBASHYAN Smbat BELARUS** RUMMO Oleg LIASHCHUK Siarhei CANADA AGBANYO Francisca DH-BIO (BIOETHICS COMMITTEE, COUNCIL OF EUROPE) HALILA Ritva **DTI FOUNDATION** MANYALICH Marti EUROPEAN ASSOCIATION OF TISSUE AND CELL BANKS (EATCB) SANCHEZ IBANEZ Jacinto HENNERBICHLER Simone **EUROPEAN COMMISSION** PUCINSKAITE-KUBIK Ingrida FEHILY Deirdre **EUROPEAN EYE BANK ASSOCIATION (EEBA) ARMITAGE** John EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) BERNEY Thierry EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND **EMBRYOLOGY (ESHRE)** LUNDIN Kersti **EUROTRANSPLANT BRANGER** Peter GEORGIA TOMADZE Gia HOLY SEE Mgr RUDELLI Paolo ISRAEL ASHKENAZI Tamar **RUSSIAN FEDERATION** GABBASOVA Lyalya **NIKOLAEV** German SCANDIATRANSPLANT ERICZON Bo-Göran SOUTH-EUROPE ALLIANCE FOR TRANPLANTS (SAT) **IMMER Franz** THE TRANSPLANTATION SOCIETY (TTS) TULLIUS Stefan **DELMONICO Francis UNITED NETWORK FOR ORGAN SHARING (UNOS) PRUETT Timothy** USA WITTEN Celia WORLD HEALTH ORGANIZATION (WHO) NUÑEZ Jose Ramón CHATZIXIROS Efstratios WORLD MARROW DONORS ASSOCIATION (WMDA) **FOEKEN Lydia**



ESSENTIAL GUIDANCE FROM EDQM

NEW!

Guide to the quality and safety of tissues and cells for human application 4th Edition Guide to the quality and safety of organs for transplantation 7th Edition



TISSUES AND CELLS



EDQM's printed publications may be ordered from www.edgm.eu/store

ISSN 2171-4118 / NIPO: 691-15-002-5

Free copies of the paper version of this Newsletter Transplant can be ordered at www.edgm.eu/store.







